#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Adversity in childhood linked to elevated striatal dopamine function in adulthood
#Text=Childhood adversity increases the risk of psychosis in adulthood.
1-1	0-9	Adversity	_	
1-2	10-12	in	_	
1-3	13-22	childhood	_	
1-4	23-29	linked	_	
1-5	30-32	to	_	
1-6	33-41	elevated	_	
1-7	42-50	striatal	_	
1-8	51-59	dopamine	_	
1-9	60-68	function	_	
1-10	69-71	in	_	
1-11	72-81	adulthood	_	
1-12	82-91	Childhood	_	
1-13	92-101	adversity	_	
1-14	102-111	increases	_	
1-15	112-115	the	_	
1-16	116-120	risk	_	
1-17	121-123	of	_	
1-18	124-133	psychosis	_	
1-19	134-136	in	_	
1-20	137-146	adulthood	_	
1-21	146-147	.	_	

#Text=Theoretical and animal models suggest that this effect may be mediated by increased striatal dopamine neurotransmission.
2-1	148-159	Theoretical	_	
2-2	160-163	and	_	
2-3	164-170	animal	_	
2-4	171-177	models	_	
2-5	178-185	suggest	_	
2-6	186-190	that	_	
2-7	191-195	this	_	
2-8	196-202	effect	_	
2-9	203-206	may	_	
2-10	207-209	be	_	
2-11	210-218	mediated	_	
2-12	219-221	by	_	
2-13	222-231	increased	_	
2-14	232-240	striatal	_	
2-15	241-249	dopamine	_	
2-16	250-267	neurotransmission	_	
2-17	267-268	.	_	

#Text=The primary objective of this study was to examine the relationship between adversity in childhood and striatal dopamine function in early adulthood.
3-1	269-272	The	_	
3-2	273-280	primary	_	
3-3	281-290	objective	_	
3-4	291-293	of	_	
3-5	294-298	this	_	
3-6	299-304	study	_	
3-7	305-308	was	_	
3-8	309-311	to	_	
3-9	312-319	examine	_	
3-10	320-323	the	_	
3-11	324-336	relationship	_	
3-12	337-344	between	_	
3-13	345-354	adversity	_	
3-14	355-357	in	_	
3-15	358-367	childhood	_	
3-16	368-371	and	_	
3-17	372-380	striatal	_	
3-18	381-389	dopamine	_	
3-19	390-398	function	_	
3-20	399-401	in	_	
3-21	402-407	early	_	
3-22	408-417	adulthood	_	
3-23	417-418	.	_	

#Text=Secondary objectives were to compare exposure to childhood adversity and striatal dopamine function in young people at ultra high risk (UHR) of psychosis and healthy volunteers.
4-1	419-428	Secondary	_	
4-2	429-439	objectives	_	
4-3	440-444	were	_	
4-4	445-447	to	_	
4-5	448-455	compare	_	
4-6	456-464	exposure	_	
4-7	465-467	to	_	
4-8	468-477	childhood	_	
4-9	478-487	adversity	_	
4-10	488-491	and	_	
4-11	492-500	striatal	_	
4-12	501-509	dopamine	_	
4-13	510-518	function	_	
4-14	519-521	in	_	
4-15	522-527	young	_	
4-16	528-534	people	_	
4-17	535-537	at	_	
4-18	538-543	ultra	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[1]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[2]	
4-19	544-548	high	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[1]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[2]	
4-20	549-553	risk	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[1]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[2]	
4-21	554-555	(	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[1]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[2]	
4-22	555-558	UHR	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[1]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[2]	
4-23	558-559	)	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[1]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[2]	
4-24	560-562	of	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[1]	
4-25	563-572	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[1]	
4-26	573-576	and	_	
4-27	577-584	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
4-28	585-595	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
4-29	595-596	.	_	

#Text=Sixty-seven young adults, comprising 47 individuals at UHR for psychosis and 20 healthy volunteers were recruited from the same geographic area and were matched for age, gender and substance use.
5-1	597-608	Sixty-seven	_	
5-2	609-614	young	_	
5-3	615-621	adults	_	
5-4	621-622	,	_	
5-5	623-633	comprising	_	
5-6	634-636	47	_	
5-7	637-648	individuals	_	
5-8	649-651	at	_	
5-9	652-655	UHR	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[4]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[5]	
5-10	656-659	for	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[4]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[5]	
5-11	660-669	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[4]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[5]	
5-12	670-673	and	_	
5-13	674-676	20	_	
5-14	677-684	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
5-15	685-695	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
5-16	696-700	were	_	
5-17	701-710	recruited	_	
5-18	711-715	from	_	
5-19	716-719	the	_	
5-20	720-724	same	_	
5-21	725-735	geographic	_	
5-22	736-740	area	_	
5-23	741-744	and	_	
5-24	745-749	were	_	
5-25	750-757	matched	_	
5-26	758-761	for	_	
5-27	762-765	age	_	
5-28	765-766	,	_	
5-29	767-773	gender	_	
5-30	774-777	and	_	
5-31	778-787	substance	_	
5-32	788-791	use	_	
5-33	791-792	.	_	

#Text=Presynaptic dopamine function in the associative striatum was assessed using 18F-DOPA positron emission tomography.
6-1	793-804	Presynaptic	_	
6-2	805-813	dopamine	_	
6-3	814-822	function	_	
6-4	823-825	in	_	
6-5	826-829	the	_	
6-6	830-841	associative	_	
6-7	842-850	striatum	_	
6-8	851-854	was	_	
6-9	855-863	assessed	_	
6-10	864-869	using	_	
6-11	870-878	18F-DOPA	_	
6-12	879-887	positron	_	
6-13	888-896	emission	_	
6-14	897-907	tomography	_	
6-15	907-908	.	_	

#Text=Childhood adversity was assessed using the Childhood Experience of Care and Abuse questionnaire.
7-1	909-918	Childhood	_	
7-2	919-928	adversity	_	
7-3	929-932	was	_	
7-4	933-941	assessed	_	
7-5	942-947	using	_	
7-6	948-951	the	_	
7-7	952-961	Childhood	http://www.case.edu/ProvCaRe/provcare#Questionnaire[7]	
7-8	962-972	Experience	http://www.case.edu/ProvCaRe/provcare#Questionnaire[7]	
7-9	973-975	of	http://www.case.edu/ProvCaRe/provcare#Questionnaire[7]	
7-10	976-980	Care	http://www.case.edu/ProvCaRe/provcare#Questionnaire[7]	
7-11	981-984	and	http://www.case.edu/ProvCaRe/provcare#Questionnaire[7]	
7-12	985-990	Abuse	http://www.case.edu/ProvCaRe/provcare#Questionnaire[7]	
7-13	991-1004	questionnaire	http://www.case.edu/ProvCaRe/provcare#Questionnaire[7]	
7-14	1004-1005	.	_	

#Text=Within the sample as a whole, both severe physical or sexual abuse (T63 = 2.92; P = 0.005), and unstable family arrangements (T57 = 2.80; P = 0.007) in childhood were associated with elevated dopamine function in the associative striatum in adulthood.
8-1	1006-1012	Within	_	
8-2	1013-1016	the	_	
8-3	1017-1023	sample	_	
8-4	1024-1026	as	_	
8-5	1027-1028	a	_	
8-6	1029-1034	whole	_	
8-7	1034-1035	,	_	
8-8	1036-1040	both	_	
8-9	1041-1047	severe	_	
8-10	1048-1056	physical	_	
8-11	1057-1059	or	_	
8-12	1060-1066	sexual	_	
8-13	1067-1072	abuse	_	
8-14	1073-1074	(	_	
8-15	1074-1077	T63	_	
8-16	1077-1078	 	_	
8-17	1078-1079	=	_	
8-18	1079-1080	 	_	
8-19	1080-1084	2.92	_	
8-20	1084-1085	;	_	
8-21	1086-1087	P	_	
8-22	1087-1088	 	_	
8-23	1088-1089	=	_	
8-24	1089-1090	 	_	
8-25	1090-1095	0.005	_	
8-26	1095-1096	)	_	
8-27	1096-1097	,	_	
8-28	1098-1101	and	_	
8-29	1102-1110	unstable	_	
8-30	1111-1117	family	_	
8-31	1118-1130	arrangements	_	
8-32	1131-1132	(	_	
8-33	1132-1135	T57	_	
8-34	1135-1136	 	_	
8-35	1136-1137	=	_	
8-36	1137-1138	 	_	
8-37	1138-1142	2.80	_	
8-38	1142-1143	;	_	
8-39	1144-1145	P	_	
8-40	1145-1146	 	_	
8-41	1146-1147	=	_	
8-42	1147-1148	 	_	
8-43	1148-1153	0.007	_	
8-44	1153-1154	)	_	
8-45	1155-1157	in	_	
8-46	1158-1167	childhood	_	
8-47	1168-1172	were	_	
8-48	1173-1183	associated	_	
8-49	1184-1188	with	_	
8-50	1189-1197	elevated	_	
8-51	1198-1206	dopamine	_	
8-52	1207-1215	function	_	
8-53	1216-1218	in	_	
8-54	1219-1222	the	_	
8-55	1223-1234	associative	_	
8-56	1235-1243	striatum	_	
8-57	1244-1246	in	_	
8-58	1247-1256	adulthood	_	
8-59	1256-1257	.	_	

#Text=Comparison of the UHR and volunteer subgroups revealed similar incidence of childhood adverse experiences, and there was no significant group difference in dopamine function.
9-1	1258-1268	Comparison	_	
9-2	1269-1271	of	_	
9-3	1272-1275	the	_	
9-4	1276-1279	UHR	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk	
9-5	1280-1283	and	_	
9-6	1284-1293	volunteer	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
9-7	1294-1303	subgroups	_	
9-8	1304-1312	revealed	_	
9-9	1313-1320	similar	_	
9-10	1321-1330	incidence	_	
9-11	1331-1333	of	_	
9-12	1334-1343	childhood	_	
9-13	1344-1351	adverse	_	
9-14	1352-1363	experiences	_	
9-15	1363-1364	,	_	
9-16	1365-1368	and	_	
9-17	1369-1374	there	_	
9-18	1375-1378	was	_	
9-19	1379-1381	no	_	
9-20	1382-1393	significant	_	
9-21	1394-1399	group	_	
9-22	1400-1410	difference	_	
9-23	1411-1413	in	_	
9-24	1414-1422	dopamine	_	
9-25	1423-1431	function	_	
9-26	1431-1432	.	_	

#Text=This study provides evidence that childhood adversity is linked to elevated striatal dopamine function in adulthood.
10-1	1433-1437	This	_	
10-2	1438-1443	study	_	
10-3	1444-1452	provides	_	
10-4	1453-1461	evidence	_	
10-5	1462-1466	that	_	
10-6	1467-1476	childhood	_	
10-7	1477-1486	adversity	_	
10-8	1487-1489	is	_	
10-9	1490-1496	linked	_	
10-10	1497-1499	to	_	
10-11	1500-1508	elevated	_	
10-12	1509-1517	striatal	_	
10-13	1518-1526	dopamine	_	
10-14	1527-1535	function	_	
10-15	1536-1538	in	_	
10-16	1539-1548	adulthood	_	
10-17	1548-1549	.	_	

#Text=Introduction
#Text=Traumatic experiences during childhood, such as physical, sexual or psychological abuse, increase the risk of mental illness in adulthood threefold.
11-1	1550-1562	Introduction	_	
11-2	1563-1572	Traumatic	_	
11-3	1573-1584	experiences	_	
11-4	1585-1591	during	_	
11-5	1592-1601	childhood	_	
11-6	1601-1602	,	_	
11-7	1603-1607	such	_	
11-8	1608-1610	as	_	
11-9	1611-1619	physical	_	
11-10	1619-1620	,	_	
11-11	1621-1627	sexual	_	
11-12	1628-1630	or	_	
11-13	1631-1644	psychological	_	
11-14	1645-1650	abuse	_	
11-15	1650-1651	,	_	
11-16	1652-1660	increase	_	
11-17	1661-1664	the	_	
11-18	1665-1669	risk	_	
11-19	1670-1672	of	_	
11-20	1673-1679	mental	_	
11-21	1680-1687	illness	_	
11-22	1688-1690	in	_	
11-23	1691-1700	adulthood	_	
11-24	1701-1710	threefold	_	
11-25	1710-1711	.	_	

#Text=The neurobiological basis of this effect is unknown.
12-1	1712-1715	The	_	
12-2	1716-1731	neurobiological	_	
12-3	1732-1737	basis	_	
12-4	1738-1740	of	_	
12-5	1741-1745	this	_	
12-6	1746-1752	effect	_	
12-7	1753-1755	is	_	
12-8	1756-1763	unknown	_	
12-9	1763-1764	.	_	

#Text=However, exposure to sustained environmental stress elevates central dopaminergic neurotransmission in animal models, and an elevation in brain dopamine function is one of the most robust neurobiological features of psychosis.
13-1	1765-1772	However	_	
13-2	1772-1773	,	_	
13-3	1774-1782	exposure	_	
13-4	1783-1785	to	_	
13-5	1786-1795	sustained	_	
13-6	1796-1809	environmental	_	
13-7	1810-1816	stress	_	
13-8	1817-1825	elevates	_	
13-9	1826-1833	central	_	
13-10	1834-1846	dopaminergic	_	
13-11	1847-1864	neurotransmission	_	
13-12	1865-1867	in	_	
13-13	1868-1874	animal	_	
13-14	1875-1881	models	_	
13-15	1881-1882	,	_	
13-16	1883-1886	and	_	
13-17	1887-1889	an	_	
13-18	1890-1899	elevation	_	
13-19	1900-1902	in	_	
13-20	1903-1908	brain	_	
13-21	1909-1917	dopamine	_	
13-22	1918-1926	function	_	
13-23	1927-1929	is	_	
13-24	1930-1933	one	_	
13-25	1934-1936	of	_	
13-26	1937-1940	the	_	
13-27	1941-1945	most	_	
13-28	1946-1952	robust	_	
13-29	1953-1968	neurobiological	_	
13-30	1969-1977	features	_	
13-31	1978-1980	of	_	
13-32	1981-1990	psychosis	_	
13-33	1990-1991	.	_	

#Text=It has thus been suggested that psychosocial stress in childhood may increase the risk of psychosis in later life through an effect on dopaminergic neurotransmission.
14-1	1992-1994	It	_	
14-2	1995-1998	has	_	
14-3	1999-2003	thus	_	
14-4	2004-2008	been	_	
14-5	2009-2018	suggested	_	
14-6	2019-2023	that	_	
14-7	2024-2036	psychosocial	_	
14-8	2037-2043	stress	_	
14-9	2044-2046	in	_	
14-10	2047-2056	childhood	_	
14-11	2057-2060	may	_	
14-12	2061-2069	increase	_	
14-13	2070-2073	the	_	
14-14	2074-2078	risk	_	
14-15	2079-2081	of	_	
14-16	2082-2091	psychosis	_	
14-17	2092-2094	in	_	
14-18	2095-2100	later	_	
14-19	2101-2105	life	_	
14-20	2106-2113	through	_	
14-21	2114-2116	an	_	
14-22	2117-2123	effect	_	
14-23	2124-2126	on	_	
14-24	2127-2139	dopaminergic	_	
14-25	2140-2157	neurotransmission	_	
14-26	2157-2158	.	_	

#Text=There is indirect evidence to support this notion from human neuroimaging studies.
15-1	2159-2164	There	_	
15-2	2165-2167	is	_	
15-3	2168-2176	indirect	_	
15-4	2177-2185	evidence	_	
15-5	2186-2188	to	_	
15-6	2189-2196	support	_	
15-7	2197-2201	this	_	
15-8	2202-2208	notion	_	
15-9	2209-2213	from	_	
15-10	2214-2219	human	_	
15-11	2220-2232	neuroimaging	_	
15-12	2233-2240	studies	_	
15-13	2240-2241	.	_	

#Text=Healthy volunteers who have experienced childhood trauma show an elevated dopaminergic response to amphetamine administration, which may be mediated by perceived stress.
16-1	2242-2249	Healthy	_	
16-2	2250-2260	volunteers	_	
16-3	2261-2264	who	_	
16-4	2265-2269	have	_	
16-5	2270-2281	experienced	_	
16-6	2282-2291	childhood	_	
16-7	2292-2298	trauma	_	
16-8	2299-2303	show	_	
16-9	2304-2306	an	_	
16-10	2307-2315	elevated	_	
16-11	2316-2328	dopaminergic	_	
16-12	2329-2337	response	_	
16-13	2338-2340	to	_	
16-14	2341-2352	amphetamine	_	
16-15	2353-2367	administration	_	
16-16	2367-2368	,	_	
16-17	2369-2374	which	_	
16-18	2375-2378	may	_	
16-19	2379-2381	be	_	
16-20	2382-2390	mediated	_	
16-21	2391-2393	by	_	
16-22	2394-2403	perceived	_	
16-23	2404-2410	stress	_	
16-24	2410-2411	.	_	

#Text=In addition, striatal dopamine release elicited by an acute psychosocial stress task is elevated in healthy college students who experienced low levels of maternal care during childhood, suggesting that childhood disadvantage may be associated with elevated dopaminergic responses to stress in later life.
17-1	2412-2414	In	_	
17-2	2415-2423	addition	_	
17-3	2423-2424	,	_	
17-4	2425-2433	striatal	_	
17-5	2434-2442	dopamine	_	
17-6	2443-2450	release	_	
17-7	2451-2459	elicited	_	
17-8	2460-2462	by	_	
17-9	2463-2465	an	_	
17-10	2466-2471	acute	_	
17-11	2472-2484	psychosocial	_	
17-12	2485-2491	stress	_	
17-13	2492-2496	task	_	
17-14	2497-2499	is	_	
17-15	2500-2508	elevated	_	
17-16	2509-2511	in	_	
17-17	2512-2519	healthy	_	
17-18	2520-2527	college	_	
17-19	2528-2536	students	_	
17-20	2537-2540	who	_	
17-21	2541-2552	experienced	_	
17-22	2553-2556	low	_	
17-23	2557-2563	levels	_	
17-24	2564-2566	of	_	
17-25	2567-2575	maternal	_	
17-26	2576-2580	care	_	
17-27	2581-2587	during	_	
17-28	2588-2597	childhood	_	
17-29	2597-2598	,	_	
17-30	2599-2609	suggesting	_	
17-31	2610-2614	that	_	
17-32	2615-2624	childhood	_	
17-33	2625-2637	disadvantage	_	
17-34	2638-2641	may	_	
17-35	2642-2644	be	_	
17-36	2645-2655	associated	_	
17-37	2656-2660	with	_	
17-38	2661-2669	elevated	_	
17-39	2670-2682	dopaminergic	_	
17-40	2683-2692	responses	_	
17-41	2693-2695	to	_	
17-42	2696-2702	stress	_	
17-43	2703-2705	in	_	
17-44	2706-2711	later	_	
17-45	2712-2716	life	_	
17-46	2716-2717	.	_	

#Text=Compared to healthy volunteers, an elevated dopaminergic response to this stress task is also seen in adults who are at high risk for psychosis, adults with schizotypy, and patients with schizophrenia.
18-1	2718-2726	Compared	_	
18-2	2727-2729	to	_	
18-3	2730-2737	healthy	_	
18-4	2738-2748	volunteers	_	
18-5	2748-2749	,	_	
18-6	2750-2752	an	_	
18-7	2753-2761	elevated	_	
18-8	2762-2774	dopaminergic	_	
18-9	2775-2783	response	_	
18-10	2784-2786	to	_	
18-11	2787-2791	this	_	
18-12	2792-2798	stress	_	
18-13	2799-2803	task	_	
18-14	2804-2806	is	_	
18-15	2807-2811	also	_	
18-16	2812-2816	seen	_	
18-17	2817-2819	in	_	
18-18	2820-2826	adults	_	
18-19	2827-2830	who	_	
18-20	2831-2834	are	_	
18-21	2835-2837	at	_	
18-22	2838-2842	high	_	
18-23	2843-2847	risk	_	
18-24	2848-2851	for	_	
18-25	2852-2861	psychosis	_	
18-26	2861-2862	,	_	
18-27	2863-2869	adults	_	
18-28	2870-2874	with	_	
18-29	2875-2885	schizotypy	_	
18-30	2885-2886	,	_	
18-31	2887-2890	and	_	
18-32	2891-2899	patients	_	
18-33	2900-2904	with	_	
18-34	2905-2918	schizophrenia	_	
18-35	2918-2919	.	_	

#Text=The social defeat hypothesis posits that repeated setbacks in social situations leads to a sensitization of mesostriatal dopamine neurotransmission, and thereby increases the risk of developing psychotic symptoms.
19-1	2920-2923	The	_	
19-2	2924-2930	social	_	
19-3	2931-2937	defeat	_	
19-4	2938-2948	hypothesis	_	
19-5	2949-2955	posits	_	
19-6	2956-2960	that	_	
19-7	2961-2969	repeated	_	
19-8	2970-2978	setbacks	_	
19-9	2979-2981	in	_	
19-10	2982-2988	social	_	
19-11	2989-2999	situations	_	
19-12	3000-3005	leads	_	
19-13	3006-3008	to	_	
19-14	3009-3010	a	_	
19-15	3011-3024	sensitization	_	
19-16	3025-3027	of	_	
19-17	3028-3040	mesostriatal	_	
19-18	3041-3049	dopamine	_	
19-19	3050-3067	neurotransmission	_	
19-20	3067-3068	,	_	
19-21	3069-3072	and	_	
19-22	3073-3080	thereby	_	
19-23	3081-3090	increases	_	
19-24	3091-3094	the	_	
19-25	3095-3099	risk	_	
19-26	3100-3102	of	_	
19-27	3103-3113	developing	_	
19-28	3114-3123	psychotic	_	
19-29	3124-3132	symptoms	_	
19-30	3132-3133	.	_	

#Text=Childhood trauma may represent one particular type of social defeat.
20-1	3134-3143	Childhood	_	
20-2	3144-3150	trauma	_	
20-3	3151-3154	may	_	
20-4	3155-3164	represent	_	
20-5	3165-3168	one	_	
20-6	3169-3179	particular	_	
20-7	3180-3184	type	_	
20-8	3185-3187	of	_	
20-9	3188-3194	social	_	
20-10	3195-3201	defeat	_	
20-11	3201-3202	.	_	

#Text=In support of the social defeat hypothesis, it has recently been reported that amphetamine-stimulated dopamine release in the striatum is elevated in young adults with severe hearing impairment, who generally experience marked social exclusion.
21-1	3203-3205	In	_	
21-2	3206-3213	support	_	
21-3	3214-3216	of	_	
21-4	3217-3220	the	_	
21-5	3221-3227	social	_	
21-6	3228-3234	defeat	_	
21-7	3235-3245	hypothesis	_	
21-8	3245-3246	,	_	
21-9	3247-3249	it	_	
21-10	3250-3253	has	_	
21-11	3254-3262	recently	_	
21-12	3263-3267	been	_	
21-13	3268-3276	reported	_	
21-14	3277-3281	that	_	
21-15	3282-3304	amphetamine-stimulated	_	
21-16	3305-3313	dopamine	_	
21-17	3314-3321	release	_	
21-18	3322-3324	in	_	
21-19	3325-3328	the	_	
21-20	3329-3337	striatum	_	
21-21	3338-3340	is	_	
21-22	3341-3349	elevated	_	
21-23	3350-3352	in	_	
21-24	3353-3358	young	_	
21-25	3359-3365	adults	_	
21-26	3366-3370	with	_	
21-27	3371-3377	severe	_	
21-28	3378-3385	hearing	_	
21-29	3386-3396	impairment	_	
21-30	3396-3397	,	_	
21-31	3398-3401	who	_	
21-32	3402-3411	generally	_	
21-33	3412-3422	experience	_	
21-34	3423-3429	marked	_	
21-35	3430-3436	social	_	
21-36	3437-3446	exclusion	_	
21-37	3446-3447	.	_	

#Text=The aim of the present study was to further examine how exposure to adversity in childhood impacts on striatal dopamine function in adulthood, in both a healthy volunteer group, and also a group at who are at ultra high risk (UHR) of developing psychosis.
22-1	3448-3451	The	_	
22-2	3452-3455	aim	_	
22-3	3456-3458	of	_	
22-4	3459-3462	the	_	
22-5	3463-3470	present	_	
22-6	3471-3476	study	_	
22-7	3477-3480	was	_	
22-8	3481-3483	to	_	
22-9	3484-3491	further	_	
22-10	3492-3499	examine	_	
22-11	3500-3503	how	_	
22-12	3504-3512	exposure	_	
22-13	3513-3515	to	_	
22-14	3516-3525	adversity	_	
22-15	3526-3528	in	_	
22-16	3529-3538	childhood	_	
22-17	3539-3546	impacts	_	
22-18	3547-3549	on	_	
22-19	3550-3558	striatal	_	
22-20	3559-3567	dopamine	_	
22-21	3568-3576	function	_	
22-22	3577-3579	in	_	
22-23	3580-3589	adulthood	_	
22-24	3589-3590	,	_	
22-25	3591-3593	in	_	
22-26	3594-3598	both	_	
22-27	3599-3600	a	_	
22-28	3601-3608	healthy	_	
22-29	3609-3618	volunteer	_	
22-30	3619-3624	group	_	
22-31	3624-3625	,	_	
22-32	3626-3629	and	_	
22-33	3630-3634	also	_	
22-34	3635-3636	a	_	
22-35	3637-3642	group	_	
22-36	3643-3645	at	_	
22-37	3646-3649	who	_	
22-38	3650-3653	are	_	
22-39	3654-3656	at	_	
22-40	3657-3662	ultra	_	
22-41	3663-3667	high	_	
22-42	3668-3672	risk	_	
22-43	3673-3674	(	_	
22-44	3674-3677	UHR	_	
22-45	3677-3678	)	_	
22-46	3679-3681	of	_	
22-47	3682-3692	developing	_	
22-48	3693-3702	psychosis	_	
22-49	3702-3703	.	_	

#Text=Both the level of striatal dopamine function and the incidence of childhood adversity tend to be higher in UHR groups, although to a lesser extent than in schizophrenia.
23-1	3704-3708	Both	_	
23-2	3709-3712	the	_	
23-3	3713-3718	level	_	
23-4	3719-3721	of	_	
23-5	3722-3730	striatal	_	
23-6	3731-3739	dopamine	_	
23-7	3740-3748	function	_	
23-8	3749-3752	and	_	
23-9	3753-3756	the	_	
23-10	3757-3766	incidence	_	
23-11	3767-3769	of	_	
23-12	3770-3779	childhood	_	
23-13	3780-3789	adversity	_	
23-14	3790-3794	tend	_	
23-15	3795-3797	to	_	
23-16	3798-3800	be	_	
23-17	3801-3807	higher	_	
23-18	3808-3810	in	_	
23-19	3811-3814	UHR	_	
23-20	3815-3821	groups	_	
23-21	3821-3822	,	_	
23-22	3823-3831	although	_	
23-23	3832-3834	to	_	
23-24	3835-3836	a	_	
23-25	3837-3843	lesser	_	
23-26	3844-3850	extent	_	
23-27	3851-3855	than	_	
23-28	3856-3858	in	_	
23-29	3859-3872	schizophrenia	_	
23-30	3872-3873	.	_	

#Text=The primary hypothesis was that striatal presynaptic dopamine function would be elevated in both UHR and healthy volunteers who experienced childhood adversity.
24-1	3874-3877	The	_	
24-2	3878-3885	primary	_	
24-3	3886-3896	hypothesis	_	
24-4	3897-3900	was	_	
24-5	3901-3905	that	_	
24-6	3906-3914	striatal	_	
24-7	3915-3926	presynaptic	_	
24-8	3927-3935	dopamine	_	
24-9	3936-3944	function	_	
24-10	3945-3950	would	_	
24-11	3951-3953	be	_	
24-12	3954-3962	elevated	_	
24-13	3963-3965	in	_	
24-14	3966-3970	both	_	
24-15	3971-3974	UHR	_	
24-16	3975-3978	and	_	
24-17	3979-3986	healthy	_	
24-18	3987-3997	volunteers	_	
24-19	3998-4001	who	_	
24-20	4002-4013	experienced	_	
24-21	4014-4023	childhood	_	
24-22	4024-4033	adversity	_	
24-23	4033-4034	.	_	

#Text=As previous studies have shown elevated dopamine responses in healthy volunteers who experienced childhood adversity, we predicted that this relationship would be seen across both groups, but to a greater degree in the UHR sample.
25-1	4035-4037	As	_	
25-2	4038-4046	previous	_	
25-3	4047-4054	studies	_	
25-4	4055-4059	have	_	
25-5	4060-4065	shown	_	
25-6	4066-4074	elevated	_	
25-7	4075-4083	dopamine	_	
25-8	4084-4093	responses	_	
25-9	4094-4096	in	_	
25-10	4097-4104	healthy	_	
25-11	4105-4115	volunteers	_	
25-12	4116-4119	who	_	
25-13	4120-4131	experienced	_	
25-14	4132-4141	childhood	_	
25-15	4142-4151	adversity	_	
25-16	4151-4152	,	_	
25-17	4153-4155	we	_	
25-18	4156-4165	predicted	_	
25-19	4166-4170	that	_	
25-20	4171-4175	this	_	
25-21	4176-4188	relationship	_	
25-22	4189-4194	would	_	
25-23	4195-4197	be	_	
25-24	4198-4202	seen	_	
25-25	4203-4209	across	_	
25-26	4210-4214	both	_	
25-27	4215-4221	groups	_	
25-28	4221-4222	,	_	
25-29	4223-4226	but	_	
25-30	4227-4229	to	_	
25-31	4230-4231	a	_	
25-32	4232-4239	greater	_	
25-33	4240-4246	degree	_	
25-34	4247-4249	in	_	
25-35	4250-4253	the	_	
25-36	4254-4257	UHR	_	
25-37	4258-4264	sample	_	
25-38	4264-4265	.	_	

#Text=Related to this, the secondary hypotheses were that exposure to childhood adversity would be higher in the UHR than healthy volunteer group, and that striatal presynaptic dopamine function would be elevated in the UHR compared to the healthy volunteer group.
26-1	4266-4273	Related	_	
26-2	4274-4276	to	_	
26-3	4277-4281	this	_	
26-4	4281-4282	,	_	
26-5	4283-4286	the	_	
26-6	4287-4296	secondary	_	
26-7	4297-4307	hypotheses	_	
26-8	4308-4312	were	_	
26-9	4313-4317	that	_	
26-10	4318-4326	exposure	_	
26-11	4327-4329	to	_	
26-12	4330-4339	childhood	_	
26-13	4340-4349	adversity	_	
26-14	4350-4355	would	_	
26-15	4356-4358	be	_	
26-16	4359-4365	higher	_	
26-17	4366-4368	in	_	
26-18	4369-4372	the	_	
26-19	4373-4376	UHR	_	
26-20	4377-4381	than	_	
26-21	4382-4389	healthy	_	
26-22	4390-4399	volunteer	_	
26-23	4400-4405	group	_	
26-24	4405-4406	,	_	
26-25	4407-4410	and	_	
26-26	4411-4415	that	_	
26-27	4416-4424	striatal	_	
26-28	4425-4436	presynaptic	_	
26-29	4437-4445	dopamine	_	
26-30	4446-4454	function	_	
26-31	4455-4460	would	_	
26-32	4461-4463	be	_	
26-33	4464-4472	elevated	_	
26-34	4473-4475	in	_	
26-35	4476-4479	the	_	
26-36	4480-4483	UHR	_	
26-37	4484-4492	compared	_	
26-38	4493-4495	to	_	
26-39	4496-4499	the	_	
26-40	4500-4507	healthy	_	
26-41	4508-4517	volunteer	_	
26-42	4518-4523	group	_	
26-43	4523-4524	.	_	

#Text=A further hypothesis was that both striatal presynaptic dopamine and childhood adversity would be positively related to the severity of psychotic symptoms.
27-1	4525-4526	A	_	
27-2	4527-4534	further	_	
27-3	4535-4545	hypothesis	_	
27-4	4546-4549	was	_	
27-5	4550-4554	that	_	
27-6	4555-4559	both	_	
27-7	4560-4568	striatal	_	
27-8	4569-4580	presynaptic	_	
27-9	4581-4589	dopamine	_	
27-10	4590-4593	and	_	
27-11	4594-4603	childhood	_	
27-12	4604-4613	adversity	_	
27-13	4614-4619	would	_	
27-14	4620-4622	be	_	
27-15	4623-4633	positively	_	
27-16	4634-4641	related	_	
27-17	4642-4644	to	_	
27-18	4645-4648	the	_	
27-19	4649-4657	severity	_	
27-20	4658-4660	of	_	
27-21	4661-4670	psychotic	_	
27-22	4671-4679	symptoms	_	
27-23	4679-4680	.	_	

#Text=Participants and methods
#Text=Participants
#Text=This study had National Health Service Research Ethics Committee and Administration of Radioactive Substances Advisory Committee approval.
28-1	4681-4693	Participants	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]	
28-2	4694-4697	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]	
28-3	4698-4705	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]	
28-4	4706-4718	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-5	4719-4723	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-6	4724-4729	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-7	4730-4733	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-8	4734-4742	National	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-9	4743-4749	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-10	4750-4757	Service	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-11	4758-4766	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-12	4767-4773	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-13	4774-4783	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-14	4784-4787	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-15	4788-4802	Administration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-16	4803-4805	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-17	4806-4817	Radioactive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-18	4818-4828	Substances	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-19	4829-4837	Advisory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-20	4838-4847	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-21	4848-4856	approval	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
28-22	4856-4857	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=All participants provided their written informed consent.
29-1	4858-4861	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-2	4862-4874	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-3	4875-4883	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-4	4884-4889	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-5	4890-4897	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-6	4898-4906	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-7	4907-4914	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-8	4914-4915	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=One group consisted of 47 individuals who met operationalized UHR criteria (over the last year, experience of attenuated psychotic symptoms, or psychotic symptoms that lasted less than a week and spontaneously remitted, or schizotypal personality disorder or a first degree relative with a psychotic disorder plus a decline in functioning) recruited from Outreach and Support in South London (OASIS), part of the South London and Maudsley National Health Service Trust.
30-1	4916-4919	One	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-2	4920-4925	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-3	4926-4935	consisted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-4	4936-4938	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-5	4939-4941	47	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-6	4942-4953	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-7	4954-4957	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-8	4958-4961	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-9	4962-4977	operationalized	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-10	4978-4981	UHR	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[12]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[13]	
30-11	4982-4990	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-12	4991-4992	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-13	4992-4996	over	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-14	4997-5000	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-15	5001-5005	last	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-16	5006-5010	year	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-17	5010-5011	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-18	5012-5022	experience	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-19	5023-5025	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-20	5026-5036	attenuated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-21	5037-5046	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-22	5047-5055	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-23	5055-5056	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-24	5057-5059	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-25	5060-5069	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-26	5070-5078	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-27	5079-5083	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-28	5084-5090	lasted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-29	5091-5095	less	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-30	5096-5100	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-31	5101-5102	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-32	5103-5107	week	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-33	5108-5111	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-34	5112-5125	spontaneously	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-35	5126-5134	remitted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-36	5134-5135	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-37	5136-5138	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-38	5139-5150	schizotypal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-39	5151-5162	personality	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-40	5163-5171	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-41	5172-5174	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-42	5175-5176	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-43	5177-5182	first	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-44	5183-5189	degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-45	5190-5198	relative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-46	5199-5203	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-47	5204-5205	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-48	5206-5215	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-49	5216-5224	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-50	5225-5229	plus	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-51	5230-5231	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-52	5232-5239	decline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-53	5240-5242	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-54	5243-5254	functioning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-55	5254-5255	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-56	5256-5265	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-57	5266-5270	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-58	5271-5279	Outreach	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-59	5280-5283	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-60	5284-5291	Support	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-61	5292-5294	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-62	5295-5300	South	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-63	5301-5307	London	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-64	5308-5309	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-65	5309-5314	OASIS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-66	5314-5315	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-67	5315-5316	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-68	5317-5321	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-69	5322-5324	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-70	5325-5328	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-71	5329-5334	South	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-72	5335-5341	London	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-73	5342-5345	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-74	5346-5354	Maudsley	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-75	5355-5363	National	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-76	5364-5370	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-77	5371-5378	Service	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-78	5379-5384	Trust	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
30-79	5384-5385	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=A second group comprised 20 healthy volunteers (Control), recruited from the same geographic area by public advertisement.
31-1	5386-5387	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-2	5388-5394	second	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-3	5395-5400	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-4	5401-5410	comprised	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-5	5411-5413	20	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-6	5414-5421	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[15]	
31-7	5422-5432	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[15]	
31-8	5433-5434	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[15]	
31-9	5434-5441	Control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[15]	
31-10	5441-5442	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[15]	
31-11	5442-5443	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-12	5444-5453	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-13	5454-5458	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-14	5459-5462	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-15	5463-5467	same	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-16	5468-5478	geographic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-17	5479-5483	area	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-18	5484-5486	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-19	5487-5493	public	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-20	5494-5507	advertisement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
31-21	5507-5508	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	

#Text=They had no personal or family history of psychiatric symptoms, and were not taking psychotropic medication.
32-1	5509-5513	They	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-2	5514-5517	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-3	5518-5520	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-4	5521-5529	personal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-5	5530-5532	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-6	5533-5539	family	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-7	5540-5547	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-8	5548-5550	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-9	5551-5562	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-10	5563-5571	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-11	5571-5572	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-12	5573-5576	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-13	5577-5581	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-14	5582-5585	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-15	5586-5592	taking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-16	5593-5605	psychotropic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-17	5606-5616	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
32-18	5616-5617	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	

#Text=Both groups included subjects who had participated in previous dopamine imaging studies, and represent those participants in whom there was existing cross-over with a separate study on childhood adversity, or those whom could be re-contacted to complete the childhood adversity questionnaire.
33-1	5618-5622	Both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-2	5623-5629	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-3	5630-5638	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-4	5639-5647	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-5	5648-5651	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-6	5652-5655	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-7	5656-5668	participated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-8	5669-5671	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-9	5672-5680	previous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-10	5681-5689	dopamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-11	5690-5697	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-12	5698-5705	studies	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-13	5705-5706	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-14	5707-5710	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-15	5711-5720	represent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-16	5721-5726	those	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-17	5727-5739	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-18	5740-5742	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-19	5743-5747	whom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-20	5748-5753	there	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-21	5754-5757	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-22	5758-5766	existing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-23	5767-5777	cross-over	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-24	5778-5782	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-25	5783-5784	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-26	5785-5793	separate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-27	5794-5799	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-28	5800-5802	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-29	5803-5812	childhood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-30	5813-5822	adversity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-31	5822-5823	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-32	5824-5826	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-33	5827-5832	those	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-34	5833-5837	whom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-35	5838-5843	could	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-36	5844-5846	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-37	5847-5859	re-contacted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-38	5860-5862	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-39	5863-5871	complete	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-40	5872-5875	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-41	5876-5885	childhood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-42	5886-5895	adversity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-43	5896-5909	questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-44	5909-5910	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=Assessment of clinical variables and childhood adversity
#Text=Psychopathology was assessed using the Comprehensive Assessment of At-Risk Mental States (CAARMS), Positive and Negative Syndrome Scale for Schizophrenia (PANSS), and the Hamilton Depression and Anxiety Rating Scales.
34-1	5911-5921	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-2	5922-5924	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-3	5925-5933	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-4	5934-5943	variables	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-5	5944-5947	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-6	5948-5957	childhood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-7	5958-5967	adversity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-8	5968-5983	Psychopathology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-9	5984-5987	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-10	5988-5996	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-11	5997-6002	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-12	6003-6006	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-13	6007-6020	Comprehensive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#CAARMSPsychosisThresholdCriteria[19]	
34-14	6021-6031	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#CAARMSPsychosisThresholdCriteria[19]	
34-15	6032-6034	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#CAARMSPsychosisThresholdCriteria[19]	
34-16	6035-6042	At-Risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#CAARMSPsychosisThresholdCriteria[19]	
34-17	6043-6049	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#CAARMSPsychosisThresholdCriteria[19]	
34-18	6050-6056	States	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#CAARMSPsychosisThresholdCriteria[19]	
34-19	6057-6058	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#CAARMSPsychosisThresholdCriteria[19]	
34-20	6058-6064	CAARMS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#CAARMSPsychosisThresholdCriteria[19]	
34-21	6064-6065	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#CAARMSPsychosisThresholdCriteria[19]	
34-22	6065-6066	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-23	6067-6075	Positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
34-24	6076-6079	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
34-25	6080-6088	Negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
34-26	6089-6097	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
34-27	6098-6103	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
34-28	6104-6107	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
34-29	6108-6121	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
34-30	6122-6123	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
34-31	6123-6128	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
34-32	6128-6129	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
34-33	6129-6130	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-34	6131-6134	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-35	6135-6138	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-36	6139-6147	Hamilton	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale[21]	
34-37	6148-6158	Depression	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale[21]	
34-38	6159-6162	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale[21]	
34-39	6163-6170	Anxiety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale[21]	
34-40	6171-6177	Rating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale[21]	
34-41	6178-6184	Scales	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale[21]	
34-42	6184-6185	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=Childhood adversity was assessed using the Childhood Experience of Care and Abuse Questionnaire (CECA-Q).
35-1	6186-6195	Childhood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
35-2	6196-6205	adversity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
35-3	6206-6209	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
35-4	6210-6218	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
35-5	6219-6224	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
35-6	6225-6228	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
35-7	6229-6238	Childhood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://www.case.edu/ProvCaRe/provcare#Questionnaire[23]	
35-8	6239-6249	Experience	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://www.case.edu/ProvCaRe/provcare#Questionnaire[23]	
35-9	6250-6252	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://www.case.edu/ProvCaRe/provcare#Questionnaire[23]	
35-10	6253-6257	Care	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://www.case.edu/ProvCaRe/provcare#Questionnaire[23]	
35-11	6258-6261	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://www.case.edu/ProvCaRe/provcare#Questionnaire[23]	
35-12	6262-6267	Abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://www.case.edu/ProvCaRe/provcare#Questionnaire[23]	
35-13	6268-6281	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://www.case.edu/ProvCaRe/provcare#Questionnaire[23]	
35-14	6282-6283	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://www.case.edu/ProvCaRe/provcare#Questionnaire[23]	
35-15	6283-6289	CECA-Q	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://www.case.edu/ProvCaRe/provcare#Questionnaire[23]	
35-16	6289-6290	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
35-17	6290-6291	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	

#Text=Participants did not have to answer any questions they were uncomfortable with.
36-1	6292-6304	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
36-2	6305-6308	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
36-3	6309-6312	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
36-4	6313-6317	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
36-5	6318-6320	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
36-6	6321-6327	answer	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
36-7	6328-6331	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
36-8	6332-6341	questions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
36-9	6342-6346	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
36-10	6347-6351	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
36-11	6352-6365	uncomfortable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
36-12	6366-6370	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
36-13	6370-6371	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	

#Text=The following adverse events were analysed: A) death or separation from either parental figure; B) severe sexual or physical abuse; C) maternal or paternal antipathy or neglect; D) more than two family arrangements (the number of different caregivers with each of whom the child lived for at least one year).
37-1	6372-6375	The	_	
37-2	6376-6385	following	_	
37-3	6386-6393	adverse	_	
37-4	6394-6400	events	_	
37-5	6401-6405	were	_	
37-6	6406-6414	analysed	_	
37-7	6414-6415	:	_	
37-8	6416-6417	A	_	
37-9	6417-6418	)	_	
37-10	6419-6424	death	_	
37-11	6425-6427	or	_	
37-12	6428-6438	separation	_	
37-13	6439-6443	from	_	
37-14	6444-6450	either	_	
37-15	6451-6459	parental	_	
37-16	6460-6466	figure	_	
37-17	6466-6467	;	_	
37-18	6468-6469	B	_	
37-19	6469-6470	)	_	
37-20	6471-6477	severe	_	
37-21	6478-6484	sexual	_	
37-22	6485-6487	or	_	
37-23	6488-6496	physical	_	
37-24	6497-6502	abuse	_	
37-25	6502-6503	;	_	
37-26	6504-6505	C	_	
37-27	6505-6506	)	_	
37-28	6507-6515	maternal	_	
37-29	6516-6518	or	_	
37-30	6519-6527	paternal	_	
37-31	6528-6537	antipathy	_	
37-32	6538-6540	or	_	
37-33	6541-6548	neglect	_	
37-34	6548-6549	;	_	
37-35	6550-6551	D	_	
37-36	6551-6552	)	_	
37-37	6553-6557	more	_	
37-38	6558-6562	than	_	
37-39	6563-6566	two	_	
37-40	6567-6573	family	_	
37-41	6574-6586	arrangements	_	
37-42	6587-6588	(	_	
37-43	6588-6591	the	_	
37-44	6592-6598	number	_	
37-45	6599-6601	of	_	
37-46	6602-6611	different	_	
37-47	6612-6622	caregivers	_	
37-48	6623-6627	with	_	
37-49	6628-6632	each	_	
37-50	6633-6635	of	_	
37-51	6636-6640	whom	_	
37-52	6641-6644	the	_	
37-53	6645-6650	child	_	
37-54	6651-6656	lived	_	
37-55	6657-6660	for	_	
37-56	6661-6663	at	_	
37-57	6664-6669	least	_	
37-58	6670-6673	one	_	
37-59	6674-6678	year	_	
37-60	6678-6679	)	_	
37-61	6679-6680	.	_	

#Text=Each was rated as either present (exposure) or absent (no exposure).
38-1	6681-6685	Each	_	
38-2	6686-6689	was	_	
38-3	6690-6695	rated	_	
38-4	6696-6698	as	_	
38-5	6699-6705	either	_	
38-6	6706-6713	present	_	
38-7	6714-6715	(	_	
38-8	6715-6723	exposure	_	
38-9	6723-6724	)	_	
38-10	6725-6727	or	_	
38-11	6728-6734	absent	_	
38-12	6735-6736	(	_	
38-13	6736-6738	no	_	
38-14	6739-6747	exposure	_	
38-15	6747-6748	)	_	
38-16	6748-6749	.	_	

#Text=As only four participants reported being brought up in a children's home or institution, this event was excluded from the analysis.
#Text=18F-DOPA PET imaging
#Text=All subjects were studied using 18F-DOPA positron emission tomography (PET) imaging.
39-1	6750-6752	As	_	
39-2	6753-6757	only	_	
39-3	6758-6762	four	_	
39-4	6763-6775	participants	_	
39-5	6776-6784	reported	_	
39-6	6785-6790	being	_	
39-7	6791-6798	brought	_	
39-8	6799-6801	up	_	
39-9	6802-6804	in	_	
39-10	6805-6806	a	_	
39-11	6807-6817	children's	_	
39-12	6818-6822	home	_	
39-13	6823-6825	or	_	
39-14	6826-6837	institution	_	
39-15	6837-6838	,	_	
39-16	6839-6843	this	_	
39-17	6844-6849	event	_	
39-18	6850-6853	was	_	
39-19	6854-6862	excluded	_	
39-20	6863-6867	from	_	
39-21	6868-6871	the	_	
39-22	6872-6880	analysis	_	
39-23	6880-6881	.	_	
39-24	6882-6890	18F-DOPA	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[25]	
39-25	6891-6894	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[25]	
39-26	6895-6902	imaging	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[25]	
39-27	6903-6906	All	_	
39-28	6907-6915	subjects	_	
39-29	6916-6920	were	_	
39-30	6921-6928	studied	_	
39-31	6929-6934	using	_	
39-32	6935-6943	18F-DOPA	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[26]	
39-33	6944-6952	positron	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[26]	
39-34	6953-6961	emission	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[26]	
39-35	6962-6972	tomography	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[26]	
39-36	6973-6974	(	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[26]	
39-37	6974-6977	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[26]	
39-38	6977-6978	)	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[26]	
39-39	6979-6986	imaging	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[26]	
39-40	6986-6987	.	_	

#Text=Data were acquired on either a CTI/Siemens ECAT HR + 962 tomograph (11 healthy volunteers; 28 UHR) or a CTI/Siemens ECAT HR ++ 966 tomograph (9 healthy volunteers; 19 UHR) (Siemens Molecular Imaging, Knoxville, TN, U.S.A.) as previously described.
40-1	6988-6992	Data	_	
40-2	6993-6997	were	_	
40-3	6998-7006	acquired	_	
40-4	7007-7009	on	_	
40-5	7010-7016	either	_	
40-6	7017-7018	a	_	
40-7	7019-7022	CTI	_	
40-8	7022-7023	/	_	
40-9	7023-7030	Siemens	_	
40-10	7031-7035	ECAT	_	
40-11	7036-7038	HR	_	
40-12	7038-7039	 	_	
40-13	7039-7040	+	_	
40-14	7041-7044	962	_	
40-15	7045-7054	tomograph	_	
40-16	7055-7056	(	_	
40-17	7056-7058	11	_	
40-18	7059-7066	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[27]	
40-19	7067-7077	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[27]	
40-20	7077-7078	;	_	
40-21	7079-7081	28	_	
40-22	7082-7085	UHR	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[28]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[29]	
40-23	7085-7086	)	_	
40-24	7087-7089	or	_	
40-25	7090-7091	a	_	
40-26	7092-7095	CTI	_	
40-27	7095-7096	/	_	
40-28	7096-7103	Siemens	_	
40-29	7104-7108	ECAT	_	
40-30	7109-7111	HR	_	
40-31	7111-7112	 	_	
40-32	7112-7113	+	_	
40-33	7113-7114	+	_	
40-34	7115-7118	966	_	
40-35	7119-7128	tomograph	_	
40-36	7129-7130	(	_	
40-37	7130-7131	9	_	
40-38	7132-7139	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[30]	
40-39	7140-7150	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[30]	
40-40	7150-7151	;	_	
40-41	7152-7154	19	_	
40-42	7155-7158	UHR	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[31]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[32]	
40-43	7158-7159	)	_	
40-44	7160-7161	(	_	
40-45	7161-7168	Siemens	_	
40-46	7169-7178	Molecular	_	
40-47	7179-7186	Imaging	_	
40-48	7186-7187	,	_	
40-49	7188-7197	Knoxville	_	
40-50	7197-7198	,	_	
40-51	7199-7201	TN	_	
40-52	7201-7202	,	_	
40-53	7203-7208	U.S.A	_	
40-54	7208-7209	.	_	
40-55	7209-7210	)	_	
40-56	7211-7213	as	_	
40-57	7214-7224	previously	_	
40-58	7225-7234	described	_	
40-59	7234-7235	.	_	

#Text=Study participants were asked to fast for 12 h before imaging.
41-1	7236-7241	Study	_	
41-2	7242-7254	participants	_	
41-3	7255-7259	were	_	
41-4	7260-7265	asked	_	
41-5	7266-7268	to	_	
41-6	7269-7273	fast	_	
41-7	7274-7277	for	_	
41-8	7278-7280	12	_	
41-9	7280-7281	 	_	
41-10	7281-7282	h	_	
41-11	7283-7289	before	_	
41-12	7290-7297	imaging	_	
41-13	7297-7298	.	_	

#Text=Urine drug screens on the morning of the scan to confirmed absence of illicit substance use.
42-1	7299-7304	Urine	_	
42-2	7305-7309	drug	_	
42-3	7310-7317	screens	_	
42-4	7318-7320	on	_	
42-5	7321-7324	the	_	
42-6	7325-7332	morning	_	
42-7	7333-7335	of	_	
42-8	7336-7339	the	_	
42-9	7340-7344	scan	_	
42-10	7345-7347	to	_	
42-11	7348-7357	confirmed	_	
42-12	7358-7365	absence	_	
42-13	7366-7368	of	_	
42-14	7369-7376	illicit	_	
42-15	7377-7386	substance	_	
42-16	7387-7390	use	_	
42-17	7390-7391	.	_	

#Text=All subjects received carbidopa (150 mg) and entacapone (400 mg) orally 1 h before imaging to reduce the formation of radiolabeled 18F-DOPA metabolites.
43-1	7392-7395	All	_	
43-2	7396-7404	subjects	_	
43-3	7405-7413	received	_	
43-4	7414-7423	carbidopa	_	
43-5	7424-7425	(	_	
43-6	7425-7428	150	_	
43-7	7428-7429	 	_	
43-8	7429-7431	mg	_	
43-9	7431-7432	)	_	
43-10	7433-7436	and	_	
43-11	7437-7447	entacapone	_	
43-12	7448-7449	(	_	
43-13	7449-7452	400	_	
43-14	7452-7453	 	_	
43-15	7453-7455	mg	_	
43-16	7455-7456	)	_	
43-17	7457-7463	orally	_	
43-18	7464-7465	1	_	
43-19	7465-7466	 	_	
43-20	7466-7467	h	_	
43-21	7468-7474	before	_	
43-22	7475-7482	imaging	_	
43-23	7483-7485	to	_	
43-24	7486-7492	reduce	_	
43-25	7493-7496	the	_	
43-26	7497-7506	formation	_	
43-27	7507-7509	of	_	
43-28	7510-7522	radiolabeled	_	
43-29	7523-7531	18F-DOPA	_	
43-30	7532-7543	metabolites	_	
43-31	7543-7544	.	_	

#Text=All data were acquired in three-dimensional mode.
44-1	7545-7548	All	_	
44-2	7549-7553	data	_	
44-3	7554-7558	were	_	
44-4	7559-7567	acquired	_	
44-5	7568-7570	in	_	
44-6	7571-7588	three-dimensional	_	
44-7	7589-7593	mode	_	
44-8	7593-7594	.	_	

#Text=A 10-minute (ECAT HR + 962) or 5-minute (ECAT HR + 966) transmission scan was performed before radiotracer injection to correct for attenuation and scatter.
45-1	7595-7596	A	_	
45-2	7597-7599	10	_	
45-3	7599-7600	-	_	
45-4	7600-7606	minute	_	
45-5	7607-7608	(	_	
45-6	7608-7612	ECAT	_	
45-7	7613-7615	HR	_	
45-8	7615-7616	 	_	
45-9	7616-7617	+	_	
45-10	7617-7618	 	_	
45-11	7618-7621	962	_	
45-12	7621-7622	)	_	
45-13	7623-7625	or	_	
45-14	7626-7627	5	_	
45-15	7627-7628	-	_	
45-16	7628-7634	minute	_	
45-17	7635-7636	(	_	
45-18	7636-7640	ECAT	_	
45-19	7641-7643	HR	_	
45-20	7643-7644	 	_	
45-21	7644-7645	+	_	
45-22	7646-7649	966	_	
45-23	7649-7650	)	_	
45-24	7651-7663	transmission	_	
45-25	7664-7668	scan	_	
45-26	7669-7672	was	_	
45-27	7673-7682	performed	_	
45-28	7683-7689	before	_	
45-29	7690-7701	radiotracer	_	
45-30	7702-7711	injection	_	
45-31	7712-7714	to	_	
45-32	7715-7722	correct	_	
45-33	7723-7726	for	_	
45-34	7727-7738	attenuation	_	
45-35	7739-7742	and	_	
45-36	7743-7750	scatter	_	
45-37	7750-7751	.	_	

#Text=Thirty seconds after the start of PET image acquisition, 180 Mbq (ECAT HR + 962) or 150 MBq (ECAT HR + 966) 18F-DOPA (± 10%) was administered by bolus intravenous injection.
46-1	7752-7758	Thirty	_	
46-2	7759-7766	seconds	_	
46-3	7767-7772	after	_	
46-4	7773-7776	the	_	
46-5	7777-7782	start	_	
46-6	7783-7785	of	_	
46-7	7786-7789	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[33]	
46-8	7790-7795	image	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[33]	
46-9	7796-7807	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[33]	
46-10	7807-7808	,	_	
46-11	7809-7812	180	_	
46-12	7812-7813	 	_	
46-13	7813-7816	Mbq	_	
46-14	7817-7818	(	_	
46-15	7818-7822	ECAT	_	
46-16	7823-7825	HR	_	
46-17	7825-7826	 	_	
46-18	7826-7827	+	_	
46-19	7828-7831	962	_	
46-20	7831-7832	)	_	
46-21	7833-7835	or	_	
46-22	7836-7839	150	_	
46-23	7839-7840	 	_	
46-24	7840-7843	MBq	_	
46-25	7844-7845	(	_	
46-26	7845-7849	ECAT	_	
46-27	7850-7852	HR	_	
46-28	7852-7853	 	_	
46-29	7853-7854	+	_	
46-30	7855-7858	966	_	
46-31	7858-7859	)	_	
46-32	7860-7868	18F-DOPA	_	
46-33	7869-7870	(	_	
46-34	7870-7871	±	_	
46-35	7871-7872	 	_	
46-36	7872-7875	10%	_	
46-37	7875-7876	)	_	
46-38	7877-7880	was	_	
46-39	7881-7893	administered	_	
46-40	7894-7896	by	_	
46-41	7897-7902	bolus	_	
46-42	7903-7914	intravenous	_	
46-43	7915-7924	injection	_	
46-44	7924-7925	.	_	

#Text=On both scanners, emission data were acquired in list mode for 95 min, and rebinned into 26 time frames.
47-1	7926-7928	On	_	
47-2	7929-7933	both	_	
47-3	7934-7942	scanners	_	
47-4	7942-7943	,	_	
47-5	7944-7952	emission	_	
47-6	7953-7957	data	_	
47-7	7958-7962	were	_	
47-8	7963-7971	acquired	_	
47-9	7972-7974	in	_	
47-10	7975-7979	list	_	
47-11	7980-7984	mode	_	
47-12	7985-7988	for	_	
47-13	7989-7991	95	_	
47-14	7991-7992	 	_	
47-15	7992-7995	min	_	
47-16	7995-7996	,	_	
47-17	7997-8000	and	_	
47-18	8001-8009	rebinned	_	
47-19	8010-8014	into	_	
47-20	8015-8017	26	_	
47-21	8018-8022	time	_	
47-22	8023-8029	frames	_	
47-23	8029-8030	.	_	

#Text=Data were reconstructed using the 3D reprojection algorithms.
48-1	8031-8035	Data	_	
48-2	8036-8040	were	_	
48-3	8041-8054	reconstructed	_	
48-4	8055-8060	using	_	
48-5	8061-8064	the	_	
48-6	8065-8067	3D	_	
48-7	8068-8080	reprojection	_	
48-8	8081-8091	algorithms	_	
48-9	8091-8092	.	_	

#Text=Head movement was corrected for by realigning denoised, nonattenuation-corrected dynamic images and applying the transformation parameters to the corresponding attenuation-corrected frames to create a movement-corrected dynamic image for analysis.
49-1	8093-8097	Head	_	
49-2	8098-8106	movement	_	
49-3	8107-8110	was	_	
49-4	8111-8120	corrected	_	
49-5	8121-8124	for	_	
49-6	8125-8127	by	_	
49-7	8128-8138	realigning	_	
49-8	8139-8147	denoised	_	
49-9	8147-8148	,	_	
49-10	8149-8173	nonattenuation-corrected	_	
49-11	8174-8181	dynamic	_	
49-12	8182-8188	images	_	
49-13	8189-8192	and	_	
49-14	8193-8201	applying	_	
49-15	8202-8205	the	_	
49-16	8206-8220	transformation	_	
49-17	8221-8231	parameters	_	
49-18	8232-8234	to	_	
49-19	8235-8238	the	_	
49-20	8239-8252	corresponding	_	
49-21	8253-8274	attenuation-corrected	_	
49-22	8275-8281	frames	_	
49-23	8282-8284	to	_	
49-24	8285-8291	create	_	
49-25	8292-8293	a	_	
49-26	8294-8312	movement-corrected	_	
49-27	8313-8320	dynamic	_	
49-28	8321-8326	image	_	
49-29	8327-8330	for	_	
49-30	8331-8339	analysis	_	
49-31	8339-8340	.	_	

#Text=Standardized striatal volumes of interest (VOI) were delineated bilaterally on a single subject T1 magnetic resonance image in Montreal Neurologic Institute (MNI) space.
50-1	8341-8353	Standardized	_	
50-2	8354-8362	striatal	_	
50-3	8363-8370	volumes	_	
50-4	8371-8373	of	_	
50-5	8374-8382	interest	_	
50-6	8383-8384	(	_	
50-7	8384-8387	VOI	_	
50-8	8387-8388	)	_	
50-9	8389-8393	were	_	
50-10	8394-8404	delineated	_	
50-11	8405-8416	bilaterally	_	
50-12	8417-8419	on	_	
50-13	8420-8421	a	_	
50-14	8422-8428	single	_	
50-15	8429-8436	subject	_	
50-16	8437-8439	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
50-17	8440-8448	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
50-18	8449-8458	resonance	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
50-19	8459-8464	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
50-20	8465-8467	in	_	
50-21	8468-8476	Montreal	_	
50-22	8477-8487	Neurologic	_	
50-23	8488-8497	Institute	_	
50-24	8498-8499	(	_	
50-25	8499-8502	MNI	_	
50-26	8502-8503	)	_	
50-27	8504-8509	space	_	
50-28	8509-8510	.	_	

#Text=These VOI included the limbic (ventral), associative and sensorimotor subdivisions of the striatum, as according to previously defined anatomical criteria.
51-1	8511-8516	These	_	
51-2	8517-8520	VOI	_	
51-3	8521-8529	included	_	
51-4	8530-8533	the	_	
51-5	8534-8540	limbic	_	
51-6	8541-8542	(	_	
51-7	8542-8549	ventral	_	
51-8	8549-8550	)	_	
51-9	8550-8551	,	_	
51-10	8552-8563	associative	_	
51-11	8564-8567	and	_	
51-12	8568-8580	sensorimotor	_	
51-13	8581-8593	subdivisions	_	
51-14	8594-8596	of	_	
51-15	8597-8600	the	_	
51-16	8601-8609	striatum	_	
51-17	8609-8610	,	_	
51-18	8611-8613	as	_	
51-19	8614-8623	according	_	
51-20	8624-8626	to	_	
51-21	8627-8637	previously	_	
51-22	8638-8645	defined	_	
51-23	8646-8656	anatomical	_	
51-24	8657-8665	criteria	_	
51-25	8665-8666	.	_	

#Text=The cerebellar reference region was defined using a probabilistic atlas.
52-1	8667-8670	The	_	
52-2	8671-8681	cerebellar	_	
52-3	8682-8691	reference	_	
52-4	8692-8698	region	_	
52-5	8699-8702	was	_	
52-6	8703-8710	defined	_	
52-7	8711-8716	using	_	
52-8	8717-8718	a	_	
52-9	8719-8732	probabilistic	_	
52-10	8733-8738	atlas	_	
52-11	8738-8739	.	_	

#Text=An 18F-DOPA template, also in MNI space, was then normalized together with the VOI map to each individual PET summation image using SPM5 (http://fil.ion.ucl.ac.uk/spm; Wellcome Department of Imaging Neuroscience, University College London).
53-1	8740-8742	An	_	
53-2	8743-8751	18F-DOPA	_	
53-3	8752-8760	template	_	
53-4	8760-8761	,	_	
53-5	8762-8766	also	_	
53-6	8767-8769	in	_	
53-7	8770-8773	MNI	_	
53-8	8774-8779	space	_	
53-9	8779-8780	,	_	
53-10	8781-8784	was	_	
53-11	8785-8789	then	_	
53-12	8790-8800	normalized	_	
53-13	8801-8809	together	_	
53-14	8810-8814	with	_	
53-15	8815-8818	the	_	
53-16	8819-8822	VOI	_	
53-17	8823-8826	map	_	
53-18	8827-8829	to	_	
53-19	8830-8834	each	_	
53-20	8835-8845	individual	_	
53-21	8846-8849	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography	
53-22	8850-8859	summation	_	
53-23	8860-8865	image	_	
53-24	8866-8871	using	_	
53-25	8872-8876	SPM5	_	
53-26	8877-8878	(	_	
53-27	8878-8882	http	_	
53-28	8882-8883	:	_	
53-29	8883-8884	/	_	
53-30	8884-8885	/	_	
53-31	8885-8902	fil.ion.ucl.ac.uk	_	
53-32	8902-8903	/	_	
53-33	8903-8906	spm	_	
53-34	8906-8907	;	_	
53-35	8908-8916	Wellcome	_	
53-36	8917-8927	Department	_	
53-37	8928-8930	of	_	
53-38	8931-8938	Imaging	_	
53-39	8939-8951	Neuroscience	_	
53-40	8951-8952	,	_	
53-41	8953-8963	University	_	
53-42	8964-8971	College	_	
53-43	8972-8978	London	_	
53-44	8978-8979	)	_	
53-45	8979-8980	.	_	

#Text=Graphical analysis, adapted for a reference tissue input function as used to estimate presynaptic dopamine synthesis capacity by calculating the rate of utilization of the dopamine precursor 18F-DOPA in the bilateral striatum, relative to the cerebellar reference tissue (kicer min− 1).
54-1	8981-8990	Graphical	_	
54-2	8991-8999	analysis	_	
54-3	8999-9000	,	_	
54-4	9001-9008	adapted	_	
54-5	9009-9012	for	_	
54-6	9013-9014	a	_	
54-7	9015-9024	reference	_	
54-8	9025-9031	tissue	_	
54-9	9032-9037	input	_	
54-10	9038-9046	function	_	
54-11	9047-9049	as	_	
54-12	9050-9054	used	_	
54-13	9055-9057	to	_	
54-14	9058-9066	estimate	_	
54-15	9067-9078	presynaptic	_	
54-16	9079-9087	dopamine	_	
54-17	9088-9097	synthesis	_	
54-18	9098-9106	capacity	_	
54-19	9107-9109	by	_	
54-20	9110-9121	calculating	_	
54-21	9122-9125	the	_	
54-22	9126-9130	rate	_	
54-23	9131-9133	of	_	
54-24	9134-9145	utilization	_	
54-25	9146-9148	of	_	
54-26	9149-9152	the	_	
54-27	9153-9161	dopamine	_	
54-28	9162-9171	precursor	_	
54-29	9172-9180	18F-DOPA	_	
54-30	9181-9183	in	_	
54-31	9184-9187	the	_	
54-32	9188-9197	bilateral	_	
54-33	9198-9206	striatum	_	
54-34	9206-9207	,	_	
54-35	9208-9216	relative	_	
54-36	9217-9219	to	_	
54-37	9220-9223	the	_	
54-38	9224-9234	cerebellar	_	
54-39	9235-9244	reference	_	
54-40	9245-9251	tissue	_	
54-41	9252-9253	(	_	
54-42	9253-9258	kicer	_	
54-43	9258-9259	 	_	
54-44	9259-9262	min	_	
54-45	9262-9263	−	_	
54-46	9263-9264	 	_	
54-47	9264-9265	1	_	
54-48	9265-9266	)	_	
54-49	9266-9267	.	_	

#Text=To control for effects of scanner model, individual subject kicer values were converted to z-scores (z = (kicer – scanner mean kicer)/scanner standard deviation (SD)) for all analyses.
55-1	9268-9270	To	_	
55-2	9271-9278	control	_	
55-3	9279-9282	for	_	
55-4	9283-9290	effects	_	
55-5	9291-9293	of	_	
55-6	9294-9301	scanner	_	
55-7	9302-9307	model	_	
55-8	9307-9308	,	_	
55-9	9309-9319	individual	_	
55-10	9320-9327	subject	_	
55-11	9328-9333	kicer	_	
55-12	9334-9340	values	_	
55-13	9341-9345	were	_	
55-14	9346-9355	converted	_	
55-15	9356-9358	to	_	
55-16	9359-9367	z-scores	_	
55-17	9368-9369	(	_	
55-18	9369-9370	z	_	
55-19	9370-9371	 	_	
55-20	9371-9372	=	_	
55-21	9372-9373	 	_	
55-22	9373-9374	(	_	
55-23	9374-9379	kicer	_	
55-24	9380-9381	–	_	
55-25	9382-9389	scanner	_	
55-26	9390-9394	mean	_	
55-27	9395-9400	kicer	_	
55-28	9400-9401	)	_	
55-29	9401-9402	/	_	
55-30	9402-9409	scanner	_	
55-31	9410-9418	standard	_	
55-32	9419-9428	deviation	_	
55-33	9429-9430	(	_	
55-34	9430-9432	SD	_	
55-35	9432-9433	)	_	
55-36	9433-9434	)	_	
55-37	9435-9438	for	_	
55-38	9439-9442	all	_	
55-39	9443-9451	analyses	_	
55-40	9451-9452	.	_	

#Text=Statistical analyses
#Text=Statistical analysis was performed in SPSS version 19.0 (IBM Corporation, Armonk, New York).
56-1	9453-9464	Statistical	_	
56-2	9465-9473	analyses	_	
56-3	9474-9485	Statistical	_	
56-4	9486-9494	analysis	_	
56-5	9495-9498	was	_	
56-6	9499-9508	performed	_	
56-7	9509-9511	in	_	
56-8	9512-9516	SPSS	_	
56-9	9517-9524	version	_	
56-10	9525-9529	19.0	_	
56-11	9530-9531	(	_	
56-12	9531-9534	IBM	_	
56-13	9535-9546	Corporation	_	
56-14	9546-9547	,	_	
56-15	9548-9554	Armonk	_	
56-16	9554-9555	,	_	
56-17	9556-9559	New	_	
56-18	9560-9564	York	_	
56-19	9564-9565	)	_	
56-20	9565-9566	.	_	

#Text=For demographic, clinical variables and measures of childhood adversity, comparisons between Control and UHR groups were performed using Fisher's Exact, Mann-Whitney U or unpaired t-tests.
57-1	9567-9570	For	_	
57-2	9571-9582	demographic	_	
57-3	9582-9583	,	_	
57-4	9584-9592	clinical	_	
57-5	9593-9602	variables	_	
57-6	9603-9606	and	_	
57-7	9607-9615	measures	_	
57-8	9616-9618	of	_	
57-9	9619-9628	childhood	_	
57-10	9629-9638	adversity	_	
57-11	9638-9639	,	_	
57-12	9640-9651	comparisons	_	
57-13	9652-9659	between	_	
57-14	9660-9667	Control	_	
57-15	9668-9671	and	_	
57-16	9672-9675	UHR	_	
57-17	9676-9682	groups	_	
57-18	9683-9687	were	_	
57-19	9688-9697	performed	_	
57-20	9698-9703	using	_	
57-21	9704-9712	Fisher's	_	
57-22	9713-9718	Exact	_	
57-23	9718-9719	,	_	
57-24	9720-9732	Mann-Whitney	_	
57-25	9733-9734	U	_	
57-26	9735-9737	or	_	
57-27	9738-9746	unpaired	_	
57-28	9747-9754	t-tests	_	
57-29	9754-9755	.	_	

#Text=The threshold for statistical significance of P < 0.05.
58-1	9756-9759	The	_	
58-2	9760-9769	threshold	_	
58-3	9770-9773	for	_	
58-4	9774-9785	statistical	_	
58-5	9786-9798	significance	_	
58-6	9799-9801	of	_	
58-7	9802-9803	P	_	
58-8	9803-9804	 	_	
58-9	9804-9805	<	_	
58-10	9805-9806	 	_	
58-11	9806-9810	0.05	_	
58-12	9810-9811	.	_	

#Text=The same approach was used to compare demographic and clinical variables in individuals exposed or not exposed to each type of childhood adversity.
59-1	9812-9815	The	_	
59-2	9816-9820	same	_	
59-3	9821-9829	approach	_	
59-4	9830-9833	was	_	
59-5	9834-9838	used	_	
59-6	9839-9841	to	_	
59-7	9842-9849	compare	_	
59-8	9850-9861	demographic	_	
59-9	9862-9865	and	_	
59-10	9866-9874	clinical	_	
59-11	9875-9884	variables	_	
59-12	9885-9887	in	_	
59-13	9888-9899	individuals	_	
59-14	9900-9907	exposed	_	
59-15	9908-9910	or	_	
59-16	9911-9914	not	_	
59-17	9915-9922	exposed	_	
59-18	9923-9925	to	_	
59-19	9926-9930	each	_	
59-20	9931-9935	type	_	
59-21	9936-9938	of	_	
59-22	9939-9948	childhood	_	
59-23	9949-9958	adversity	_	
59-24	9958-9959	.	_	

#Text=The impact of exposures to childhood adversity on striatal dopamine function were determined using independent samples t-tests (exposure versus non-exposure).
60-1	9960-9963	The	_	
60-2	9964-9970	impact	_	
60-3	9971-9973	of	_	
60-4	9974-9983	exposures	_	
60-5	9984-9986	to	_	
60-6	9987-9996	childhood	_	
60-7	9997-10006	adversity	_	
60-8	10007-10009	on	_	
60-9	10010-10018	striatal	_	
60-10	10019-10027	dopamine	_	
60-11	10028-10036	function	_	
60-12	10037-10041	were	_	
60-13	10042-10052	determined	_	
60-14	10053-10058	using	_	
60-15	10059-10070	independent	_	
60-16	10071-10078	samples	_	
60-17	10079-10086	t-tests	_	
60-18	10087-10088	(	_	
60-19	10088-10096	exposure	_	
60-20	10097-10103	versus	_	
60-21	10104-10116	non-exposure	_	
60-22	10116-10117	)	_	
60-23	10117-10118	.	_	

#Text=Effect size was calculated as Cohen's d.
61-1	10119-10125	Effect	_	
61-2	10126-10130	size	_	
61-3	10131-10134	was	_	
61-4	10135-10145	calculated	_	
61-5	10146-10148	as	_	
61-6	10149-10156	Cohen's	_	
61-7	10157-10158	d	_	
61-8	10158-10159	.	_	

#Text=Secondary analysis employed univariate ANOVA to explore potential influences of group (Control versus UHR) and substance use on the relationships between exposures to childhood adversity and dopamine function.
62-1	10160-10169	Secondary	_	
62-2	10170-10178	analysis	_	
62-3	10179-10187	employed	_	
62-4	10188-10198	univariate	_	
62-5	10199-10204	ANOVA	_	
62-6	10205-10207	to	_	
62-7	10208-10215	explore	_	
62-8	10216-10225	potential	_	
62-9	10226-10236	influences	_	
62-10	10237-10239	of	_	
62-11	10240-10245	group	_	
62-12	10246-10247	(	_	
62-13	10247-10254	Control	_	
62-14	10255-10261	versus	_	
62-15	10262-10265	UHR	_	
62-16	10265-10266	)	_	
62-17	10267-10270	and	_	
62-18	10271-10280	substance	_	
62-19	10281-10284	use	_	
62-20	10285-10287	on	_	
62-21	10288-10291	the	_	
62-22	10292-10305	relationships	_	
62-23	10306-10313	between	_	
62-24	10314-10323	exposures	_	
62-25	10324-10326	to	_	
62-26	10327-10336	childhood	_	
62-27	10337-10346	adversity	_	
62-28	10347-10350	and	_	
62-29	10351-10359	dopamine	_	
62-30	10360-10368	function	_	
62-31	10368-10369	.	_	

#Text=After confirming normality of distribution, relationships between the severity of total prodromal symptoms (total CAARMS score) in the UHR group and striatal dopamine function (z-score) were explored Pearson's correlation coefficient.
63-1	10370-10375	After	_	
63-2	10376-10386	confirming	_	
63-3	10387-10396	normality	_	
63-4	10397-10399	of	_	
63-5	10400-10412	distribution	_	
63-6	10412-10413	,	_	
63-7	10414-10427	relationships	_	
63-8	10428-10435	between	_	
63-9	10436-10439	the	_	
63-10	10440-10448	severity	_	
63-11	10449-10451	of	_	
63-12	10452-10457	total	_	
63-13	10458-10467	prodromal	_	
63-14	10468-10476	symptoms	_	
63-15	10477-10478	(	_	
63-16	10478-10483	total	_	
63-17	10484-10490	CAARMS	_	
63-18	10491-10496	score	_	
63-19	10496-10497	)	_	
63-20	10498-10500	in	_	
63-21	10501-10504	the	_	
63-22	10505-10508	UHR	_	
63-23	10509-10514	group	_	
63-24	10515-10518	and	_	
63-25	10519-10527	striatal	_	
63-26	10528-10536	dopamine	_	
63-27	10537-10545	function	_	
63-28	10546-10547	(	_	
63-29	10547-10554	z-score	_	
63-30	10554-10555	)	_	
63-31	10556-10560	were	_	
63-32	10561-10569	explored	_	
63-33	10570-10579	Pearson's	_	
63-34	10580-10591	correlation	_	
63-35	10592-10603	coefficient	_	
63-36	10603-10604	.	_	

#Text=Results
#Text=Description of the UHR and control samples
#Text=There were no significant differences between the UHR and Control groups in demographic features or substance use (Table 1).
64-1	10605-10612	Results	_	
64-2	10613-10624	Description	_	
64-3	10625-10627	of	_	
64-4	10628-10631	the	_	
64-5	10632-10635	UHR	_	
64-6	10636-10639	and	_	
64-7	10640-10647	control	_	
64-8	10648-10655	samples	_	
64-9	10656-10661	There	_	
64-10	10662-10666	were	_	
64-11	10667-10669	no	_	
64-12	10670-10681	significant	_	
64-13	10682-10693	differences	_	
64-14	10694-10701	between	_	
64-15	10702-10705	the	_	
64-16	10706-10709	UHR	_	
64-17	10710-10713	and	_	
64-18	10714-10721	Control	_	
64-19	10722-10728	groups	_	
64-20	10729-10731	in	_	
64-21	10732-10743	demographic	_	
64-22	10744-10752	features	_	
64-23	10753-10755	or	_	
64-24	10756-10765	substance	_	
64-25	10766-10769	use	_	
64-26	10770-10771	(	_	
64-27	10771-10776	Table	_	
64-28	10777-10778	1	_	
64-29	10778-10779	)	_	
64-30	10779-10780	.	_	

#Text=As expected, all symptom scores were significantly higher in the UHR group (Table 1).
65-1	10781-10783	As	_	
65-2	10784-10792	expected	_	
65-3	10792-10793	,	_	
65-4	10794-10797	all	_	
65-5	10798-10805	symptom	_	
65-6	10806-10812	scores	_	
65-7	10813-10817	were	_	
65-8	10818-10831	significantly	_	
65-9	10832-10838	higher	_	
65-10	10839-10841	in	_	
65-11	10842-10845	the	_	
65-12	10846-10849	UHR	_	
65-13	10850-10855	group	_	
65-14	10856-10857	(	_	
65-15	10857-10862	Table	_	
65-16	10863-10864	1	_	
65-17	10864-10865	)	_	
65-18	10865-10866	.	_	

#Text=Two of the UHR participants were taking antipsychotic medication (olanzapine, 7.5 mg; quetiapine, 25 mg).
66-1	10867-10870	Two	_	
66-2	10871-10873	of	_	
66-3	10874-10877	the	_	
66-4	10878-10881	UHR	_	
66-5	10882-10894	participants	_	
66-6	10895-10899	were	_	
66-7	10900-10906	taking	_	
66-8	10907-10920	antipsychotic	_	
66-9	10921-10931	medication	_	
66-10	10932-10933	(	_	
66-11	10933-10943	olanzapine	_	
66-12	10943-10944	,	_	
66-13	10945-10948	7.5	_	
66-14	10948-10949	 	_	
66-15	10949-10951	mg	_	
66-16	10951-10952	;	_	
66-17	10953-10963	quetiapine	_	
66-18	10963-10964	,	_	
66-19	10965-10967	25	_	
66-20	10967-10968	 	_	
66-21	10968-10970	mg	_	
66-22	10970-10971	)	_	
66-23	10971-10972	.	_	

#Text=Experiences of childhood adversity
#Text=Within the total sample, the proportion of participants reporting each type of childhood adversity ranged from 25% for more than two family arrangements, to 62% for parental loss or separation (Table 2).
67-1	10973-10984	Experiences	_	
67-2	10985-10987	of	_	
67-3	10988-10997	childhood	_	
67-4	10998-11007	adversity	_	
67-5	11008-11014	Within	_	
67-6	11015-11018	the	_	
67-7	11019-11024	total	_	
67-8	11025-11031	sample	_	
67-9	11031-11032	,	_	
67-10	11033-11036	the	_	
67-11	11037-11047	proportion	_	
67-12	11048-11050	of	_	
67-13	11051-11063	participants	_	
67-14	11064-11073	reporting	_	
67-15	11074-11078	each	_	
67-16	11079-11083	type	_	
67-17	11084-11086	of	_	
67-18	11087-11096	childhood	_	
67-19	11097-11106	adversity	_	
67-20	11107-11113	ranged	_	
67-21	11114-11118	from	_	
67-22	11119-11122	25%	_	
67-23	11123-11126	for	_	
67-24	11127-11131	more	_	
67-25	11132-11136	than	_	
67-26	11137-11140	two	_	
67-27	11141-11147	family	_	
67-28	11148-11160	arrangements	_	
67-29	11160-11161	,	_	
67-30	11162-11164	to	_	
67-31	11165-11168	62%	_	
67-32	11169-11172	for	_	
67-33	11173-11181	parental	_	
67-34	11182-11186	loss	_	
67-35	11187-11189	or	_	
67-36	11190-11200	separation	_	
67-37	11201-11202	(	_	
67-38	11202-11207	Table	_	
67-39	11208-11209	2	_	
67-40	11209-11210	)	_	
67-41	11210-11211	.	_	

#Text=Within the total sample, there were no differences in demographic measures or reported substance misuse between participants who reported exposure to each type of childhood adversity and participants who did not (Supplementary Table S1).
68-1	11212-11218	Within	_	
68-2	11219-11222	the	_	
68-3	11223-11228	total	_	
68-4	11229-11235	sample	_	
68-5	11235-11236	,	_	
68-6	11237-11242	there	_	
68-7	11243-11247	were	_	
68-8	11248-11250	no	_	
68-9	11251-11262	differences	_	
68-10	11263-11265	in	_	
68-11	11266-11277	demographic	_	
68-12	11278-11286	measures	_	
68-13	11287-11289	or	_	
68-14	11290-11298	reported	_	
68-15	11299-11308	substance	_	
68-16	11309-11315	misuse	_	
68-17	11316-11323	between	_	
68-18	11324-11336	participants	_	
68-19	11337-11340	who	_	
68-20	11341-11349	reported	_	
68-21	11350-11358	exposure	_	
68-22	11359-11361	to	_	
68-23	11362-11366	each	_	
68-24	11367-11371	type	_	
68-25	11372-11374	of	_	
68-26	11375-11384	childhood	_	
68-27	11385-11394	adversity	_	
68-28	11395-11398	and	_	
68-29	11399-11411	participants	_	
68-30	11412-11415	who	_	
68-31	11416-11419	did	_	
68-32	11420-11423	not	_	
68-33	11424-11425	(	_	
68-34	11425-11438	Supplementary	_	
68-35	11439-11444	Table	_	
68-36	11445-11447	S1	_	
68-37	11447-11448	)	_	
68-38	11448-11449	.	_	

#Text=Presynaptic dopamine function following childhood adversity
#Text=In the associative striatum, dopamine function was significantly higher in participants who had experienced severe physical or sexual abuse in childhood compared to those who had not (T63 = 2.92; P = 0.005; Table 3; Fig. 1, left).
69-1	11450-11461	Presynaptic	_	
69-2	11462-11470	dopamine	_	
69-3	11471-11479	function	_	
69-4	11480-11489	following	_	
69-5	11490-11499	childhood	_	
69-6	11500-11509	adversity	_	
69-7	11510-11512	In	_	
69-8	11513-11516	the	_	
69-9	11517-11528	associative	_	
69-10	11529-11537	striatum	_	
69-11	11537-11538	,	_	
69-12	11539-11547	dopamine	_	
69-13	11548-11556	function	_	
69-14	11557-11560	was	_	
69-15	11561-11574	significantly	_	
69-16	11575-11581	higher	_	
69-17	11582-11584	in	_	
69-18	11585-11597	participants	_	
69-19	11598-11601	who	_	
69-20	11602-11605	had	_	
69-21	11606-11617	experienced	_	
69-22	11618-11624	severe	_	
69-23	11625-11633	physical	_	
69-24	11634-11636	or	_	
69-25	11637-11643	sexual	_	
69-26	11644-11649	abuse	_	
69-27	11650-11652	in	_	
69-28	11653-11662	childhood	_	
69-29	11663-11671	compared	_	
69-30	11672-11674	to	_	
69-31	11675-11680	those	_	
69-32	11681-11684	who	_	
69-33	11685-11688	had	_	
69-34	11689-11692	not	_	
69-35	11693-11694	(	_	
69-36	11694-11697	T63	_	
69-37	11697-11698	 	_	
69-38	11698-11699	=	_	
69-39	11699-11700	 	_	
69-40	11700-11704	2.92	_	
69-41	11704-11705	;	_	
69-42	11706-11707	P	_	
69-43	11707-11708	 	_	
69-44	11708-11709	=	_	
69-45	11709-11710	 	_	
69-46	11710-11715	0.005	_	
69-47	11715-11716	;	_	
69-48	11717-11722	Table	_	
69-49	11723-11724	3	_	
69-50	11724-11725	;	_	
69-51	11726-11729	Fig	_	
69-52	11729-11730	.	_	
69-53	11731-11732	1	_	
69-54	11732-11733	,	_	
69-55	11734-11738	left	_	
69-56	11738-11739	)	_	
69-57	11739-11740	.	_	

#Text=Dopamine function in this region was also elevated in participants who had experienced more than two family arrangements compared to those who had not (T57 = 2.80; P = 0.007; Table 3; Fig. 1, right).
70-1	11741-11749	Dopamine	_	
70-2	11750-11758	function	_	
70-3	11759-11761	in	_	
70-4	11762-11766	this	_	
70-5	11767-11773	region	_	
70-6	11774-11777	was	_	
70-7	11778-11782	also	_	
70-8	11783-11791	elevated	_	
70-9	11792-11794	in	_	
70-10	11795-11807	participants	_	
70-11	11808-11811	who	_	
70-12	11812-11815	had	_	
70-13	11816-11827	experienced	_	
70-14	11828-11832	more	_	
70-15	11833-11837	than	_	
70-16	11838-11841	two	_	
70-17	11842-11848	family	_	
70-18	11849-11861	arrangements	_	
70-19	11862-11870	compared	_	
70-20	11871-11873	to	_	
70-21	11874-11879	those	_	
70-22	11880-11883	who	_	
70-23	11884-11887	had	_	
70-24	11888-11891	not	_	
70-25	11892-11893	(	_	
70-26	11893-11896	T57	_	
70-27	11896-11897	 	_	
70-28	11897-11898	=	_	
70-29	11898-11899	 	_	
70-30	11899-11903	2.80	_	
70-31	11903-11904	;	_	
70-32	11905-11906	P	_	
70-33	11906-11907	 	_	
70-34	11907-11908	=	_	
70-35	11908-11909	 	_	
70-36	11909-11914	0.007	_	
70-37	11914-11915	;	_	
70-38	11916-11921	Table	_	
70-39	11922-11923	3	_	
70-40	11923-11924	;	_	
70-41	11925-11928	Fig	_	
70-42	11928-11929	.	_	
70-43	11930-11931	1	_	
70-44	11931-11932	,	_	
70-45	11933-11938	right	_	
70-46	11938-11939	)	_	
70-47	11939-11940	.	_	

#Text=Both of these findings were associated with medium to large effect sizes (Cohen's d = 0.75 and 0.86 respectively).
71-1	11941-11945	Both	_	
71-2	11946-11948	of	_	
71-3	11949-11954	these	_	
71-4	11955-11963	findings	_	
71-5	11964-11968	were	_	
71-6	11969-11979	associated	_	
71-7	11980-11984	with	_	
71-8	11985-11991	medium	_	
71-9	11992-11994	to	_	
71-10	11995-12000	large	_	
71-11	12001-12007	effect	_	
71-12	12008-12013	sizes	_	
71-13	12014-12015	(	_	
71-14	12015-12022	Cohen's	_	
71-15	12023-12024	d	_	
71-16	12024-12025	 	_	
71-17	12025-12026	=	_	
71-18	12026-12027	 	_	
71-19	12027-12031	0.75	_	
71-20	12032-12035	and	_	
71-21	12036-12040	0.86	_	
71-22	12041-12053	respectively	_	
71-23	12053-12054	)	_	
71-24	12054-12055	.	_	

#Text=Overall, of the twenty-six participants who reported sexual or physical abuse, eight also reported multiple family arrangements.
72-1	12056-12063	Overall	_	
72-2	12063-12064	,	_	
72-3	12065-12067	of	_	
72-4	12068-12071	the	_	
72-5	12072-12082	twenty-six	_	
72-6	12083-12095	participants	_	
72-7	12096-12099	who	_	
72-8	12100-12108	reported	_	
72-9	12109-12115	sexual	_	
72-10	12116-12118	or	_	
72-11	12119-12127	physical	_	
72-12	12128-12133	abuse	_	
72-13	12133-12134	,	_	
72-14	12135-12140	eight	_	
72-15	12141-12145	also	_	
72-16	12146-12154	reported	_	
72-17	12155-12163	multiple	_	
72-18	12164-12170	family	_	
72-19	12171-12183	arrangements	_	
72-20	12183-12184	.	_	

#Text=When both physical/sexual abuse and multiple family arrangements were included in the same model, the effect of multiple family arrangements remained significant (F1,58 = 5.96; P = 0.018), while the effect of sexual/physical abuse approached significance (F1,58 = 3.50; P = 0.067).
73-1	12185-12189	When	_	
73-2	12190-12194	both	_	
73-3	12195-12203	physical	_	
73-4	12203-12204	/	_	
73-5	12204-12210	sexual	_	
73-6	12211-12216	abuse	_	
73-7	12217-12220	and	_	
73-8	12221-12229	multiple	_	
73-9	12230-12236	family	_	
73-10	12237-12249	arrangements	_	
73-11	12250-12254	were	_	
73-12	12255-12263	included	_	
73-13	12264-12266	in	_	
73-14	12267-12270	the	_	
73-15	12271-12275	same	_	
73-16	12276-12281	model	_	
73-17	12281-12282	,	_	
73-18	12283-12286	the	_	
73-19	12287-12293	effect	_	
73-20	12294-12296	of	_	
73-21	12297-12305	multiple	_	
73-22	12306-12312	family	_	
73-23	12313-12325	arrangements	_	
73-24	12326-12334	remained	_	
73-25	12335-12346	significant	_	
73-26	12347-12348	(	_	
73-27	12348-12353	F1,58	_	
73-28	12353-12354	 	_	
73-29	12354-12355	=	_	
73-30	12355-12356	 	_	
73-31	12356-12360	5.96	_	
73-32	12360-12361	;	_	
73-33	12362-12363	P	_	
73-34	12363-12364	 	_	
73-35	12364-12365	=	_	
73-36	12365-12366	 	_	
73-37	12366-12371	0.018	_	
73-38	12371-12372	)	_	
73-39	12372-12373	,	_	
73-40	12374-12379	while	_	
73-41	12380-12383	the	_	
73-42	12384-12390	effect	_	
73-43	12391-12393	of	_	
73-44	12394-12400	sexual	_	
73-45	12400-12401	/	_	
73-46	12401-12409	physical	_	
73-47	12410-12415	abuse	_	
73-48	12416-12426	approached	_	
73-49	12427-12439	significance	_	
73-50	12440-12441	(	_	
73-51	12441-12446	F1,58	_	
73-52	12446-12447	 	_	
73-53	12447-12448	=	_	
73-54	12448-12449	 	_	
73-55	12449-12453	3.50	_	
73-56	12453-12454	;	_	
73-57	12455-12456	P	_	
73-58	12456-12457	 	_	
73-59	12457-12458	=	_	
73-60	12458-12459	 	_	
73-61	12459-12464	0.067	_	
73-62	12464-12465	)	_	
73-63	12465-12466	.	_	

#Text=The elevations in dopamine function remained significant when the two UHR individuals who were taking antipsychotic medication were excluded from the analysis (sexual or physical abuse: T61 = 2.75; P = 0.008; family arrangements: T55 = 2.85; P = 0.005), and when group (UHR or Control) was included as a factor in the analyses (sexual or physical abuse: F1,61 = 6.53; P = 0.01; more than two family arrangements: F1,55 = 0.50; P = 0.02).
74-1	12467-12470	The	_	
74-2	12471-12481	elevations	_	
74-3	12482-12484	in	_	
74-4	12485-12493	dopamine	_	
74-5	12494-12502	function	_	
74-6	12503-12511	remained	_	
74-7	12512-12523	significant	_	
74-8	12524-12528	when	_	
74-9	12529-12532	the	_	
74-10	12533-12536	two	_	
74-11	12537-12540	UHR	_	
74-12	12541-12552	individuals	_	
74-13	12553-12556	who	_	
74-14	12557-12561	were	_	
74-15	12562-12568	taking	_	
74-16	12569-12582	antipsychotic	_	
74-17	12583-12593	medication	_	
74-18	12594-12598	were	_	
74-19	12599-12607	excluded	_	
74-20	12608-12612	from	_	
74-21	12613-12616	the	_	
74-22	12617-12625	analysis	_	
74-23	12626-12627	(	_	
74-24	12627-12633	sexual	_	
74-25	12634-12636	or	_	
74-26	12637-12645	physical	_	
74-27	12646-12651	abuse	_	
74-28	12651-12652	:	_	
74-29	12653-12656	T61	_	
74-30	12656-12657	 	_	
74-31	12657-12658	=	_	
74-32	12658-12659	 	_	
74-33	12659-12663	2.75	_	
74-34	12663-12664	;	_	
74-35	12665-12666	P	_	
74-36	12666-12667	 	_	
74-37	12667-12668	=	_	
74-38	12668-12669	 	_	
74-39	12669-12674	0.008	_	
74-40	12674-12675	;	_	
74-41	12676-12682	family	_	
74-42	12683-12695	arrangements	_	
74-43	12695-12696	:	_	
74-44	12697-12700	T55	_	
74-45	12700-12701	 	_	
74-46	12701-12702	=	_	
74-47	12702-12703	 	_	
74-48	12703-12707	2.85	_	
74-49	12707-12708	;	_	
74-50	12709-12710	P	_	
74-51	12710-12711	 	_	
74-52	12711-12712	=	_	
74-53	12712-12713	 	_	
74-54	12713-12718	0.005	_	
74-55	12718-12719	)	_	
74-56	12719-12720	,	_	
74-57	12721-12724	and	_	
74-58	12725-12729	when	_	
74-59	12730-12735	group	_	
74-60	12736-12737	(	_	
74-61	12737-12740	UHR	_	
74-62	12741-12743	or	_	
74-63	12744-12751	Control	_	
74-64	12751-12752	)	_	
74-65	12753-12756	was	_	
74-66	12757-12765	included	_	
74-67	12766-12768	as	_	
74-68	12769-12770	a	_	
74-69	12771-12777	factor	_	
74-70	12778-12780	in	_	
74-71	12781-12784	the	_	
74-72	12785-12793	analyses	_	
74-73	12794-12795	(	_	
74-74	12795-12801	sexual	_	
74-75	12802-12804	or	_	
74-76	12805-12813	physical	_	
74-77	12814-12819	abuse	_	
74-78	12819-12820	:	_	
74-79	12821-12826	F1,61	_	
74-80	12826-12827	 	_	
74-81	12827-12828	=	_	
74-82	12828-12829	 	_	
74-83	12829-12833	6.53	_	
74-84	12833-12834	;	_	
74-85	12835-12836	P	_	
74-86	12836-12837	 	_	
74-87	12837-12838	=	_	
74-88	12838-12839	 	_	
74-89	12839-12843	0.01	_	
74-90	12843-12844	;	_	
74-91	12845-12849	more	_	
74-92	12850-12854	than	_	
74-93	12855-12858	two	_	
74-94	12859-12865	family	_	
74-95	12866-12878	arrangements	_	
74-96	12878-12879	:	_	
74-97	12880-12885	F1,55	_	
74-98	12885-12886	 	_	
74-99	12886-12887	=	_	
74-100	12887-12888	 	_	
74-101	12888-12892	0.50	_	
74-102	12892-12893	;	_	
74-103	12894-12895	P	_	
74-104	12895-12896	 	_	
74-105	12896-12897	=	_	
74-106	12897-12898	 	_	
74-107	12898-12902	0.02	_	
74-108	12902-12903	)	_	
74-109	12903-12904	.	_	

#Text=There were no significant interactions between group and adversity (sexual or physical abuse * group interaction: F1,61 = 0.29; P = 0.59; more than two family arrangements * group interaction: F1,55 = 0.27; P = 0.60).
75-1	12905-12910	There	_	
75-2	12911-12915	were	_	
75-3	12916-12918	no	_	
75-4	12919-12930	significant	_	
75-5	12931-12943	interactions	_	
75-6	12944-12951	between	_	
75-7	12952-12957	group	_	
75-8	12958-12961	and	_	
75-9	12962-12971	adversity	_	
75-10	12972-12973	(	_	
75-11	12973-12979	sexual	_	
75-12	12980-12982	or	_	
75-13	12983-12991	physical	_	
75-14	12992-12997	abuse	_	
75-15	12998-12999	*	_	
75-16	13000-13005	group	_	
75-17	13006-13017	interaction	_	
75-18	13017-13018	:	_	
75-19	13019-13024	F1,61	_	
75-20	13024-13025	 	_	
75-21	13025-13026	=	_	
75-22	13026-13027	 	_	
75-23	13027-13031	0.29	_	
75-24	13031-13032	;	_	
75-25	13033-13034	P	_	
75-26	13034-13035	 	_	
75-27	13035-13036	=	_	
75-28	13036-13037	 	_	
75-29	13037-13041	0.59	_	
75-30	13041-13042	;	_	
75-31	13043-13047	more	_	
75-32	13048-13052	than	_	
75-33	13053-13056	two	_	
75-34	13057-13063	family	_	
75-35	13064-13076	arrangements	_	
75-36	13077-13078	*	_	
75-37	13079-13084	group	_	
75-38	13085-13096	interaction	_	
75-39	13096-13097	:	_	
75-40	13098-13103	F1,55	_	
75-41	13103-13104	 	_	
75-42	13104-13105	=	_	
75-43	13105-13106	 	_	
75-44	13106-13110	0.27	_	
75-45	13110-13111	;	_	
75-46	13112-13113	P	_	
75-47	13113-13114	 	_	
75-48	13114-13115	=	_	
75-49	13115-13116	 	_	
75-50	13116-13120	0.60	_	
75-51	13120-13121	)	_	
75-52	13121-13122	.	_	

#Text=When analysis was restricted to only the UHR group, these elevations approached significance (both P = 0.06; Supplementary Table S2).
76-1	13123-13127	When	_	
76-2	13128-13136	analysis	_	
76-3	13137-13140	was	_	
76-4	13141-13151	restricted	_	
76-5	13152-13154	to	_	
76-6	13155-13159	only	_	
76-7	13160-13163	the	_	
76-8	13164-13167	UHR	_	
76-9	13168-13173	group	_	
76-10	13173-13174	,	_	
76-11	13175-13180	these	_	
76-12	13181-13191	elevations	_	
76-13	13192-13202	approached	_	
76-14	13203-13215	significance	_	
76-15	13216-13217	(	_	
76-16	13217-13221	both	_	
76-17	13222-13223	P	_	
76-18	13223-13224	 	_	
76-19	13224-13225	=	_	
76-20	13225-13226	 	_	
76-21	13226-13230	0.06	_	
76-22	13230-13231	;	_	
76-23	13232-13245	Supplementary	_	
76-24	13246-13251	Table	_	
76-25	13252-13254	S2	_	
76-26	13254-13255	)	_	
76-27	13255-13256	.	_	

#Text=The elevations in associative striatal dopamine function across UHR and Control participants exposed to either sexual or physical abuse, or to more than two family arrangements, also remained significant when age, gender, smoking or alcohol drinking status, or use of cannabis, cocaine, amphetamine, ecstasy or ketamine were entered as fixed factors in the analyses (all P < 0.05).
77-1	13257-13260	The	_	
77-2	13261-13271	elevations	_	
77-3	13272-13274	in	_	
77-4	13275-13286	associative	_	
77-5	13287-13295	striatal	_	
77-6	13296-13304	dopamine	_	
77-7	13305-13313	function	_	
77-8	13314-13320	across	_	
77-9	13321-13324	UHR	_	
77-10	13325-13328	and	_	
77-11	13329-13336	Control	_	
77-12	13337-13349	participants	_	
77-13	13350-13357	exposed	_	
77-14	13358-13360	to	_	
77-15	13361-13367	either	_	
77-16	13368-13374	sexual	_	
77-17	13375-13377	or	_	
77-18	13378-13386	physical	_	
77-19	13387-13392	abuse	_	
77-20	13392-13393	,	_	
77-21	13394-13396	or	_	
77-22	13397-13399	to	_	
77-23	13400-13404	more	_	
77-24	13405-13409	than	_	
77-25	13410-13413	two	_	
77-26	13414-13420	family	_	
77-27	13421-13433	arrangements	_	
77-28	13433-13434	,	_	
77-29	13435-13439	also	_	
77-30	13440-13448	remained	_	
77-31	13449-13460	significant	_	
77-32	13461-13465	when	_	
77-33	13466-13469	age	_	
77-34	13469-13470	,	_	
77-35	13471-13477	gender	_	
77-36	13477-13478	,	_	
77-37	13479-13486	smoking	_	
77-38	13487-13489	or	_	
77-39	13490-13497	alcohol	_	
77-40	13498-13506	drinking	_	
77-41	13507-13513	status	_	
77-42	13513-13514	,	_	
77-43	13515-13517	or	_	
77-44	13518-13521	use	_	
77-45	13522-13524	of	_	
77-46	13525-13533	cannabis	_	
77-47	13533-13534	,	_	
77-48	13535-13542	cocaine	_	
77-49	13542-13543	,	_	
77-50	13544-13555	amphetamine	_	
77-51	13555-13556	,	_	
77-52	13557-13564	ecstasy	_	
77-53	13565-13567	or	_	
77-54	13568-13576	ketamine	_	
77-55	13577-13581	were	_	
77-56	13582-13589	entered	_	
77-57	13590-13592	as	_	
77-58	13593-13598	fixed	_	
77-59	13599-13606	factors	_	
77-60	13607-13609	in	_	
77-61	13610-13613	the	_	
77-62	13614-13622	analyses	_	
77-63	13623-13624	(	_	
77-64	13624-13627	all	_	
77-65	13628-13629	P	_	
77-66	13629-13630	 	_	
77-67	13630-13631	<	_	
77-68	13631-13632	 	_	
77-69	13632-13636	0.05	_	
77-70	13636-13637	)	_	
77-71	13637-13638	.	_	

#Text=The same pattern of findings was evident when the region of interest comprised the whole striatum, with both severe physical or sexual abuse and multiple family arrangements again associated with significantly elevated dopamine function (Supplementary Table S3), albeit with slightly smaller effect sizes than for the associative striatum (d = 0.55 and 0.77 respectively).
78-1	13639-13642	The	_	
78-2	13643-13647	same	_	
78-3	13648-13655	pattern	_	
78-4	13656-13658	of	_	
78-5	13659-13667	findings	_	
78-6	13668-13671	was	_	
78-7	13672-13679	evident	_	
78-8	13680-13684	when	_	
78-9	13685-13688	the	_	
78-10	13689-13695	region	_	
78-11	13696-13698	of	_	
78-12	13699-13707	interest	_	
78-13	13708-13717	comprised	_	
78-14	13718-13721	the	_	
78-15	13722-13727	whole	_	
78-16	13728-13736	striatum	_	
78-17	13736-13737	,	_	
78-18	13738-13742	with	_	
78-19	13743-13747	both	_	
78-20	13748-13754	severe	_	
78-21	13755-13763	physical	_	
78-22	13764-13766	or	_	
78-23	13767-13773	sexual	_	
78-24	13774-13779	abuse	_	
78-25	13780-13783	and	_	
78-26	13784-13792	multiple	_	
78-27	13793-13799	family	_	
78-28	13800-13812	arrangements	_	
78-29	13813-13818	again	_	
78-30	13819-13829	associated	_	
78-31	13830-13834	with	_	
78-32	13835-13848	significantly	_	
78-33	13849-13857	elevated	_	
78-34	13858-13866	dopamine	_	
78-35	13867-13875	function	_	
78-36	13876-13877	(	_	
78-37	13877-13890	Supplementary	_	
78-38	13891-13896	Table	_	
78-39	13897-13899	S3	_	
78-40	13899-13900	)	_	
78-41	13900-13901	,	_	
78-42	13902-13908	albeit	_	
78-43	13909-13913	with	_	
78-44	13914-13922	slightly	_	
78-45	13923-13930	smaller	_	
78-46	13931-13937	effect	_	
78-47	13938-13943	sizes	_	
78-48	13944-13948	than	_	
78-49	13949-13952	for	_	
78-50	13953-13956	the	_	
78-51	13957-13968	associative	_	
78-52	13969-13977	striatum	_	
78-53	13978-13979	(	_	
78-54	13979-13980	d	_	
78-55	13980-13981	 	_	
78-56	13981-13982	=	_	
78-57	13982-13983	 	_	
78-58	13983-13987	0.55	_	
78-59	13988-13991	and	_	
78-60	13992-13996	0.77	_	
78-61	13997-14009	respectively	_	
78-62	14009-14010	)	_	
78-63	14010-14011	.	_	

#Text=Experiencing more than two family arrangements was also associated with increased dopamine function in the sensorimotor striatum (T57 = 2.40; P = 0.02; d = 0.76; Supplementary Table S3), but otherwise dopamine function in the limbic and sensorimotor subregions was not significantly different in participants who did and did not report adverse childhood experiences.
79-1	14012-14024	Experiencing	_	
79-2	14025-14029	more	_	
79-3	14030-14034	than	_	
79-4	14035-14038	two	_	
79-5	14039-14045	family	_	
79-6	14046-14058	arrangements	_	
79-7	14059-14062	was	_	
79-8	14063-14067	also	_	
79-9	14068-14078	associated	_	
79-10	14079-14083	with	_	
79-11	14084-14093	increased	_	
79-12	14094-14102	dopamine	_	
79-13	14103-14111	function	_	
79-14	14112-14114	in	_	
79-15	14115-14118	the	_	
79-16	14119-14131	sensorimotor	_	
79-17	14132-14140	striatum	_	
79-18	14141-14142	(	_	
79-19	14142-14145	T57	_	
79-20	14145-14146	 	_	
79-21	14146-14147	=	_	
79-22	14147-14148	 	_	
79-23	14148-14152	2.40	_	
79-24	14152-14153	;	_	
79-25	14154-14155	P	_	
79-26	14155-14156	 	_	
79-27	14156-14157	=	_	
79-28	14157-14158	 	_	
79-29	14158-14162	0.02	_	
79-30	14162-14163	;	_	
79-31	14164-14165	d	_	
79-32	14165-14166	 	_	
79-33	14166-14167	=	_	
79-34	14167-14168	 	_	
79-35	14168-14172	0.76	_	
79-36	14172-14173	;	_	
79-37	14174-14187	Supplementary	_	
79-38	14188-14193	Table	_	
79-39	14194-14196	S3	_	
79-40	14196-14197	)	_	
79-41	14197-14198	,	_	
79-42	14199-14202	but	_	
79-43	14203-14212	otherwise	_	
79-44	14213-14221	dopamine	_	
79-45	14222-14230	function	_	
79-46	14231-14233	in	_	
79-47	14234-14237	the	_	
79-48	14238-14244	limbic	_	
79-49	14245-14248	and	_	
79-50	14249-14261	sensorimotor	_	
79-51	14262-14272	subregions	_	
79-52	14273-14276	was	_	
79-53	14277-14280	not	_	
79-54	14281-14294	significantly	_	
79-55	14295-14304	different	_	
79-56	14305-14307	in	_	
79-57	14308-14320	participants	_	
79-58	14321-14324	who	_	
79-59	14325-14328	did	_	
79-60	14329-14332	and	_	
79-61	14333-14336	did	_	
79-62	14337-14340	not	_	
79-63	14341-14347	report	_	
79-64	14348-14355	adverse	_	
79-65	14356-14365	childhood	_	
79-66	14366-14377	experiences	_	
79-67	14377-14378	.	_	

#Text=Childhood adversity in the UHR compared to control group
#Text=When exposures to each type of childhood adversity in UHR and volunteer groups were compared, only physical or sexual abuse was more commonly reported in the UHR group (P = 0.03; Table 2).
80-1	14379-14388	Childhood	_	
80-2	14389-14398	adversity	_	
80-3	14399-14401	in	_	
80-4	14402-14405	the	_	
80-5	14406-14409	UHR	_	
80-6	14410-14418	compared	_	
80-7	14419-14421	to	_	
80-8	14422-14429	control	_	
80-9	14430-14435	group	_	
80-10	14436-14440	When	_	
80-11	14441-14450	exposures	_	
80-12	14451-14453	to	_	
80-13	14454-14458	each	_	
80-14	14459-14463	type	_	
80-15	14464-14466	of	_	
80-16	14467-14476	childhood	_	
80-17	14477-14486	adversity	_	
80-18	14487-14489	in	_	
80-19	14490-14493	UHR	_	
80-20	14494-14497	and	_	
80-21	14498-14507	volunteer	_	
80-22	14508-14514	groups	_	
80-23	14515-14519	were	_	
80-24	14520-14528	compared	_	
80-25	14528-14529	,	_	
80-26	14530-14534	only	_	
80-27	14535-14543	physical	_	
80-28	14544-14546	or	_	
80-29	14547-14553	sexual	_	
80-30	14554-14559	abuse	_	
80-31	14560-14563	was	_	
80-32	14564-14568	more	_	
80-33	14569-14577	commonly	_	
80-34	14578-14586	reported	_	
80-35	14587-14589	in	_	
80-36	14590-14593	the	_	
80-37	14594-14597	UHR	_	
80-38	14598-14603	group	_	
80-39	14604-14605	(	_	
80-40	14605-14606	P	_	
80-41	14606-14607	 	_	
80-42	14607-14608	=	_	
80-43	14608-14609	 	_	
80-44	14609-14613	0.03	_	
80-45	14613-14614	;	_	
80-46	14615-14620	Table	_	
80-47	14621-14622	2	_	
80-48	14622-14623	)	_	
80-49	14623-14624	.	_	

#Text=Presynaptic dopamine function in the UHR compared to Control group
#Text=There were no significant differences in striatal presynaptic dopamine function between the UHR and Control groups (Table 4).
81-1	14625-14636	Presynaptic	_	
81-2	14637-14645	dopamine	_	
81-3	14646-14654	function	_	
81-4	14655-14657	in	_	
81-5	14658-14661	the	_	
81-6	14662-14665	UHR	_	
81-7	14666-14674	compared	_	
81-8	14675-14677	to	_	
81-9	14678-14685	Control	_	
81-10	14686-14691	group	_	
81-11	14692-14697	There	_	
81-12	14698-14702	were	_	
81-13	14703-14705	no	_	
81-14	14706-14717	significant	_	
81-15	14718-14729	differences	_	
81-16	14730-14732	in	_	
81-17	14733-14741	striatal	_	
81-18	14742-14753	presynaptic	_	
81-19	14754-14762	dopamine	_	
81-20	14763-14771	function	_	
81-21	14772-14779	between	_	
81-22	14780-14783	the	_	
81-23	14784-14787	UHR	_	
81-24	14788-14791	and	_	
81-25	14792-14799	Control	_	
81-26	14800-14806	groups	_	
81-27	14807-14808	(	_	
81-28	14808-14813	Table	_	
81-29	14814-14815	4	_	
81-30	14815-14816	)	_	
81-31	14816-14817	.	_	

#Text=Relationships between dopamine function or childhood adversity and symptoms in the UHR group
#Text=In the UHR group, the positive correlation between the severity of total prodromal symptoms (total CAARMS score) and dopamine function (z-score) was significant in the sensorimotor striatum (n = 47; r = 0.30; P = 0.04) but not in the associative (n = 47; r = 0.20; P = 0.19), limbic (n = 47; r = 0.04; P = 0.80 or whole striatum (n = 47; r = 0.23; P = 0.13).
82-1	14818-14831	Relationships	_	
82-2	14832-14839	between	_	
82-3	14840-14848	dopamine	_	
82-4	14849-14857	function	_	
82-5	14858-14860	or	_	
82-6	14861-14870	childhood	_	
82-7	14871-14880	adversity	_	
82-8	14881-14884	and	_	
82-9	14885-14893	symptoms	_	
82-10	14894-14896	in	_	
82-11	14897-14900	the	_	
82-12	14901-14904	UHR	_	
82-13	14905-14910	group	_	
82-14	14911-14913	In	_	
82-15	14914-14917	the	_	
82-16	14918-14921	UHR	_	
82-17	14922-14927	group	_	
82-18	14927-14928	,	_	
82-19	14929-14932	the	_	
82-20	14933-14941	positive	_	
82-21	14942-14953	correlation	_	
82-22	14954-14961	between	_	
82-23	14962-14965	the	_	
82-24	14966-14974	severity	_	
82-25	14975-14977	of	_	
82-26	14978-14983	total	_	
82-27	14984-14993	prodromal	_	
82-28	14994-15002	symptoms	_	
82-29	15003-15004	(	_	
82-30	15004-15009	total	_	
82-31	15010-15016	CAARMS	_	
82-32	15017-15022	score	_	
82-33	15022-15023	)	_	
82-34	15024-15027	and	_	
82-35	15028-15036	dopamine	_	
82-36	15037-15045	function	_	
82-37	15046-15047	(	_	
82-38	15047-15054	z-score	_	
82-39	15054-15055	)	_	
82-40	15056-15059	was	_	
82-41	15060-15071	significant	_	
82-42	15072-15074	in	_	
82-43	15075-15078	the	_	
82-44	15079-15091	sensorimotor	_	
82-45	15092-15100	striatum	_	
82-46	15101-15102	(	_	
82-47	15102-15103	n	_	
82-48	15103-15104	 	_	
82-49	15104-15105	=	_	
82-50	15105-15106	 	_	
82-51	15106-15108	47	_	
82-52	15108-15109	;	_	
82-53	15110-15111	r	_	
82-54	15111-15112	 	_	
82-55	15112-15113	=	_	
82-56	15113-15114	 	_	
82-57	15114-15118	0.30	_	
82-58	15118-15119	;	_	
82-59	15120-15121	P	_	
82-60	15121-15122	 	_	
82-61	15122-15123	=	_	
82-62	15123-15124	 	_	
82-63	15124-15128	0.04	_	
82-64	15128-15129	)	_	
82-65	15130-15133	but	_	
82-66	15134-15137	not	_	
82-67	15138-15140	in	_	
82-68	15141-15144	the	_	
82-69	15145-15156	associative	_	
82-70	15157-15158	(	_	
82-71	15158-15159	n	_	
82-72	15159-15160	 	_	
82-73	15160-15161	=	_	
82-74	15161-15162	 	_	
82-75	15162-15164	47	_	
82-76	15164-15165	;	_	
82-77	15166-15167	r	_	
82-78	15167-15168	 	_	
82-79	15168-15169	=	_	
82-80	15169-15170	 	_	
82-81	15170-15174	0.20	_	
82-82	15174-15175	;	_	
82-83	15176-15177	P	_	
82-84	15177-15178	 	_	
82-85	15178-15179	=	_	
82-86	15179-15180	 	_	
82-87	15180-15184	0.19	_	
82-88	15184-15185	)	_	
82-89	15185-15186	,	_	
82-90	15187-15193	limbic	_	
82-91	15194-15195	(	_	
82-92	15195-15196	n	_	
82-93	15196-15197	 	_	
82-94	15197-15198	=	_	
82-95	15198-15199	 	_	
82-96	15199-15201	47	_	
82-97	15201-15202	;	_	
82-98	15203-15204	r	_	
82-99	15204-15205	 	_	
82-100	15205-15206	=	_	
82-101	15206-15207	 	_	
82-102	15207-15211	0.04	_	
82-103	15211-15212	;	_	
82-104	15213-15214	P	_	
82-105	15214-15215	 	_	
82-106	15215-15216	=	_	
82-107	15216-15217	 	_	
82-108	15217-15221	0.80	_	
82-109	15222-15224	or	_	
82-110	15225-15230	whole	_	
82-111	15231-15239	striatum	_	
82-112	15240-15241	(	_	
82-113	15241-15242	n	_	
82-114	15242-15243	 	_	
82-115	15243-15244	=	_	
82-116	15244-15245	 	_	
82-117	15245-15247	47	_	
82-118	15247-15248	;	_	
82-119	15249-15250	r	_	
82-120	15250-15251	 	_	
82-121	15251-15252	=	_	
82-122	15252-15253	 	_	
82-123	15253-15257	0.23	_	
82-124	15257-15258	;	_	
82-125	15259-15260	P	_	
82-126	15260-15261	 	_	
82-127	15261-15262	=	_	
82-128	15262-15263	 	_	
82-129	15263-15267	0.13	_	
82-130	15267-15268	)	_	
82-131	15268-15269	.	_	

#Text=There were no significant differences in prodromal symptom severity, anxiety or depression between individuals who had or had not been exposed to each type of adversity (P > 0.05).
83-1	15270-15275	There	_	
83-2	15276-15280	were	_	
83-3	15281-15283	no	_	
83-4	15284-15295	significant	_	
83-5	15296-15307	differences	_	
83-6	15308-15310	in	_	
83-7	15311-15320	prodromal	_	
83-8	15321-15328	symptom	_	
83-9	15329-15337	severity	_	
83-10	15337-15338	,	_	
83-11	15339-15346	anxiety	_	
83-12	15347-15349	or	_	
83-13	15350-15360	depression	_	
83-14	15361-15368	between	_	
83-15	15369-15380	individuals	_	
83-16	15381-15384	who	_	
83-17	15385-15388	had	_	
83-18	15389-15391	or	_	
83-19	15392-15395	had	_	
83-20	15396-15399	not	_	
83-21	15400-15404	been	_	
83-22	15405-15412	exposed	_	
83-23	15413-15415	to	_	
83-24	15416-15420	each	_	
83-25	15421-15425	type	_	
83-26	15426-15428	of	_	
83-27	15429-15438	adversity	_	
83-28	15439-15440	(	_	
83-29	15440-15441	P	_	
83-30	15441-15442	 	_	
83-31	15442-15443	>	_	
83-32	15443-15444	 	_	
83-33	15444-15448	0.05	_	
83-34	15448-15449	)	_	
83-35	15449-15450	.	_	

#Text=Discussion
#Text=An elevation in striatal dopamine function in adults who have been exposed to childhood adversity is consistent with animal studies linking psychogenic stress to striatal dopaminergic elevation, and with the recent finding of elevated dopaminergic responses to amphetamine in healthy volunteers exposed to childhood adversity.
84-1	15451-15461	Discussion	_	
84-2	15462-15464	An	_	
84-3	15465-15474	elevation	_	
84-4	15475-15477	in	_	
84-5	15478-15486	striatal	_	
84-6	15487-15495	dopamine	_	
84-7	15496-15504	function	_	
84-8	15505-15507	in	_	
84-9	15508-15514	adults	_	
84-10	15515-15518	who	_	
84-11	15519-15523	have	_	
84-12	15524-15528	been	_	
84-13	15529-15536	exposed	_	
84-14	15537-15539	to	_	
84-15	15540-15549	childhood	_	
84-16	15550-15559	adversity	_	
84-17	15560-15562	is	_	
84-18	15563-15573	consistent	_	
84-19	15574-15578	with	_	
84-20	15579-15585	animal	_	
84-21	15586-15593	studies	_	
84-22	15594-15601	linking	_	
84-23	15602-15613	psychogenic	_	
84-24	15614-15620	stress	_	
84-25	15621-15623	to	_	
84-26	15624-15632	striatal	_	
84-27	15633-15645	dopaminergic	_	
84-28	15646-15655	elevation	_	
84-29	15655-15656	,	_	
84-30	15657-15660	and	_	
84-31	15661-15665	with	_	
84-32	15666-15669	the	_	
84-33	15670-15676	recent	_	
84-34	15677-15684	finding	_	
84-35	15685-15687	of	_	
84-36	15688-15696	elevated	_	
84-37	15697-15709	dopaminergic	_	
84-38	15710-15719	responses	_	
84-39	15720-15722	to	_	
84-40	15723-15734	amphetamine	_	
84-41	15735-15737	in	_	
84-42	15738-15745	healthy	_	
84-43	15746-15756	volunteers	_	
84-44	15757-15764	exposed	_	
84-45	15765-15767	to	_	
84-46	15768-15777	childhood	_	
84-47	15778-15787	adversity	_	
84-48	15787-15788	.	_	

#Text=Elevated dopamine function in the associative striatum was linked to severe (sexual or physical) abuse, and to multiple family arrangements, which may be a proxy marker for other stressors, including abuse.
85-1	15789-15797	Elevated	_	
85-2	15798-15806	dopamine	_	
85-3	15807-15815	function	_	
85-4	15816-15818	in	_	
85-5	15819-15822	the	_	
85-6	15823-15834	associative	_	
85-7	15835-15843	striatum	_	
85-8	15844-15847	was	_	
85-9	15848-15854	linked	_	
85-10	15855-15857	to	_	
85-11	15858-15864	severe	_	
85-12	15865-15866	(	_	
85-13	15866-15872	sexual	_	
85-14	15873-15875	or	_	
85-15	15876-15884	physical	_	
85-16	15884-15885	)	_	
85-17	15886-15891	abuse	_	
85-18	15891-15892	,	_	
85-19	15893-15896	and	_	
85-20	15897-15899	to	_	
85-21	15900-15908	multiple	_	
85-22	15909-15915	family	_	
85-23	15916-15928	arrangements	_	
85-24	15928-15929	,	_	
85-25	15930-15935	which	_	
85-26	15936-15939	may	_	
85-27	15940-15942	be	_	
85-28	15943-15944	a	_	
85-29	15945-15950	proxy	_	
85-30	15951-15957	marker	_	
85-31	15958-15961	for	_	
85-32	15962-15967	other	_	
85-33	15968-15977	stressors	_	
85-34	15977-15978	,	_	
85-35	15979-15988	including	_	
85-36	15989-15994	abuse	_	
85-37	15994-15995	.	_	

#Text=Exposure to stressors in childhood and elevated brain dopamine function in early adulthood have each been independently identified as major psychosocial and neurobiological risk factors for psychosis.
86-1	15996-16004	Exposure	_	
86-2	16005-16007	to	_	
86-3	16008-16017	stressors	_	
86-4	16018-16020	in	_	
86-5	16021-16030	childhood	_	
86-6	16031-16034	and	_	
86-7	16035-16043	elevated	_	
86-8	16044-16049	brain	_	
86-9	16050-16058	dopamine	_	
86-10	16059-16067	function	_	
86-11	16068-16070	in	_	
86-12	16071-16076	early	_	
86-13	16077-16086	adulthood	_	
86-14	16087-16091	have	_	
86-15	16092-16096	each	_	
86-16	16097-16101	been	_	
86-17	16102-16115	independently	_	
86-18	16116-16126	identified	_	
86-19	16127-16129	as	_	
86-20	16130-16135	major	_	
86-21	16136-16148	psychosocial	_	
86-22	16149-16152	and	_	
86-23	16153-16168	neurobiological	_	
86-24	16169-16173	risk	_	
86-25	16174-16181	factors	_	
86-26	16182-16185	for	_	
86-27	16186-16195	psychosis	_	
86-28	16195-16196	.	_	

#Text=Our findings link these factors in the same individuals, and illustrate how adverse environmental influences could impact on brain development to alter the risk of a later psychotic illness.
87-1	16197-16200	Our	_	
87-2	16201-16209	findings	_	
87-3	16210-16214	link	_	
87-4	16215-16220	these	_	
87-5	16221-16228	factors	_	
87-6	16229-16231	in	_	
87-7	16232-16235	the	_	
87-8	16236-16240	same	_	
87-9	16241-16252	individuals	_	
87-10	16252-16253	,	_	
87-11	16254-16257	and	_	
87-12	16258-16268	illustrate	_	
87-13	16269-16272	how	_	
87-14	16273-16280	adverse	_	
87-15	16281-16294	environmental	_	
87-16	16295-16305	influences	_	
87-17	16306-16311	could	_	
87-18	16312-16318	impact	_	
87-19	16319-16321	on	_	
87-20	16322-16327	brain	_	
87-21	16328-16339	development	_	
87-22	16340-16342	to	_	
87-23	16343-16348	alter	_	
87-24	16349-16352	the	_	
87-25	16353-16357	risk	_	
87-26	16358-16360	of	_	
87-27	16361-16362	a	_	
87-28	16363-16368	later	_	
87-29	16369-16378	psychotic	_	
87-30	16379-16386	illness	_	
87-31	16386-16387	.	_	

#Text=Physical and sexual abuse can be viewed as a forms of intentional harm which lead to enduring feelings of humiliation, which would place our findings of increased striatal dopamine function in people who experienced these forms of abuse as consistent with the social defeat hypothesis.
88-1	16388-16396	Physical	_	
88-2	16397-16400	and	_	
88-3	16401-16407	sexual	_	
88-4	16408-16413	abuse	_	
88-5	16414-16417	can	_	
88-6	16418-16420	be	_	
88-7	16421-16427	viewed	_	
88-8	16428-16430	as	_	
88-9	16431-16432	a	_	
88-10	16433-16438	forms	_	
88-11	16439-16441	of	_	
88-12	16442-16453	intentional	_	
88-13	16454-16458	harm	_	
88-14	16459-16464	which	_	
88-15	16465-16469	lead	_	
88-16	16470-16472	to	_	
88-17	16473-16481	enduring	_	
88-18	16482-16490	feelings	_	
88-19	16491-16493	of	_	
88-20	16494-16505	humiliation	_	
88-21	16505-16506	,	_	
88-22	16507-16512	which	_	
88-23	16513-16518	would	_	
88-24	16519-16524	place	_	
88-25	16525-16528	our	_	
88-26	16529-16537	findings	_	
88-27	16538-16540	of	_	
88-28	16541-16550	increased	_	
88-29	16551-16559	striatal	_	
88-30	16560-16568	dopamine	_	
88-31	16569-16577	function	_	
88-32	16578-16580	in	_	
88-33	16581-16587	people	_	
88-34	16588-16591	who	_	
88-35	16592-16603	experienced	_	
88-36	16604-16609	these	_	
88-37	16610-16615	forms	_	
88-38	16616-16618	of	_	
88-39	16619-16624	abuse	_	
88-40	16625-16627	as	_	
88-41	16628-16638	consistent	_	
88-42	16639-16643	with	_	
88-43	16644-16647	the	_	
88-44	16648-16654	social	_	
88-45	16655-16661	defeat	_	
88-46	16662-16672	hypothesis	_	
88-47	16672-16673	.	_	

#Text=In relation to this, it is perhaps interesting that we found no association between dopamine function and parental loss or separation, which are forms of trauma that do not necessarily or directly involve intentional harm to the child.
89-1	16674-16676	In	_	
89-2	16677-16685	relation	_	
89-3	16686-16688	to	_	
89-4	16689-16693	this	_	
89-5	16693-16694	,	_	
89-6	16695-16697	it	_	
89-7	16698-16700	is	_	
89-8	16701-16708	perhaps	_	
89-9	16709-16720	interesting	_	
89-10	16721-16725	that	_	
89-11	16726-16728	we	_	
89-12	16729-16734	found	_	
89-13	16735-16737	no	_	
89-14	16738-16749	association	_	
89-15	16750-16757	between	_	
89-16	16758-16766	dopamine	_	
89-17	16767-16775	function	_	
89-18	16776-16779	and	_	
89-19	16780-16788	parental	_	
89-20	16789-16793	loss	_	
89-21	16794-16796	or	_	
89-22	16797-16807	separation	_	
89-23	16807-16808	,	_	
89-24	16809-16814	which	_	
89-25	16815-16818	are	_	
89-26	16819-16824	forms	_	
89-27	16825-16827	of	_	
89-28	16828-16834	trauma	_	
89-29	16835-16839	that	_	
89-30	16840-16842	do	_	
89-31	16843-16846	not	_	
89-32	16847-16858	necessarily	_	
89-33	16859-16861	or	_	
89-34	16862-16870	directly	_	
89-35	16871-16878	involve	_	
89-36	16879-16890	intentional	_	
89-37	16891-16895	harm	_	
89-38	16896-16898	to	_	
89-39	16899-16902	the	_	
89-40	16903-16908	child	_	
89-41	16908-16909	.	_	

#Text=The elevation in striatal dopamine function in subjects with a history of childhood adversity was not attributable to increased substance use in these individuals, as they did not use illicit drugs more than individuals who had not experienced adverse events in childhood, and the findings remained significant after controlling for substance misuse.
90-1	16910-16913	The	_	
90-2	16914-16923	elevation	_	
90-3	16924-16926	in	_	
90-4	16927-16935	striatal	_	
90-5	16936-16944	dopamine	_	
90-6	16945-16953	function	_	
90-7	16954-16956	in	_	
90-8	16957-16965	subjects	_	
90-9	16966-16970	with	_	
90-10	16971-16972	a	_	
90-11	16973-16980	history	_	
90-12	16981-16983	of	_	
90-13	16984-16993	childhood	_	
90-14	16994-17003	adversity	_	
90-15	17004-17007	was	_	
90-16	17008-17011	not	_	
90-17	17012-17024	attributable	_	
90-18	17025-17027	to	_	
90-19	17028-17037	increased	_	
90-20	17038-17047	substance	_	
90-21	17048-17051	use	_	
90-22	17052-17054	in	_	
90-23	17055-17060	these	_	
90-24	17061-17072	individuals	_	
90-25	17072-17073	,	_	
90-26	17074-17076	as	_	
90-27	17077-17081	they	_	
90-28	17082-17085	did	_	
90-29	17086-17089	not	_	
90-30	17090-17093	use	_	
90-31	17094-17101	illicit	_	
90-32	17102-17107	drugs	_	
90-33	17108-17112	more	_	
90-34	17113-17117	than	_	
90-35	17118-17129	individuals	_	
90-36	17130-17133	who	_	
90-37	17134-17137	had	_	
90-38	17138-17141	not	_	
90-39	17142-17153	experienced	_	
90-40	17154-17161	adverse	_	
90-41	17162-17168	events	_	
90-42	17169-17171	in	_	
90-43	17172-17181	childhood	_	
90-44	17181-17182	,	_	
90-45	17183-17186	and	_	
90-46	17187-17190	the	_	
90-47	17191-17199	findings	_	
90-48	17200-17208	remained	_	
90-49	17209-17220	significant	_	
90-50	17221-17226	after	_	
90-51	17227-17238	controlling	_	
90-52	17239-17242	for	_	
90-53	17243-17252	substance	_	
90-54	17253-17259	misuse	_	
90-55	17259-17260	.	_	

#Text=The relationships between childhood adverse events and dopamine function were not corrected for multiple comparisons.
91-1	17261-17264	The	_	
91-2	17265-17278	relationships	_	
91-3	17279-17286	between	_	
91-4	17287-17296	childhood	_	
91-5	17297-17304	adverse	_	
91-6	17305-17311	events	_	
91-7	17312-17315	and	_	
91-8	17316-17324	dopamine	_	
91-9	17325-17333	function	_	
91-10	17334-17338	were	_	
91-11	17339-17342	not	_	
91-12	17343-17352	corrected	_	
91-13	17353-17356	for	_	
91-14	17357-17365	multiple	_	
91-15	17366-17377	comparisons	_	
91-16	17377-17378	.	_	

#Text=While the reported relationships between multiple family arrangements or physical or sexual abuse and dopamine function in the associative striatum would have survived correction, the relationship between multiple family arrangements and dopamine in the sensorimotor striatum would not, and therefore warrants confirmation in a larger sample.
92-1	17379-17384	While	_	
92-2	17385-17388	the	_	
92-3	17389-17397	reported	_	
92-4	17398-17411	relationships	_	
92-5	17412-17419	between	_	
92-6	17420-17428	multiple	_	
92-7	17429-17435	family	_	
92-8	17436-17448	arrangements	_	
92-9	17449-17451	or	_	
92-10	17452-17460	physical	_	
92-11	17461-17463	or	_	
92-12	17464-17470	sexual	_	
92-13	17471-17476	abuse	_	
92-14	17477-17480	and	_	
92-15	17481-17489	dopamine	_	
92-16	17490-17498	function	_	
92-17	17499-17501	in	_	
92-18	17502-17505	the	_	
92-19	17506-17517	associative	_	
92-20	17518-17526	striatum	_	
92-21	17527-17532	would	_	
92-22	17533-17537	have	_	
92-23	17538-17546	survived	_	
92-24	17547-17557	correction	_	
92-25	17557-17558	,	_	
92-26	17559-17562	the	_	
92-27	17563-17575	relationship	_	
92-28	17576-17583	between	_	
92-29	17584-17592	multiple	_	
92-30	17593-17599	family	_	
92-31	17600-17612	arrangements	_	
92-32	17613-17616	and	_	
92-33	17617-17625	dopamine	_	
92-34	17626-17628	in	_	
92-35	17629-17632	the	_	
92-36	17633-17645	sensorimotor	_	
92-37	17646-17654	striatum	_	
92-38	17655-17660	would	_	
92-39	17661-17664	not	_	
92-40	17664-17665	,	_	
92-41	17666-17669	and	_	
92-42	17670-17679	therefore	_	
92-43	17680-17688	warrants	_	
92-44	17689-17701	confirmation	_	
92-45	17702-17704	in	_	
92-46	17705-17706	a	_	
92-47	17707-17713	larger	_	
92-48	17714-17720	sample	_	
92-49	17720-17721	.	_	

#Text=There was no evidence that the relationship between childhood adversity and dopamine function was different in people with a high risk of psychosis and healthy volunteers, although the relatively small number of participants in the healthy volunteer group may have limited the power to observe a difference in the relationship between adversity and dopamine function between these groups.
93-1	17722-17727	There	_	
93-2	17728-17731	was	_	
93-3	17732-17734	no	_	
93-4	17735-17743	evidence	_	
93-5	17744-17748	that	_	
93-6	17749-17752	the	_	
93-7	17753-17765	relationship	_	
93-8	17766-17773	between	_	
93-9	17774-17783	childhood	_	
93-10	17784-17793	adversity	_	
93-11	17794-17797	and	_	
93-12	17798-17806	dopamine	_	
93-13	17807-17815	function	_	
93-14	17816-17819	was	_	
93-15	17820-17829	different	_	
93-16	17830-17832	in	_	
93-17	17833-17839	people	_	
93-18	17840-17844	with	_	
93-19	17845-17846	a	_	
93-20	17847-17851	high	_	
93-21	17852-17856	risk	_	
93-22	17857-17859	of	_	
93-23	17860-17869	psychosis	_	
93-24	17870-17873	and	_	
93-25	17874-17881	healthy	_	
93-26	17882-17892	volunteers	_	
93-27	17892-17893	,	_	
93-28	17894-17902	although	_	
93-29	17903-17906	the	_	
93-30	17907-17917	relatively	_	
93-31	17918-17923	small	_	
93-32	17924-17930	number	_	
93-33	17931-17933	of	_	
93-34	17934-17946	participants	_	
93-35	17947-17949	in	_	
93-36	17950-17953	the	_	
93-37	17954-17961	healthy	_	
93-38	17962-17971	volunteer	_	
93-39	17972-17977	group	_	
93-40	17978-17981	may	_	
93-41	17982-17986	have	_	
93-42	17987-17994	limited	_	
93-43	17995-17998	the	_	
93-44	17999-18004	power	_	
93-45	18005-18007	to	_	
93-46	18008-18015	observe	_	
93-47	18016-18017	a	_	
93-48	18018-18028	difference	_	
93-49	18029-18031	in	_	
93-50	18032-18035	the	_	
93-51	18036-18048	relationship	_	
93-52	18049-18056	between	_	
93-53	18057-18066	adversity	_	
93-54	18067-18070	and	_	
93-55	18071-18079	dopamine	_	
93-56	18080-18088	function	_	
93-57	18089-18096	between	_	
93-58	18097-18102	these	_	
93-59	18103-18109	groups	_	
93-60	18109-18110	.	_	

#Text=While non-significant, the tendency towards higher levels of both striatal dopamine function and of exposure to adversity in the UHR group may suggest that the significant relationships between adversity and elevated dopamine function across UHR and healthy volunteers were primarily driven by the UHR group, and when analysis was restricted to the UHR group alone these findings approached significance.
94-1	18111-18116	While	_	
94-2	18117-18132	non-significant	_	
94-3	18132-18133	,	_	
94-4	18134-18137	the	_	
94-5	18138-18146	tendency	_	
94-6	18147-18154	towards	_	
94-7	18155-18161	higher	_	
94-8	18162-18168	levels	_	
94-9	18169-18171	of	_	
94-10	18172-18176	both	_	
94-11	18177-18185	striatal	_	
94-12	18186-18194	dopamine	_	
94-13	18195-18203	function	_	
94-14	18204-18207	and	_	
94-15	18208-18210	of	_	
94-16	18211-18219	exposure	_	
94-17	18220-18222	to	_	
94-18	18223-18232	adversity	_	
94-19	18233-18235	in	_	
94-20	18236-18239	the	_	
94-21	18240-18243	UHR	_	
94-22	18244-18249	group	_	
94-23	18250-18253	may	_	
94-24	18254-18261	suggest	_	
94-25	18262-18266	that	_	
94-26	18267-18270	the	_	
94-27	18271-18282	significant	_	
94-28	18283-18296	relationships	_	
94-29	18297-18304	between	_	
94-30	18305-18314	adversity	_	
94-31	18315-18318	and	_	
94-32	18319-18327	elevated	_	
94-33	18328-18336	dopamine	_	
94-34	18337-18345	function	_	
94-35	18346-18352	across	_	
94-36	18353-18356	UHR	_	
94-37	18357-18360	and	_	
94-38	18361-18368	healthy	_	
94-39	18369-18379	volunteers	_	
94-40	18380-18384	were	_	
94-41	18385-18394	primarily	_	
94-42	18395-18401	driven	_	
94-43	18402-18404	by	_	
94-44	18405-18408	the	_	
94-45	18409-18412	UHR	_	
94-46	18413-18418	group	_	
94-47	18418-18419	,	_	
94-48	18420-18423	and	_	
94-49	18424-18428	when	_	
94-50	18429-18437	analysis	_	
94-51	18438-18441	was	_	
94-52	18442-18452	restricted	_	
94-53	18453-18455	to	_	
94-54	18456-18459	the	_	
94-55	18460-18463	UHR	_	
94-56	18464-18469	group	_	
94-57	18470-18475	alone	_	
94-58	18476-18481	these	_	
94-59	18482-18490	findings	_	
94-60	18491-18501	approached	_	
94-61	18502-18514	significance	_	
94-62	18514-18515	.	_	

#Text=The elevation in dopamine function in those exposed to childhood adversity was particularly evident in the associative subdivision of the striatum.
95-1	18516-18519	The	_	
95-2	18520-18529	elevation	_	
95-3	18530-18532	in	_	
95-4	18533-18541	dopamine	_	
95-5	18542-18550	function	_	
95-6	18551-18553	in	_	
95-7	18554-18559	those	_	
95-8	18560-18567	exposed	_	
95-9	18568-18570	to	_	
95-10	18571-18580	childhood	_	
95-11	18581-18590	adversity	_	
95-12	18591-18594	was	_	
95-13	18595-18607	particularly	_	
95-14	18608-18615	evident	_	
95-15	18616-18618	in	_	
95-16	18619-18622	the	_	
95-17	18623-18634	associative	_	
95-18	18635-18646	subdivision	_	
95-19	18647-18649	of	_	
95-20	18650-18653	the	_	
95-21	18654-18662	striatum	_	
95-22	18662-18663	.	_	

#Text=This is the same striatal subregion where the most robust dopaminergic findings are seen in schizophrenia.
96-1	18664-18668	This	_	
96-2	18669-18671	is	_	
96-3	18672-18675	the	_	
96-4	18676-18680	same	_	
96-5	18681-18689	striatal	_	
96-6	18690-18699	subregion	_	
96-7	18700-18705	where	_	
96-8	18706-18709	the	_	
96-9	18710-18714	most	_	
96-10	18715-18721	robust	_	
96-11	18722-18734	dopaminergic	_	
96-12	18735-18743	findings	_	
96-13	18744-18747	are	_	
96-14	18748-18752	seen	_	
96-15	18753-18755	in	_	
96-16	18756-18769	schizophrenia	_	
96-17	18769-18770	.	_	

#Text=The reported incidence of childhood adversities by both the UHR and Control participants was relatively high.
97-1	18771-18774	The	_	
97-2	18775-18783	reported	_	
97-3	18784-18793	incidence	_	
97-4	18794-18796	of	_	
97-5	18797-18806	childhood	_	
97-6	18807-18818	adversities	_	
97-7	18819-18821	by	_	
97-8	18822-18826	both	_	
97-9	18827-18830	the	_	
97-10	18831-18834	UHR	_	
97-11	18835-18838	and	_	
97-12	18839-18846	Control	_	
97-13	18847-18859	participants	_	
97-14	18860-18863	was	_	
97-15	18864-18874	relatively	_	
97-16	18875-18879	high	_	
97-17	18879-18880	.	_	

#Text=The volunteers were recruited from a geographical area (in South East London) that has unusually high levels of social and economic deprivation, and previous studies have found that childhood adversity is relatively common among the local population.
98-1	18881-18884	The	_	
98-2	18885-18895	volunteers	_	
98-3	18896-18900	were	_	
98-4	18901-18910	recruited	_	
98-5	18911-18915	from	_	
98-6	18916-18917	a	_	
98-7	18918-18930	geographical	_	
98-8	18931-18935	area	_	
98-9	18936-18937	(	_	
98-10	18937-18939	in	_	
98-11	18940-18945	South	_	
98-12	18946-18950	East	_	
98-13	18951-18957	London	_	
98-14	18957-18958	)	_	
98-15	18959-18963	that	_	
98-16	18964-18967	has	_	
98-17	18968-18977	unusually	_	
98-18	18978-18982	high	_	
98-19	18983-18989	levels	_	
98-20	18990-18992	of	_	
98-21	18993-18999	social	_	
98-22	19000-19003	and	_	
98-23	19004-19012	economic	_	
98-24	19013-19024	deprivation	_	
98-25	19024-19025	,	_	
98-26	19026-19029	and	_	
98-27	19030-19038	previous	_	
98-28	19039-19046	studies	_	
98-29	19047-19051	have	_	
98-30	19052-19057	found	_	
98-31	19058-19062	that	_	
98-32	19063-19072	childhood	_	
98-33	19073-19082	adversity	_	
98-34	19083-19085	is	_	
98-35	19086-19096	relatively	_	
98-36	19097-19103	common	_	
98-37	19104-19109	among	_	
98-38	19110-19113	the	_	
98-39	19114-19119	local	_	
98-40	19120-19130	population	_	
98-41	19130-19131	.	_	

#Text=However meta-analysis in patients with psychotic disorders suggest that they are nearly three times more likely to have experienced childhood adversities than controls.
99-1	19132-19139	However	_	
99-2	19140-19153	meta-analysis	_	
99-3	19154-19156	in	_	
99-4	19157-19165	patients	_	
99-5	19166-19170	with	_	
99-6	19171-19180	psychotic	_	
99-7	19181-19190	disorders	_	
99-8	19191-19198	suggest	_	
99-9	19199-19203	that	_	
99-10	19204-19208	they	_	
99-11	19209-19212	are	_	
99-12	19213-19219	nearly	_	
99-13	19220-19225	three	_	
99-14	19226-19231	times	_	
99-15	19232-19236	more	_	
99-16	19237-19243	likely	_	
99-17	19244-19246	to	_	
99-18	19247-19251	have	_	
99-19	19252-19263	experienced	_	
99-20	19264-19273	childhood	_	
99-21	19274-19285	adversities	_	
99-22	19286-19290	than	_	
99-23	19291-19299	controls	_	
99-24	19299-19300	.	_	

#Text=In the individuals included in the present study, striatal dopamine function was numerically but not significantly elevated in the UHR compared to healthy volunteer group.
100-1	19301-19303	In	_	
100-2	19304-19307	the	_	
100-3	19308-19319	individuals	_	
100-4	19320-19328	included	_	
100-5	19329-19331	in	_	
100-6	19332-19335	the	_	
100-7	19336-19343	present	_	
100-8	19344-19349	study	_	
100-9	19349-19350	,	_	
100-10	19351-19359	striatal	_	
100-11	19360-19368	dopamine	_	
100-12	19369-19377	function	_	
100-13	19378-19381	was	_	
100-14	19382-19393	numerically	_	
100-15	19394-19397	but	_	
100-16	19398-19401	not	_	
100-17	19402-19415	significantly	_	
100-18	19416-19424	elevated	_	
100-19	19425-19427	in	_	
100-20	19428-19431	the	_	
100-21	19432-19435	UHR	_	
100-22	19436-19444	compared	_	
100-23	19445-19447	to	_	
100-24	19448-19455	healthy	_	
100-25	19456-19465	volunteer	_	
100-26	19466-19471	group	_	
100-27	19471-19472	.	_	

#Text=This cohort represents a subsample from our previous studies that detected a significant elevation in striatal dopamine function in UHR compared to healthy volunteers overall.
101-1	19473-19477	This	_	
101-2	19478-19484	cohort	_	
101-3	19485-19495	represents	_	
101-4	19496-19497	a	_	
101-5	19498-19507	subsample	_	
101-6	19508-19512	from	_	
101-7	19513-19516	our	_	
101-8	19517-19525	previous	_	
101-9	19526-19533	studies	_	
101-10	19534-19538	that	_	
101-11	19539-19547	detected	_	
101-12	19548-19549	a	_	
101-13	19550-19561	significant	_	
101-14	19562-19571	elevation	_	
101-15	19572-19574	in	_	
101-16	19575-19583	striatal	_	
101-17	19584-19592	dopamine	_	
101-18	19593-19601	function	_	
101-19	19602-19604	in	_	
101-20	19605-19608	UHR	_	
101-21	19609-19617	compared	_	
101-22	19618-19620	to	_	
101-23	19621-19628	healthy	_	
101-24	19629-19639	volunteers	_	
101-25	19640-19647	overall	_	
101-26	19647-19648	.	_	

#Text=In UHR samples, the elevation in dopamine function is less marked than in schizophrenia and is mainly driven by the subgroup of UHR subjects who later develop psychosis.
102-1	19649-19651	In	_	
102-2	19652-19655	UHR	_	
102-3	19656-19663	samples	_	
102-4	19663-19664	,	_	
102-5	19665-19668	the	_	
102-6	19669-19678	elevation	_	
102-7	19679-19681	in	_	
102-8	19682-19690	dopamine	_	
102-9	19691-19699	function	_	
102-10	19700-19702	is	_	
102-11	19703-19707	less	_	
102-12	19708-19714	marked	_	
102-13	19715-19719	than	_	
102-14	19720-19722	in	_	
102-15	19723-19736	schizophrenia	_	
102-16	19737-19740	and	_	
102-17	19741-19743	is	_	
102-18	19744-19750	mainly	_	
102-19	19751-19757	driven	_	
102-20	19758-19760	by	_	
102-21	19761-19764	the	_	
102-22	19765-19773	subgroup	_	
102-23	19774-19776	of	_	
102-24	19777-19780	UHR	_	
102-25	19781-19789	subjects	_	
102-26	19790-19793	who	_	
102-27	19794-19799	later	_	
102-28	19800-19807	develop	_	
102-29	19808-19817	psychosis	_	
102-30	19817-19818	.	_	

#Text=This, along with the relatively high incidences of childhood adversities in the healthy volunteer sample, may account for the overlap in values for striatal dopamine synthesis capacity between the UHR and healthy volunteers.
103-1	19819-19823	This	_	
103-2	19823-19824	,	_	
103-3	19825-19830	along	_	
103-4	19831-19835	with	_	
103-5	19836-19839	the	_	
103-6	19840-19850	relatively	_	
103-7	19851-19855	high	_	
103-8	19856-19866	incidences	_	
103-9	19867-19869	of	_	
103-10	19870-19879	childhood	_	
103-11	19880-19891	adversities	_	
103-12	19892-19894	in	_	
103-13	19895-19898	the	_	
103-14	19899-19906	healthy	_	
103-15	19907-19916	volunteer	_	
103-16	19917-19923	sample	_	
103-17	19923-19924	,	_	
103-18	19925-19928	may	_	
103-19	19929-19936	account	_	
103-20	19937-19940	for	_	
103-21	19941-19944	the	_	
103-22	19945-19952	overlap	_	
103-23	19953-19955	in	_	
103-24	19956-19962	values	_	
103-25	19963-19966	for	_	
103-26	19967-19975	striatal	_	
103-27	19976-19984	dopamine	_	
103-28	19985-19994	synthesis	_	
103-29	19995-20003	capacity	_	
103-30	20004-20011	between	_	
103-31	20012-20015	the	_	
103-32	20016-20019	UHR	_	
103-33	20020-20023	and	_	
103-34	20024-20031	healthy	_	
103-35	20032-20042	volunteers	_	
103-36	20042-20043	.	_	

#Text=The putative relationship between childhood adversity, dopamine function and risk of psychosis could be further investigated in a large prospective study, which would determine how these factors relate to long-term clinical outcome in UHR subjects.
104-1	20044-20047	The	_	
104-2	20048-20056	putative	_	
104-3	20057-20069	relationship	_	
104-4	20070-20077	between	_	
104-5	20078-20087	childhood	_	
104-6	20088-20097	adversity	_	
104-7	20097-20098	,	_	
104-8	20099-20107	dopamine	_	
104-9	20108-20116	function	_	
104-10	20117-20120	and	_	
104-11	20121-20125	risk	_	
104-12	20126-20128	of	_	
104-13	20129-20138	psychosis	_	
104-14	20139-20144	could	_	
104-15	20145-20147	be	_	
104-16	20148-20155	further	_	
104-17	20156-20168	investigated	_	
104-18	20169-20171	in	_	
104-19	20172-20173	a	_	
104-20	20174-20179	large	_	
104-21	20180-20191	prospective	_	
104-22	20192-20197	study	_	
104-23	20197-20198	,	_	
104-24	20199-20204	which	_	
104-25	20205-20210	would	_	
104-26	20211-20220	determine	_	
104-27	20221-20224	how	_	
104-28	20225-20230	these	_	
104-29	20231-20238	factors	_	
104-30	20239-20245	relate	_	
104-31	20246-20248	to	_	
104-32	20249-20258	long-term	_	
104-33	20259-20267	clinical	_	
104-34	20268-20275	outcome	_	
104-35	20276-20278	in	_	
104-36	20279-20282	UHR	_	
104-37	20283-20291	subjects	_	
104-38	20291-20292	.	_	

#Text=However, an effect of adverse psychosocial experiences on dopamine function might only impact on the risk of illness if there are interactions with other factors that have also been implicated in psychosis, such as psychosocial exposures in adulthood or genetic risk factors.
105-1	20293-20300	However	_	
105-2	20300-20301	,	_	
105-3	20302-20304	an	_	
105-4	20305-20311	effect	_	
105-5	20312-20314	of	_	
105-6	20315-20322	adverse	_	
105-7	20323-20335	psychosocial	_	
105-8	20336-20347	experiences	_	
105-9	20348-20350	on	_	
105-10	20351-20359	dopamine	_	
105-11	20360-20368	function	_	
105-12	20369-20374	might	_	
105-13	20375-20379	only	_	
105-14	20380-20386	impact	_	
105-15	20387-20389	on	_	
105-16	20390-20393	the	_	
105-17	20394-20398	risk	_	
105-18	20399-20401	of	_	
105-19	20402-20409	illness	_	
105-20	20410-20412	if	_	
105-21	20413-20418	there	_	
105-22	20419-20422	are	_	
105-23	20423-20435	interactions	_	
105-24	20436-20440	with	_	
105-25	20441-20446	other	_	
105-26	20447-20454	factors	_	
105-27	20455-20459	that	_	
105-28	20460-20464	have	_	
105-29	20465-20469	also	_	
105-30	20470-20474	been	_	
105-31	20475-20485	implicated	_	
105-32	20486-20488	in	_	
105-33	20489-20498	psychosis	_	
105-34	20498-20499	,	_	
105-35	20500-20504	such	_	
105-36	20505-20507	as	_	
105-37	20508-20520	psychosocial	_	
105-38	20521-20530	exposures	_	
105-39	20531-20533	in	_	
105-40	20534-20543	adulthood	_	
105-41	20544-20546	or	_	
105-42	20547-20554	genetic	_	
105-43	20555-20559	risk	_	
105-44	20560-20567	factors	_	
105-45	20567-20568	.	_	

#Text=This would be consistent with current aetiological models of mental illness, which propose that these involve complex gene-environment, gene-gene and environment-environment interactions.
106-1	20569-20573	This	_	
106-2	20574-20579	would	_	
106-3	20580-20582	be	_	
106-4	20583-20593	consistent	_	
106-5	20594-20598	with	_	
106-6	20599-20606	current	_	
106-7	20607-20619	aetiological	_	
106-8	20620-20626	models	_	
106-9	20627-20629	of	_	
106-10	20630-20636	mental	_	
106-11	20637-20644	illness	_	
106-12	20644-20645	,	_	
106-13	20646-20651	which	_	
106-14	20652-20659	propose	_	
106-15	20660-20664	that	_	
106-16	20665-20670	these	_	
106-17	20671-20678	involve	_	
106-18	20679-20686	complex	_	
106-19	20687-20703	gene-environment	_	
106-20	20703-20704	,	_	
106-21	20705-20714	gene-gene	_	
106-22	20715-20718	and	_	
106-23	20719-20742	environment-environment	_	
106-24	20743-20755	interactions	_	
106-25	20755-20756	.	_	

#Text=One limitation of the present study (and most other adult studies of childhood abuse) is that the assessment of childhood adversity relied on retrospective reporting, which may be influenced by current psychopathology.
107-1	20757-20760	One	_	
107-2	20761-20771	limitation	_	
107-3	20772-20774	of	_	
107-4	20775-20778	the	_	
107-5	20779-20786	present	_	
107-6	20787-20792	study	_	
107-7	20793-20794	(	_	
107-8	20794-20797	and	_	
107-9	20798-20802	most	_	
107-10	20803-20808	other	_	
107-11	20809-20814	adult	_	
107-12	20815-20822	studies	_	
107-13	20823-20825	of	_	
107-14	20826-20835	childhood	_	
107-15	20836-20841	abuse	_	
107-16	20841-20842	)	_	
107-17	20843-20845	is	_	
107-18	20846-20850	that	_	
107-19	20851-20854	the	_	
107-20	20855-20865	assessment	_	
107-21	20866-20868	of	_	
107-22	20869-20878	childhood	_	
107-23	20879-20888	adversity	_	
107-24	20889-20895	relied	_	
107-25	20896-20898	on	_	
107-26	20899-20912	retrospective	_	
107-27	20913-20922	reporting	_	
107-28	20922-20923	,	_	
107-29	20924-20929	which	_	
107-30	20930-20933	may	_	
107-31	20934-20936	be	_	
107-32	20937-20947	influenced	_	
107-33	20948-20950	by	_	
107-34	20951-20958	current	_	
107-35	20959-20974	psychopathology	_	
107-36	20974-20975	.	_	

#Text=Nonetheless patients' retrospective reports of abuse tend to be stable, accurate and unaffected by current symptoms.
108-1	20976-20987	Nonetheless	_	
108-2	20988-20996	patients	_	
108-3	20996-20997	'	_	
108-4	20998-21011	retrospective	_	
108-5	21012-21019	reports	_	
108-6	21020-21022	of	_	
108-7	21023-21028	abuse	_	
108-8	21029-21033	tend	_	
108-9	21034-21036	to	_	
108-10	21037-21039	be	_	
108-11	21040-21046	stable	_	
108-12	21046-21047	,	_	
108-13	21048-21056	accurate	_	
108-14	21057-21060	and	_	
108-15	21061-21071	unaffected	_	
108-16	21072-21074	by	_	
108-17	21075-21082	current	_	
108-18	21083-21091	symptoms	_	
108-19	21091-21092	.	_	

#Text=The low number of exposures to some forms or markers of psychosocial stress (such as being taken into local authority care) limited the analysis to relatively common factors.
109-1	21093-21096	The	_	
109-2	21097-21100	low	_	
109-3	21101-21107	number	_	
109-4	21108-21110	of	_	
109-5	21111-21120	exposures	_	
109-6	21121-21123	to	_	
109-7	21124-21128	some	_	
109-8	21129-21134	forms	_	
109-9	21135-21137	or	_	
109-10	21138-21145	markers	_	
109-11	21146-21148	of	_	
109-12	21149-21161	psychosocial	_	
109-13	21162-21168	stress	_	
109-14	21169-21170	(	_	
109-15	21170-21174	such	_	
109-16	21175-21177	as	_	
109-17	21178-21183	being	_	
109-18	21184-21189	taken	_	
109-19	21190-21194	into	_	
109-20	21195-21200	local	_	
109-21	21201-21210	authority	_	
109-22	21211-21215	care	_	
109-23	21215-21216	)	_	
109-24	21217-21224	limited	_	
109-25	21225-21228	the	_	
109-26	21229-21237	analysis	_	
109-27	21238-21240	to	_	
109-28	21241-21251	relatively	_	
109-29	21252-21258	common	_	
109-30	21259-21266	factors	_	
109-31	21266-21267	.	_	

#Text=These issues could be addressed in large scale prospective studies of children with detailed psychosocial evaluations, neuroimaging measures, and long term follow up.
110-1	21268-21273	These	_	
110-2	21274-21280	issues	_	
110-3	21281-21286	could	_	
110-4	21287-21289	be	_	
110-5	21290-21299	addressed	_	
110-6	21300-21302	in	_	
110-7	21303-21308	large	_	
110-8	21309-21314	scale	_	
110-9	21315-21326	prospective	_	
110-10	21327-21334	studies	_	
110-11	21335-21337	of	_	
110-12	21338-21346	children	_	
110-13	21347-21351	with	_	
110-14	21352-21360	detailed	_	
110-15	21361-21373	psychosocial	_	
110-16	21374-21385	evaluations	_	
110-17	21385-21386	,	_	
110-18	21387-21399	neuroimaging	_	
110-19	21400-21408	measures	_	
110-20	21408-21409	,	_	
110-21	21410-21413	and	_	
110-22	21414-21418	long	_	
110-23	21419-21423	term	_	
110-24	21424-21430	follow	_	
110-25	21431-21433	up	_	
110-26	21433-21434	.	_	

#Text=Disclosure
#Text=AE has received consultancy fees from Heptares Therapeutics Ltd. and worked on research funded by Hoffman la Roche.
111-1	21435-21445	Disclosure	_	
111-2	21446-21448	AE	_	
111-3	21449-21452	has	_	
111-4	21453-21461	received	_	
111-5	21462-21473	consultancy	_	
111-6	21474-21478	fees	_	
111-7	21479-21483	from	_	
111-8	21484-21492	Heptares	_	
111-9	21493-21505	Therapeutics	_	
111-10	21506-21509	Ltd	_	
111-11	21509-21510	.	_	
111-12	21511-21514	and	_	
111-13	21515-21521	worked	_	
111-14	21522-21524	on	_	
111-15	21525-21533	research	_	
111-16	21534-21540	funded	_	
111-17	21541-21543	by	_	
111-18	21544-21551	Hoffman	_	
111-19	21552-21554	la	_	
111-20	21555-21560	Roche	_	
111-21	21560-21561	.	_	

#Text=ODH has received unrestricted investigator-led charitable funding from or spoken at meetings organized by Astra-Zeneca, Bristol-Myers Squibb, Janssen, Hoffman la Roche, Leyden-Delta and Eli Lilly.
112-1	21562-21565	ODH	_	
112-2	21566-21569	has	_	
112-3	21570-21578	received	_	
112-4	21579-21591	unrestricted	_	
112-5	21592-21608	investigator-led	_	
112-6	21609-21619	charitable	_	
112-7	21620-21627	funding	_	
112-8	21628-21632	from	_	
112-9	21633-21635	or	_	
112-10	21636-21642	spoken	_	
112-11	21643-21645	at	_	
112-12	21646-21654	meetings	_	
112-13	21655-21664	organized	_	
112-14	21665-21667	by	_	
112-15	21668-21680	Astra-Zeneca	_	
112-16	21680-21681	,	_	
112-17	21682-21695	Bristol-Myers	_	
112-18	21696-21702	Squibb	_	
112-19	21702-21703	,	_	
112-20	21704-21711	Janssen	_	
112-21	21711-21712	,	_	
112-22	21713-21720	Hoffman	_	
112-23	21721-21723	la	_	
112-24	21724-21729	Roche	_	
112-25	21729-21730	,	_	
112-26	21731-21743	Leyden-Delta	_	
112-27	21744-21747	and	_	
112-28	21748-21751	Eli	_	
112-29	21752-21757	Lilly	_	
112-30	21757-21758	.	_	

#Text=RMM has received honoraria from Janssen, Eli Lilly, Astra-Zeneca, Bristol-Myers Squibb, and Hoffman la Roche.
113-1	21759-21762	RMM	_	
113-2	21763-21766	has	_	
113-3	21767-21775	received	_	
113-4	21776-21785	honoraria	_	
113-5	21786-21790	from	_	
113-6	21791-21798	Janssen	_	
113-7	21798-21799	,	_	
113-8	21800-21803	Eli	_	
113-9	21804-21809	Lilly	_	
113-10	21809-21810	,	_	
113-11	21811-21823	Astra-Zeneca	_	
113-12	21823-21824	,	_	
113-13	21825-21838	Bristol-Myers	_	
113-14	21839-21845	Squibb	_	
113-15	21845-21846	,	_	
113-16	21847-21850	and	_	
113-17	21851-21858	Hoffman	_	
113-18	21859-21861	la	_	
113-19	21862-21867	Roche	_	
113-20	21867-21868	.	_	

#Text=PM has received consultancy fees from Hoffman la Roche and Sunovion.
114-1	21869-21871	PM	_	
114-2	21872-21875	has	_	
114-3	21876-21884	received	_	
114-4	21885-21896	consultancy	_	
114-5	21897-21901	fees	_	
114-6	21902-21906	from	_	
114-7	21907-21914	Hoffman	_	
114-8	21915-21917	la	_	
114-9	21918-21923	Roche	_	
114-10	21924-21927	and	_	
114-11	21928-21936	Sunovion	_	
114-12	21936-21937	.	_	

#Text=The remaining authors declare no potential conflicts of interest.
115-1	21938-21941	The	_	
115-2	21942-21951	remaining	_	
115-3	21952-21959	authors	_	
115-4	21960-21967	declare	_	
115-5	21968-21970	no	_	
115-6	21971-21980	potential	_	
115-7	21981-21990	conflicts	_	
115-8	21991-21993	of	_	
115-9	21994-22002	interest	_	
115-10	22002-22003	.	_	

#Text=Conflict of interest
#Text=AE has received consultancy fees from Heptares Therapeutics Ltd. and worked on research funded by Hoffman la Roche.
116-1	22004-22012	Conflict	_	
116-2	22013-22015	of	_	
116-3	22016-22024	interest	_	
116-4	22025-22027	AE	_	
116-5	22028-22031	has	_	
116-6	22032-22040	received	_	
116-7	22041-22052	consultancy	_	
116-8	22053-22057	fees	_	
116-9	22058-22062	from	_	
116-10	22063-22071	Heptares	_	
116-11	22072-22084	Therapeutics	_	
116-12	22085-22088	Ltd	_	
116-13	22088-22089	.	_	
116-14	22090-22093	and	_	
116-15	22094-22100	worked	_	
116-16	22101-22103	on	_	
116-17	22104-22112	research	_	
116-18	22113-22119	funded	_	
116-19	22120-22122	by	_	
116-20	22123-22130	Hoffman	_	
116-21	22131-22133	la	_	
116-22	22134-22139	Roche	_	
116-23	22139-22140	.	_	

#Text=ODH has received unrestricted investigator-led charitable funding from or spoken at meetings organized by Astra-Zeneca, Bristol-Myers Squibb, Janssen, Hoffman la Roche, Leyden-Delta and Eli Lilly.
117-1	22141-22144	ODH	_	
117-2	22145-22148	has	_	
117-3	22149-22157	received	_	
117-4	22158-22170	unrestricted	_	
117-5	22171-22187	investigator-led	_	
117-6	22188-22198	charitable	_	
117-7	22199-22206	funding	_	
117-8	22207-22211	from	_	
117-9	22212-22214	or	_	
117-10	22215-22221	spoken	_	
117-11	22222-22224	at	_	
117-12	22225-22233	meetings	_	
117-13	22234-22243	organized	_	
117-14	22244-22246	by	_	
117-15	22247-22259	Astra-Zeneca	_	
117-16	22259-22260	,	_	
117-17	22261-22274	Bristol-Myers	_	
117-18	22275-22281	Squibb	_	
117-19	22281-22282	,	_	
117-20	22283-22290	Janssen	_	
117-21	22290-22291	,	_	
117-22	22292-22299	Hoffman	_	
117-23	22300-22302	la	_	
117-24	22303-22308	Roche	_	
117-25	22308-22309	,	_	
117-26	22310-22322	Leyden-Delta	_	
117-27	22323-22326	and	_	
117-28	22327-22330	Eli	_	
117-29	22331-22336	Lilly	_	
117-30	22336-22337	.	_	

#Text=RMM has received honoraria from Janssen, Eli Lilly, Astra-Zeneca, Bristol-Myers Squibb, and Hoffman la Roche.
118-1	22338-22341	RMM	_	
118-2	22342-22345	has	_	
118-3	22346-22354	received	_	
118-4	22355-22364	honoraria	_	
118-5	22365-22369	from	_	
118-6	22370-22377	Janssen	_	
118-7	22377-22378	,	_	
118-8	22379-22382	Eli	_	
118-9	22383-22388	Lilly	_	
118-10	22388-22389	,	_	
118-11	22390-22402	Astra-Zeneca	_	
118-12	22402-22403	,	_	
118-13	22404-22417	Bristol-Myers	_	
118-14	22418-22424	Squibb	_	
118-15	22424-22425	,	_	
118-16	22426-22429	and	_	
118-17	22430-22437	Hoffman	_	
118-18	22438-22440	la	_	
118-19	22441-22446	Roche	_	
118-20	22446-22447	.	_	

#Text=PM has received consultancy fees from Hoffman la Roche and Sunovion.
119-1	22448-22450	PM	_	
119-2	22451-22454	has	_	
119-3	22455-22463	received	_	
119-4	22464-22475	consultancy	_	
119-5	22476-22480	fees	_	
119-6	22481-22485	from	_	
119-7	22486-22493	Hoffman	_	
119-8	22494-22496	la	_	
119-9	22497-22502	Roche	_	
119-10	22503-22506	and	_	
119-11	22507-22515	Sunovion	_	
119-12	22515-22516	.	_	

#Text=The remaining authors declare no potential conflicts of interest.
120-1	22517-22520	The	_	
120-2	22521-22530	remaining	_	
120-3	22531-22538	authors	_	
120-4	22539-22546	declare	_	
120-5	22547-22549	no	_	
120-6	22550-22559	potential	_	
120-7	22560-22569	conflicts	_	
120-8	22570-22572	of	_	
120-9	22573-22581	interest	_	
120-10	22581-22582	.	_	

#Text=Contributors
#Text=AE, LV, OH, PA, RM and PM designed the study.
121-1	22583-22595	Contributors	_	
121-2	22596-22598	AE	_	
121-3	22598-22599	,	_	
121-4	22600-22602	LV	_	
121-5	22602-22603	,	_	
121-6	22604-22606	OH	_	
121-7	22606-22607	,	_	
121-8	22608-22610	PA	_	
121-9	22610-22611	,	_	
121-10	22612-22614	RM	_	
121-11	22615-22618	and	_	
121-12	22619-22621	PM	_	
121-13	22622-22630	designed	_	
121-14	22631-22634	the	_	
121-15	22635-22640	study	_	
121-16	22640-22641	.	_	

#Text=AE, LV, OH, FD, CC, TW-B, MB, SB acquired the study data; AE, FD, MB, JC, JL analysed the study data.
122-1	22642-22644	AE	_	
122-2	22644-22645	,	_	
122-3	22646-22648	LV	_	
122-4	22648-22649	,	_	
122-5	22650-22652	OH	_	
122-6	22652-22653	,	_	
122-7	22654-22656	FD	_	
122-8	22656-22657	,	_	
122-9	22658-22660	CC	_	
122-10	22660-22661	,	_	
122-11	22662-22666	TW-B	_	
122-12	22666-22667	,	_	
122-13	22668-22670	MB	_	
122-14	22670-22671	,	_	
122-15	22672-22674	SB	_	
122-16	22675-22683	acquired	_	
122-17	22684-22687	the	_	
122-18	22688-22693	study	_	
122-19	22694-22698	data	_	
122-20	22698-22699	;	_	
122-21	22700-22702	AE	_	
122-22	22702-22703	,	_	
122-23	22704-22706	FD	_	
122-24	22706-22707	,	_	
122-25	22708-22710	MB	_	
122-26	22710-22711	,	_	
122-27	22712-22714	JC	_	
122-28	22714-22715	,	_	
122-29	22716-22718	JL	_	
122-30	22719-22727	analysed	_	
122-31	22728-22731	the	_	
122-32	22732-22737	study	_	
122-33	22738-22742	data	_	
122-34	22742-22743	.	_	

#Text=All authors contributed to and approved the final manuscript.
123-1	22744-22747	All	_	
123-2	22748-22755	authors	_	
123-3	22756-22767	contributed	_	
123-4	22768-22770	to	_	
123-5	22771-22774	and	_	
123-6	22775-22783	approved	_	
123-7	22784-22787	the	_	
123-8	22788-22793	final	_	
123-9	22794-22804	manuscript	_	
123-10	22804-22805	.	_	

#Text=Role of funding source
#Text=The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
124-1	22806-22810	Role	_	
124-2	22811-22813	of	_	
124-3	22814-22821	funding	_	
124-4	22822-22828	source	_	
124-5	22829-22832	The	_	
124-6	22833-22840	funding	_	
124-7	22841-22847	source	_	
124-8	22848-22851	had	_	
124-9	22852-22854	no	_	
124-10	22855-22859	role	_	
124-11	22860-22862	in	_	
124-12	22863-22866	the	_	
124-13	22867-22873	design	_	
124-14	22874-22877	and	_	
124-15	22878-22885	conduct	_	
124-16	22886-22888	of	_	
124-17	22889-22892	the	_	
124-18	22893-22898	study	_	
124-19	22898-22899	;	_	
124-20	22900-22910	collection	_	
124-21	22910-22911	,	_	
124-22	22912-22922	management	_	
124-23	22922-22923	,	_	
124-24	22924-22932	analysis	_	
124-25	22932-22933	,	_	
124-26	22934-22937	and	_	
124-27	22938-22952	interpretation	_	
124-28	22953-22955	of	_	
124-29	22956-22959	the	_	
124-30	22960-22964	data	_	
124-31	22964-22965	;	_	
124-32	22966-22977	preparation	_	
124-33	22977-22978	,	_	
124-34	22979-22985	review	_	
124-35	22985-22986	,	_	
124-36	22987-22989	or	_	
124-37	22990-22998	approval	_	
124-38	22999-23001	of	_	
124-39	23002-23005	the	_	
124-40	23006-23016	manuscript	_	
124-41	23016-23017	;	_	
124-42	23018-23021	and	_	
124-43	23022-23030	decision	_	
124-44	23031-23033	to	_	
124-45	23034-23040	submit	_	
124-46	23041-23044	the	_	
124-47	23045-23055	manuscript	_	
124-48	23056-23059	for	_	
124-49	23060-23071	publication	_	
124-50	23071-23072	.	_	

#Text=References
#Text=Interchangeability of stress and amphetamine in sensitization
#Text=The childhood experience of care and abuse questionnaire (CECA.Q): validation in a community series
#Text=Testing the psychosis continuum: differential impact of genetic and nongenetic risk factors and comorbid psychopathology across the entire spectrum of psychosis
#Text=Caregiver instability and early life changes among infants reported to the child welfare system
#Text=Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort
#Text=Reliability and comparability of psychosis patients' retrospective reports of childhood abuse
#Text=Trauma and current symptoms of PTSD in a South East London community
#Text=Increased release of dopamine in the striata of young adults with hearing impairment and its relevance for the social defeat hypothesis of schizophrenia
#Text=The assessment of anxiety states by rating
#Text=A rating scale for depression
#Text=Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe
#Text=The dopamine hypothesis of schizophrenia: version III–the final common pathway
#Text=Pathways to schizophrenia: the impact of environmental factors
#Text=Elevated striatal dopamine function linked to prodromal signs of schizophrenia
#Text=Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study
#Text=Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study
#Text=The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies
#Text=The positive and negative syndrome scale (PANSS) for schizophrenia
#Text=Increased synaptic dopamine function in associative regions of the striatum in schizophrenia
#Text=Reported history of child sexual abuse in schizophrenia: associations with heightened symptom levels and poorer participation over four months in vocational rehabilitation
#Text=Imaging human mesolimbic dopamine transmission with positron emission tomography.
125-1	23073-23083	References	_	
125-2	23084-23102	Interchangeability	_	
125-3	23103-23105	of	_	
125-4	23106-23112	stress	_	
125-5	23113-23116	and	_	
125-6	23117-23128	amphetamine	_	
125-7	23129-23131	in	_	
125-8	23132-23145	sensitization	_	
125-9	23146-23149	The	_	
125-10	23150-23159	childhood	_	
125-11	23160-23170	experience	_	
125-12	23171-23173	of	_	
125-13	23174-23178	care	_	
125-14	23179-23182	and	_	
125-15	23183-23188	abuse	_	
125-16	23189-23202	questionnaire	_	
125-17	23203-23204	(	_	
125-18	23204-23210	CECA.Q	_	
125-19	23210-23211	)	_	
125-20	23211-23212	:	_	
125-21	23213-23223	validation	_	
125-22	23224-23226	in	_	
125-23	23227-23228	a	_	
125-24	23229-23238	community	_	
125-25	23239-23245	series	_	
125-26	23246-23253	Testing	_	
125-27	23254-23257	the	_	
125-28	23258-23267	psychosis	_	
125-29	23268-23277	continuum	_	
125-30	23277-23278	:	_	
125-31	23279-23291	differential	_	
125-32	23292-23298	impact	_	
125-33	23299-23301	of	_	
125-34	23302-23309	genetic	_	
125-35	23310-23313	and	_	
125-36	23314-23324	nongenetic	_	
125-37	23325-23329	risk	_	
125-38	23330-23337	factors	_	
125-39	23338-23341	and	_	
125-40	23342-23350	comorbid	_	
125-41	23351-23366	psychopathology	_	
125-42	23367-23373	across	_	
125-43	23374-23377	the	_	
125-44	23378-23384	entire	_	
125-45	23385-23393	spectrum	_	
125-46	23394-23396	of	_	
125-47	23397-23406	psychosis	_	
125-48	23407-23416	Caregiver	_	
125-49	23417-23428	instability	_	
125-50	23429-23432	and	_	
125-51	23433-23438	early	_	
125-52	23439-23443	life	_	
125-53	23444-23451	changes	_	
125-54	23452-23457	among	_	
125-55	23458-23465	infants	_	
125-56	23466-23474	reported	_	
125-57	23475-23477	to	_	
125-58	23478-23481	the	_	
125-59	23482-23487	child	_	
125-60	23488-23495	welfare	_	
125-61	23496-23502	system	_	
125-62	23503-23514	Presynaptic	_	
125-63	23515-23523	striatal	_	
125-64	23524-23532	dopamine	_	
125-65	23533-23544	dysfunction	_	
125-66	23545-23547	in	_	
125-67	23548-23554	people	_	
125-68	23555-23557	at	_	
125-69	23558-23568	ultra-high	_	
125-70	23569-23573	risk	_	
125-71	23574-23577	for	_	
125-72	23578-23587	psychosis	_	
125-73	23587-23588	:	_	
125-74	23589-23597	findings	_	
125-75	23598-23600	in	_	
125-76	23601-23602	a	_	
125-77	23603-23609	second	_	
125-78	23610-23616	cohort	_	
125-79	23617-23628	Reliability	_	
125-80	23629-23632	and	_	
125-81	23633-23646	comparability	_	
125-82	23647-23649	of	_	
125-83	23650-23659	psychosis	_	
125-84	23660-23668	patients	_	
125-85	23668-23669	'	_	
125-86	23670-23683	retrospective	_	
125-87	23684-23691	reports	_	
125-88	23692-23694	of	_	
125-89	23695-23704	childhood	_	
125-90	23705-23710	abuse	_	
125-91	23711-23717	Trauma	_	
125-92	23718-23721	and	_	
125-93	23722-23729	current	_	
125-94	23730-23738	symptoms	_	
125-95	23739-23741	of	_	
125-96	23742-23746	PTSD	_	
125-97	23747-23749	in	_	
125-98	23750-23751	a	_	
125-99	23752-23757	South	_	
125-100	23758-23762	East	_	
125-101	23763-23769	London	_	
125-102	23770-23779	community	_	
125-103	23780-23789	Increased	_	
125-104	23790-23797	release	_	
125-105	23798-23800	of	_	
125-106	23801-23809	dopamine	_	
125-107	23810-23812	in	_	
125-108	23813-23816	the	_	
125-109	23817-23824	striata	_	
125-110	23825-23827	of	_	
125-111	23828-23833	young	_	
125-112	23834-23840	adults	_	
125-113	23841-23845	with	_	
125-114	23846-23853	hearing	_	
125-115	23854-23864	impairment	_	
125-116	23865-23868	and	_	
125-117	23869-23872	its	_	
125-118	23873-23882	relevance	_	
125-119	23883-23886	for	_	
125-120	23887-23890	the	_	
125-121	23891-23897	social	_	
125-122	23898-23904	defeat	_	
125-123	23905-23915	hypothesis	_	
125-124	23916-23918	of	_	
125-125	23919-23932	schizophrenia	_	
125-126	23933-23936	The	_	
125-127	23937-23947	assessment	_	
125-128	23948-23950	of	_	
125-129	23951-23958	anxiety	_	
125-130	23959-23965	states	_	
125-131	23966-23968	by	_	
125-132	23969-23975	rating	_	
125-133	23976-23977	A	_	
125-134	23978-23984	rating	_	
125-135	23985-23990	scale	_	
125-136	23991-23994	for	_	
125-137	23995-24005	depression	_	
125-138	24006-24023	Three-dimensional	_	
125-139	24024-24031	maximum	_	
125-140	24032-24043	probability	_	
125-141	24044-24049	atlas	_	
125-142	24050-24052	of	_	
125-143	24053-24056	the	_	
125-144	24057-24062	human	_	
125-145	24063-24068	brain	_	
125-146	24068-24069	,	_	
125-147	24070-24074	with	_	
125-148	24075-24085	particular	_	
125-149	24086-24095	reference	_	
125-150	24096-24098	to	_	
125-151	24099-24102	the	_	
125-152	24103-24111	temporal	_	
125-153	24112-24116	lobe	_	
125-154	24117-24120	The	_	
125-155	24121-24129	dopamine	_	
125-156	24130-24140	hypothesis	_	
125-157	24141-24143	of	_	
125-158	24144-24157	schizophrenia	_	
125-159	24157-24158	:	_	
125-160	24159-24166	version	_	
125-161	24167-24174	III–the	_	
125-162	24175-24180	final	_	
125-163	24181-24187	common	_	
125-164	24188-24195	pathway	_	
125-165	24196-24204	Pathways	_	
125-166	24205-24207	to	_	
125-167	24208-24221	schizophrenia	_	
125-168	24221-24222	:	_	
125-169	24223-24226	the	_	
125-170	24227-24233	impact	_	
125-171	24234-24236	of	_	
125-172	24237-24250	environmental	_	
125-173	24251-24258	factors	_	
125-174	24259-24267	Elevated	_	
125-175	24268-24276	striatal	_	
125-176	24277-24285	dopamine	_	
125-177	24286-24294	function	_	
125-178	24295-24301	linked	_	
125-179	24302-24304	to	_	
125-180	24305-24314	prodromal	_	
125-181	24315-24320	signs	_	
125-182	24321-24323	of	_	
125-183	24324-24337	schizophrenia	_	
125-184	24338-24349	Progressive	_	
125-185	24350-24358	increase	_	
125-186	24359-24361	in	_	
125-187	24362-24370	striatal	_	
125-188	24371-24379	dopamine	_	
125-189	24380-24389	synthesis	_	
125-190	24390-24398	capacity	_	
125-191	24399-24401	as	_	
125-192	24402-24410	patients	_	
125-193	24411-24418	develop	_	
125-194	24419-24428	psychosis	_	
125-195	24428-24429	:	_	
125-196	24430-24431	a	_	
125-197	24432-24435	PET	_	
125-198	24436-24441	study	_	
125-199	24442-24450	Dopamine	_	
125-200	24451-24460	synthesis	_	
125-201	24461-24469	capacity	_	
125-202	24470-24476	before	_	
125-203	24477-24482	onset	_	
125-204	24483-24485	of	_	
125-205	24486-24495	psychosis	_	
125-206	24495-24496	:	_	
125-207	24497-24498	a	_	
125-208	24499-24510	prospective	_	
125-209	24511-24512	[	_	
125-210	24512-24515	18F	_	
125-211	24515-24516	]	_	
125-212	24516-24517	-	_	
125-213	24517-24521	DOPA	_	
125-214	24522-24525	PET	_	
125-215	24526-24533	imaging	_	
125-216	24534-24539	study	_	
125-217	24540-24543	The	_	
125-218	24544-24550	nature	_	
125-219	24551-24553	of	_	
125-220	24554-24562	dopamine	_	
125-221	24563-24574	dysfunction	_	
125-222	24575-24577	in	_	
125-223	24578-24591	schizophrenia	_	
125-224	24592-24595	and	_	
125-225	24596-24600	what	_	
125-226	24601-24605	this	_	
125-227	24606-24611	means	_	
125-228	24612-24615	for	_	
125-229	24616-24625	treatment	_	
125-230	24625-24626	:	_	
125-231	24627-24640	meta-analysis	_	
125-232	24641-24643	of	_	
125-233	24644-24651	imaging	_	
125-234	24652-24659	studies	_	
125-235	24660-24663	The	_	
125-236	24664-24672	positive	_	
125-237	24673-24676	and	_	
125-238	24677-24685	negative	_	
125-239	24686-24694	syndrome	_	
125-240	24695-24700	scale	_	
125-241	24701-24702	(	_	
125-242	24702-24707	PANSS	_	
125-243	24707-24708	)	_	
125-244	24709-24712	for	_	
125-245	24713-24726	schizophrenia	_	
125-246	24727-24736	Increased	_	
125-247	24737-24745	synaptic	_	
125-248	24746-24754	dopamine	_	
125-249	24755-24763	function	_	
125-250	24764-24766	in	_	
125-251	24767-24778	associative	_	
125-252	24779-24786	regions	_	
125-253	24787-24789	of	_	
125-254	24790-24793	the	_	
125-255	24794-24802	striatum	_	
125-256	24803-24805	in	_	
125-257	24806-24819	schizophrenia	_	
125-258	24820-24828	Reported	_	
125-259	24829-24836	history	_	
125-260	24837-24839	of	_	
125-261	24840-24845	child	_	
125-262	24846-24852	sexual	_	
125-263	24853-24858	abuse	_	
125-264	24859-24861	in	_	
125-265	24862-24875	schizophrenia	_	
125-266	24875-24876	:	_	
125-267	24877-24889	associations	_	
125-268	24890-24894	with	_	
125-269	24895-24905	heightened	_	
125-270	24906-24913	symptom	_	
125-271	24914-24920	levels	_	
125-272	24921-24924	and	_	
125-273	24925-24931	poorer	_	
125-274	24932-24945	participation	_	
125-275	24946-24950	over	_	
125-276	24951-24955	four	_	
125-277	24956-24962	months	_	
125-278	24963-24965	in	_	
125-279	24966-24976	vocational	_	
125-280	24977-24991	rehabilitation	_	
125-281	24992-24999	Imaging	_	
125-282	25000-25005	human	_	
125-283	25006-25016	mesolimbic	_	
125-284	25017-25025	dopamine	_	
125-285	25026-25038	transmission	_	
125-286	25039-25043	with	_	
125-287	25044-25052	positron	_	
125-288	25053-25061	emission	_	
125-289	25062-25072	tomography	_	
125-290	25072-25073	.	_	

#Text=Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum
#Text=Imaging human mesolimbic dopamine transmission with positron emission tomography: I.
126-1	25074-25078	Part	_	
126-2	25079-25081	II	_	
126-3	25081-25082	:	_	
126-4	25083-25102	amphetamine-induced	_	
126-5	25103-25111	dopamine	_	
126-6	25112-25119	release	_	
126-7	25120-25122	in	_	
126-8	25123-25126	the	_	
126-9	25127-25137	functional	_	
126-10	25138-25150	subdivisions	_	
126-11	25151-25153	of	_	
126-12	25154-25157	the	_	
126-13	25158-25166	striatum	_	
126-14	25167-25174	Imaging	_	
126-15	25175-25180	human	_	
126-16	25181-25191	mesolimbic	_	
126-17	25192-25200	dopamine	_	
126-18	25201-25213	transmission	_	
126-19	25214-25218	with	_	
126-20	25219-25227	positron	_	
126-21	25228-25236	emission	_	
126-22	25237-25247	tomography	_	
126-23	25247-25248	:	_	
126-24	25249-25250	I	_	
126-25	25250-25251	.	_	

#Text=Accuracy and precision of D(2) receptor parameter measurements in ventral striatum
#Text=Increased stress-induced dopamine release in psychosis
#Text=Molecular genetic gene-environment studies using candidate genes in schizophrenia: a systematic review
#Text=Modelling the interplay between childhood and adult adversity in pathways to psychosis: initial evidence from the AESOP study
#Text=History of childhood adversity is positively associated with ventral striatal dopamine responses to amphetamine
#Text=Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data.
127-1	25252-25260	Accuracy	_	
127-2	25261-25264	and	_	
127-3	25265-25274	precision	_	
127-4	25275-25277	of	_	
127-5	25278-25279	D	_	
127-6	25279-25280	(	_	
127-7	25280-25281	2	_	
127-8	25281-25282	)	_	
127-9	25283-25291	receptor	_	
127-10	25292-25301	parameter	_	
127-11	25302-25314	measurements	_	
127-12	25315-25317	in	_	
127-13	25318-25325	ventral	_	
127-14	25326-25334	striatum	_	
127-15	25335-25344	Increased	_	
127-16	25345-25359	stress-induced	_	
127-17	25360-25368	dopamine	_	
127-18	25369-25376	release	_	
127-19	25377-25379	in	_	
127-20	25380-25389	psychosis	_	
127-21	25390-25399	Molecular	_	
127-22	25400-25407	genetic	_	
127-23	25408-25424	gene-environment	_	
127-24	25425-25432	studies	_	
127-25	25433-25438	using	_	
127-26	25439-25448	candidate	_	
127-27	25449-25454	genes	_	
127-28	25455-25457	in	_	
127-29	25458-25471	schizophrenia	_	
127-30	25471-25472	:	_	
127-31	25473-25474	a	_	
127-32	25475-25485	systematic	_	
127-33	25486-25492	review	_	
127-34	25493-25502	Modelling	_	
127-35	25503-25506	the	_	
127-36	25507-25516	interplay	_	
127-37	25517-25524	between	_	
127-38	25525-25534	childhood	_	
127-39	25535-25538	and	_	
127-40	25539-25544	adult	_	
127-41	25545-25554	adversity	_	
127-42	25555-25557	in	_	
127-43	25558-25566	pathways	_	
127-44	25567-25569	to	_	
127-45	25570-25579	psychosis	_	
127-46	25579-25580	:	_	
127-47	25581-25588	initial	_	
127-48	25589-25597	evidence	_	
127-49	25598-25602	from	_	
127-50	25603-25606	the	_	
127-51	25607-25612	AESOP	_	
127-52	25613-25618	study	_	
127-53	25619-25626	History	_	
127-54	25627-25629	of	_	
127-55	25630-25639	childhood	_	
127-56	25640-25649	adversity	_	
127-57	25650-25652	is	_	
127-58	25653-25663	positively	_	
127-59	25664-25674	associated	_	
127-60	25675-25679	with	_	
127-61	25680-25687	ventral	_	
127-62	25688-25696	striatal	_	
127-63	25697-25705	dopamine	_	
127-64	25706-25715	responses	_	
127-65	25716-25718	to	_	
127-66	25719-25730	amphetamine	_	
127-67	25731-25740	Graphical	_	
127-68	25741-25751	evaluation	_	
127-69	25752-25754	of	_	
127-70	25755-25769	blood-to-brain	_	
127-71	25770-25778	transfer	_	
127-72	25779-25788	constants	_	
127-73	25789-25793	from	_	
127-74	25794-25807	multiple-time	_	
127-75	25808-25814	uptake	_	
127-76	25815-25819	data	_	
127-77	25819-25820	.	_	

#Text=Generalizations
#Text=Identification of young people at risk of psychosis: validation of Personal Assessment and Crisis Evaluation Clinic intake criteria
#Text=Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]raclopride
#Text=Social defeat: risk factor for schizophrenia?
128-1	25821-25836	Generalizations	_	
128-2	25837-25851	Identification	_	
128-3	25852-25854	of	_	
128-4	25855-25860	young	_	
128-5	25861-25867	people	_	
128-6	25868-25870	at	_	
128-7	25871-25875	risk	_	
128-8	25876-25878	of	_	
128-9	25879-25888	psychosis	_	
128-10	25888-25889	:	_	
128-11	25890-25900	validation	_	
128-12	25901-25903	of	_	
128-13	25904-25912	Personal	_	
128-14	25913-25923	Assessment	_	
128-15	25924-25927	and	_	
128-16	25928-25934	Crisis	_	
128-17	25935-25945	Evaluation	_	
128-18	25946-25952	Clinic	_	
128-19	25953-25959	intake	_	
128-20	25960-25968	criteria	_	
128-21	25969-25977	Dopamine	_	
128-22	25978-25985	release	_	
128-23	25986-25988	in	_	
128-24	25989-25997	response	_	
128-25	25998-26000	to	_	
128-26	26001-26002	a	_	
128-27	26003-26016	psychological	_	
128-28	26017-26023	stress	_	
128-29	26024-26026	in	_	
128-30	26027-26033	humans	_	
128-31	26034-26037	and	_	
128-32	26038-26041	its	_	
128-33	26042-26054	relationship	_	
128-34	26055-26057	to	_	
128-35	26058-26063	early	_	
128-36	26064-26068	life	_	
128-37	26069-26077	maternal	_	
128-38	26078-26082	care	_	
128-39	26082-26083	:	_	
128-40	26084-26085	a	_	
128-41	26086-26094	positron	_	
128-42	26095-26103	emission	_	
128-43	26104-26114	tomography	_	
128-44	26115-26120	study	_	
128-45	26121-26126	using	_	
128-46	26127-26128	[	_	
128-47	26128-26131	11C	_	
128-48	26131-26132	]	_	
128-49	26132-26142	raclopride	_	
128-50	26143-26149	Social	_	
128-51	26150-26156	defeat	_	
128-52	26156-26157	:	_	
128-53	26158-26162	risk	_	
128-54	26163-26169	factor	_	
128-55	26170-26173	for	_	
128-56	26174-26187	schizophrenia	_	
128-57	26187-26188	?	_	

#Text=The social defeat hypothesis of schizophrenia: an update
#Text=Stress-induced dopamine release in humans at risk of psychosis: a [11C]raclopride PET study
#Text=Automated 3-D registration of MR and CT images of the head
#Text=Developmental pathology, dopamine, and stress: a model for the age of onset of schizophrenia symptoms
#Text=Social defeat stress selectively alters mesocorticolimbic dopamine release: an in vivo microdialysis study
#Text=Multiresolution analysis of emission tomography images in the wavelet domain
#Text=Multi-resolution Bayesian regression in PET dynamic studies using wavelets
#Text=Aversive stimuli alter ventral tegmental area dopamine neuron activity via a common action in the ventral hippocampus
#Text=Childhood trauma as a cause of psychosis: linking genes, psychology, and biology.
129-1	26189-26192	The	_	
129-2	26193-26199	social	_	
129-3	26200-26206	defeat	_	
129-4	26207-26217	hypothesis	_	
129-5	26218-26220	of	_	
129-6	26221-26234	schizophrenia	_	
129-7	26234-26235	:	_	
129-8	26236-26238	an	_	
129-9	26239-26245	update	_	
129-10	26246-26260	Stress-induced	_	
129-11	26261-26269	dopamine	_	
129-12	26270-26277	release	_	
129-13	26278-26280	in	_	
129-14	26281-26287	humans	_	
129-15	26288-26290	at	_	
129-16	26291-26295	risk	_	
129-17	26296-26298	of	_	
129-18	26299-26308	psychosis	_	
129-19	26308-26309	:	_	
129-20	26310-26311	a	_	
129-21	26312-26313	[	_	
129-22	26313-26316	11C	_	
129-23	26316-26317	]	_	
129-24	26317-26327	raclopride	_	
129-25	26328-26331	PET	_	
129-26	26332-26337	study	_	
129-27	26338-26347	Automated	_	
129-28	26348-26349	3	_	
129-29	26349-26350	-	_	
129-30	26350-26351	D	_	
129-31	26352-26364	registration	_	
129-32	26365-26367	of	_	
129-33	26368-26370	MR	_	
129-34	26371-26374	and	_	
129-35	26375-26377	CT	_	
129-36	26378-26384	images	_	
129-37	26385-26387	of	_	
129-38	26388-26391	the	_	
129-39	26392-26396	head	_	
129-40	26397-26410	Developmental	_	
129-41	26411-26420	pathology	_	
129-42	26420-26421	,	_	
129-43	26422-26430	dopamine	_	
129-44	26430-26431	,	_	
129-45	26432-26435	and	_	
129-46	26436-26442	stress	_	
129-47	26442-26443	:	_	
129-48	26444-26445	a	_	
129-49	26446-26451	model	_	
129-50	26452-26455	for	_	
129-51	26456-26459	the	_	
129-52	26460-26463	age	_	
129-53	26464-26466	of	_	
129-54	26467-26472	onset	_	
129-55	26473-26475	of	_	
129-56	26476-26489	schizophrenia	_	
129-57	26490-26498	symptoms	_	
129-58	26499-26505	Social	_	
129-59	26506-26512	defeat	_	
129-60	26513-26519	stress	_	
129-61	26520-26531	selectively	_	
129-62	26532-26538	alters	_	
129-63	26539-26556	mesocorticolimbic	_	
129-64	26557-26565	dopamine	_	
129-65	26566-26573	release	_	
129-66	26573-26574	:	_	
129-67	26575-26577	an	_	
129-68	26578-26580	in	_	
129-69	26581-26585	vivo	_	
129-70	26586-26599	microdialysis	_	
129-71	26600-26605	study	_	
129-72	26606-26621	Multiresolution	_	
129-73	26622-26630	analysis	_	
129-74	26631-26633	of	_	
129-75	26634-26642	emission	_	
129-76	26643-26653	tomography	_	
129-77	26654-26660	images	_	
129-78	26661-26663	in	_	
129-79	26664-26667	the	_	
129-80	26668-26675	wavelet	_	
129-81	26676-26682	domain	_	
129-82	26683-26699	Multi-resolution	_	
129-83	26700-26708	Bayesian	_	
129-84	26709-26719	regression	_	
129-85	26720-26722	in	_	
129-86	26723-26726	PET	_	
129-87	26727-26734	dynamic	_	
129-88	26735-26742	studies	_	
129-89	26743-26748	using	_	
129-90	26749-26757	wavelets	_	
129-91	26758-26766	Aversive	_	
129-92	26767-26774	stimuli	_	
129-93	26775-26780	alter	_	
129-94	26781-26788	ventral	_	
129-95	26789-26798	tegmental	_	
129-96	26799-26803	area	_	
129-97	26804-26812	dopamine	_	
129-98	26813-26819	neuron	_	
129-99	26820-26828	activity	_	
129-100	26829-26832	via	_	
129-101	26833-26834	a	_	
129-102	26835-26841	common	_	
129-103	26842-26848	action	_	
129-104	26849-26851	in	_	
129-105	26852-26855	the	_	
129-106	26856-26863	ventral	_	
129-107	26864-26875	hippocampus	_	
129-108	26876-26885	Childhood	_	
129-109	26886-26892	trauma	_	
129-110	26893-26895	as	_	
129-111	26896-26897	a	_	
129-112	26898-26903	cause	_	
129-113	26904-26906	of	_	
129-114	26907-26916	psychosis	_	
129-115	26916-26917	:	_	
129-116	26918-26925	linking	_	
129-117	26926-26931	genes	_	
129-118	26931-26932	,	_	
129-119	26933-26943	psychology	_	
129-120	26943-26944	,	_	
129-121	26945-26948	and	_	
129-122	26949-26956	biology	_	
129-123	26956-26957	.	_	

#Text=Canadian Journal of Psychiatry
#Text=Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies
#Text=Adult psychiatric disorder and childhood experiences.
130-1	26958-26966	Canadian	_	
130-2	26967-26974	Journal	_	
130-3	26975-26977	of	_	
130-4	26978-26988	Psychiatry	_	
130-5	26989-26998	Childhood	_	
130-6	26999-27010	adversities	_	
130-7	27011-27019	increase	_	
130-8	27020-27023	the	_	
130-9	27024-27028	risk	_	
130-10	27029-27031	of	_	
130-11	27032-27041	psychosis	_	
130-12	27041-27042	:	_	
130-13	27043-27044	a	_	
130-14	27045-27058	meta-analysis	_	
130-15	27059-27061	of	_	
130-16	27062-27077	patient-control	_	
130-17	27077-27078	,	_	
130-18	27079-27090	prospective	_	
130-19	27090-27091	-	_	
130-20	27092-27095	and	_	
130-21	27096-27111	cross-sectional	_	
130-22	27112-27118	cohort	_	
130-23	27119-27126	studies	_	
130-24	27127-27132	Adult	_	
130-25	27133-27144	psychiatric	_	
130-26	27145-27153	disorder	_	
130-27	27154-27157	and	_	
130-28	27158-27167	childhood	_	
130-29	27168-27179	experiences	_	
130-30	27179-27180	.	_	

#Text=The validity of retrospective data
#Text=Supplementary data
#Text=Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.schres.2016.06.005.
131-1	27181-27184	The	_	
131-2	27185-27193	validity	_	
131-3	27194-27196	of	_	
131-4	27197-27210	retrospective	_	
131-5	27211-27215	data	_	
131-6	27216-27229	Supplementary	_	
131-7	27230-27234	data	_	
131-8	27235-27248	Supplementary	_	
131-9	27249-27253	data	_	
131-10	27254-27256	to	_	
131-11	27257-27261	this	_	
131-12	27262-27269	article	_	
131-13	27270-27273	can	_	
131-14	27274-27276	be	_	
131-15	27277-27282	found	_	
131-16	27283-27289	online	_	
131-17	27290-27292	at	_	
131-18	27293-27297	http	_	
131-19	27297-27298	:	_	
131-20	27298-27299	/	_	
131-21	27299-27300	/	_	
131-22	27300-27310	dx.doi.org	_	
131-23	27310-27311	/	_	
131-24	27311-27318	10.1016	_	
131-25	27318-27319	/	_	
131-26	27319-27327	j.schres	_	
131-27	27327-27339	.2016.06.005	_	
131-28	27339-27340	.	_	

#Text=Presynaptic dopamine function (18F-DOPA kicerz-score) in the associative striatum is elevated in young adults who experienced severe sexual or physical abuse (left panel) or unstable family arrangements (right panel) during childhood.
132-1	27341-27352	Presynaptic	_	
132-2	27353-27361	dopamine	_	
132-3	27362-27370	function	_	
132-4	27371-27372	(	_	
132-5	27372-27380	18F-DOPA	_	
132-6	27381-27393	kicerz-score	_	
132-7	27393-27394	)	_	
132-8	27395-27397	in	_	
132-9	27398-27401	the	_	
132-10	27402-27413	associative	_	
132-11	27414-27422	striatum	_	
132-12	27423-27425	is	_	
132-13	27426-27434	elevated	_	
132-14	27435-27437	in	_	
132-15	27438-27443	young	_	
132-16	27444-27450	adults	_	
132-17	27451-27454	who	_	
132-18	27455-27466	experienced	_	
132-19	27467-27473	severe	_	
132-20	27474-27480	sexual	_	
132-21	27481-27483	or	_	
132-22	27484-27492	physical	_	
132-23	27493-27498	abuse	_	
132-24	27499-27500	(	_	
132-25	27500-27504	left	_	
132-26	27505-27510	panel	_	
132-27	27510-27511	)	_	
132-28	27512-27514	or	_	
132-29	27515-27523	unstable	_	
132-30	27524-27530	family	_	
132-31	27531-27543	arrangements	_	
132-32	27544-27545	(	_	
132-33	27545-27550	right	_	
132-34	27551-27556	panel	_	
132-35	27556-27557	)	_	
132-36	27558-27564	during	_	
132-37	27565-27574	childhood	_	
132-38	27574-27575	.	_	

#Text=Fig. 1
#Text=Demographic characteristics, substance use and symptoms in the total sample, control and UHR groups.
133-1	27576-27579	Fig	_	
133-2	27579-27580	.	_	
133-3	27581-27582	1	_	
133-4	27583-27594	Demographic	_	
133-5	27595-27610	characteristics	_	
133-6	27610-27611	,	_	
133-7	27612-27621	substance	_	
133-8	27622-27625	use	_	
133-9	27626-27629	and	_	
133-10	27630-27638	symptoms	_	
133-11	27639-27641	in	_	
133-12	27642-27645	the	_	
133-13	27646-27651	total	_	
133-14	27652-27658	sample	_	
133-15	27658-27659	,	_	
133-16	27660-27667	control	_	
133-17	27668-27671	and	_	
133-18	27672-27675	UHR	_	
133-19	27676-27682	groups	_	
133-20	27682-27683	.	_	

#Text=Table 1\t \t
#Text=\tTotal (n = 67)\tControl(n = 20)\tUHR(n = 47)\tStatistic\t \tDemographics\t\t\t\t\t \t Male/female\t39/28\t12/8\t27/20\tP > 0.99\t \t Age, mean ± sd\t23.7 ± 4.5\t23.8 ± 4.3\t23.6 ± 4.6\tT = 0.15; P = 0.88\t \t Handedness, right/left\t58/9\t16/4\t42/5\tP = 0.43\t \tSubstance use\t\t\t\t\t \t Non-smoker/smoker\t35/22\t13/7\t22/25\tP = 0.19\t \t Non-drinker/drinker\t17/50\t4/16\t13/34\tP = 0.55\t \t Cigarettes/day\t3.8 ± 5.3\t2.3 ± 3.8\t4.5 ± 5.7\tT = 1.58; P = 0.12\t \t Alcohol units/week\t6.7 ± 7.9\t8.4 ± 8.6\t6.0 ± 7.6\tT = 0.26; P = 0.26\t \t Cannabis 0/1/2/3/4\t20/18/9/9/11\t8/6/3/0/3\t12/12/6/9/8\tP > 0.99\t \t Cocaine 0/1/2/3/4\t43/14/4/4/2\t16/3/0/1/0\t27/11/4/3/2\tP > 0.99\t \t Amphetamine 0/1/2/3/4\t52/11/1/3/0\t18/2/0/0/0\t34/9/1/3/0\tP > 0.99\t \t Ecstasy 0/1/2/3/4\t39/18/6/4/0\t14/3/3/0/0\t25/15/3/4/0\tP > 0.99\t \t Ketamine 0/1/2/3/4\t61/3/1/1/0\t18/1/0/0/0\t43/2/1/1/0\tP > 0.99\t \tSymptoms\t\t\t\t\t \t CAARMS total\t\t2.2 ± 2.8\t41.3 ± 18.1\tT = 9.59; P < 0.001\t \t CAARMS positive\t\t0.3 ± 0.6\t7.7 ± 3.3\tT = 10.0; P < 0.001\t \t PANSS positive\t\t7.0 ± 0.0\t12.9 ± 4.3\tT = 6.10; P < 0.001\t \t PANSS negative\t\t7.0 ± 0.0\t11.5 ± 5.2\tT = 3.90; P < 0.001\t \t PANSS general\t\t16.3 ± 0.6\t27.2 ± 7.6\tT = 6.44; P < 0.001\t \t PANSS total\t\t30.3 ± 0.6\t51.7 ± 14.3\tT = 6.68; P < 0.001\t \t Hamilton anxiety\t\t0.8 ± 1.2\t11.9 ± 9.8\tT = 5.03; P < 0.001\t \t Hamilton depression\t\t0.8 ± 1.2\t11.6 ± 8.4\tT = 5.77; P < 0.001\t \t
#Text=CAARMS: Comprehensive Assessment for At Risk Mental States; PANSS: Positive And Negative Syndrome Scale.
134-1	27684-27689	Table	_	
134-2	27690-27691	1	_	
134-3	27696-27701	Total	_	
134-4	27702-27703	(	_	
134-5	27703-27704	n	_	
134-6	27704-27705	 	_	
134-7	27705-27706	=	_	
134-8	27706-27707	 	_	
134-9	27707-27709	67	_	
134-10	27709-27710	)	_	
134-11	27711-27718	Control	_	
134-12	27718-27719	(	_	
134-13	27719-27720	n	_	
134-14	27720-27721	 	_	
134-15	27721-27722	=	_	
134-16	27722-27723	 	_	
134-17	27723-27725	20	_	
134-18	27725-27726	)	_	
134-19	27727-27730	UHR	_	
134-20	27730-27731	(	_	
134-21	27731-27732	n	_	
134-22	27732-27733	 	_	
134-23	27733-27734	=	_	
134-24	27734-27735	 	_	
134-25	27735-27737	47	_	
134-26	27737-27738	)	_	
134-27	27739-27748	Statistic	_	
134-28	27751-27763	Demographics	_	
134-29	27770-27771	 	_	
134-30	27771-27775	Male	_	
134-31	27775-27776	/	_	
134-32	27776-27782	female	_	
134-33	27783-27785	39	_	
134-34	27785-27786	/	_	
134-35	27786-27788	28	_	
134-36	27789-27791	12	_	
134-37	27791-27792	/	_	
134-38	27792-27793	8	_	
134-39	27794-27796	27	_	
134-40	27796-27797	/	_	
134-41	27797-27799	20	_	
134-42	27800-27801	P	_	
134-43	27801-27802	 	_	
134-44	27802-27803	>	_	
134-45	27803-27804	 	_	
134-46	27804-27808	0.99	_	
134-47	27811-27812	 	_	
134-48	27812-27815	Age	_	
134-49	27815-27816	,	_	
134-50	27817-27821	mean	_	
134-51	27821-27822	 	_	
134-52	27822-27823	±	_	
134-53	27823-27824	 	_	
134-54	27824-27826	sd	_	
134-55	27827-27831	23.7	_	
134-56	27831-27832	 	_	
134-57	27832-27833	±	_	
134-58	27833-27834	 	_	
134-59	27834-27837	4.5	_	
134-60	27838-27842	23.8	_	
134-61	27842-27843	 	_	
134-62	27843-27844	±	_	
134-63	27844-27845	 	_	
134-64	27845-27848	4.3	_	
134-65	27849-27853	23.6	_	
134-66	27853-27854	 	_	
134-67	27854-27855	±	_	
134-68	27855-27856	 	_	
134-69	27856-27859	4.6	_	
134-70	27860-27861	T	_	
134-71	27861-27862	 	_	
134-72	27862-27863	=	_	
134-73	27863-27864	 	_	
134-74	27864-27868	0.15	_	
134-75	27868-27869	;	_	
134-76	27870-27871	P	_	
134-77	27871-27872	 	_	
134-78	27872-27873	=	_	
134-79	27873-27874	 	_	
134-80	27874-27878	0.88	_	
134-81	27881-27882	 	_	
134-82	27882-27892	Handedness	_	
134-83	27892-27893	,	_	
134-84	27894-27899	right	_	
134-85	27899-27900	/	_	
134-86	27900-27904	left	_	
134-87	27905-27907	58	_	
134-88	27907-27908	/	_	
134-89	27908-27909	9	_	
134-90	27910-27912	16	_	
134-91	27912-27913	/	_	
134-92	27913-27914	4	_	
134-93	27915-27917	42	_	
134-94	27917-27918	/	_	
134-95	27918-27919	5	_	
134-96	27920-27921	P	_	
134-97	27921-27922	 	_	
134-98	27922-27923	=	_	
134-99	27923-27924	 	_	
134-100	27924-27928	0.43	_	
134-101	27931-27940	Substance	_	
134-102	27941-27944	use	_	
134-103	27951-27952	 	_	
134-104	27952-27962	Non-smoker	_	
134-105	27962-27963	/	_	
134-106	27963-27969	smoker	_	
134-107	27970-27972	35	_	
134-108	27972-27973	/	_	
134-109	27973-27975	22	_	
134-110	27976-27978	13	_	
134-111	27978-27979	/	_	
134-112	27979-27980	7	_	
134-113	27981-27983	22	_	
134-114	27983-27984	/	_	
134-115	27984-27986	25	_	
134-116	27987-27988	P	_	
134-117	27988-27989	 	_	
134-118	27989-27990	=	_	
134-119	27990-27991	 	_	
134-120	27991-27995	0.19	_	
134-121	27998-27999	 	_	
134-122	27999-28010	Non-drinker	_	
134-123	28010-28011	/	_	
134-124	28011-28018	drinker	_	
134-125	28019-28021	17	_	
134-126	28021-28022	/	_	
134-127	28022-28024	50	_	
134-128	28025-28026	4	_	
134-129	28026-28027	/	_	
134-130	28027-28029	16	_	
134-131	28030-28032	13	_	
134-132	28032-28033	/	_	
134-133	28033-28035	34	_	
134-134	28036-28037	P	_	
134-135	28037-28038	 	_	
134-136	28038-28039	=	_	
134-137	28039-28040	 	_	
134-138	28040-28044	0.55	_	
134-139	28047-28048	 	_	
134-140	28048-28058	Cigarettes	_	
134-141	28058-28059	/	_	
134-142	28059-28062	day	_	
134-143	28063-28066	3.8	_	
134-144	28066-28067	 	_	
134-145	28067-28068	±	_	
134-146	28068-28069	 	_	
134-147	28069-28072	5.3	_	
134-148	28073-28076	2.3	_	
134-149	28076-28077	 	_	
134-150	28077-28078	±	_	
134-151	28078-28079	 	_	
134-152	28079-28082	3.8	_	
134-153	28083-28086	4.5	_	
134-154	28086-28087	 	_	
134-155	28087-28088	±	_	
134-156	28088-28089	 	_	
134-157	28089-28092	5.7	_	
134-158	28093-28094	T	_	
134-159	28094-28095	 	_	
134-160	28095-28096	=	_	
134-161	28096-28097	 	_	
134-162	28097-28101	1.58	_	
134-163	28101-28102	;	_	
134-164	28103-28104	P	_	
134-165	28104-28105	 	_	
134-166	28105-28106	=	_	
134-167	28106-28107	 	_	
134-168	28107-28111	0.12	_	
134-169	28114-28115	 	_	
134-170	28115-28122	Alcohol	_	
134-171	28123-28128	units	_	
134-172	28128-28129	/	_	
134-173	28129-28133	week	_	
134-174	28134-28137	6.7	_	
134-175	28137-28138	 	_	
134-176	28138-28139	±	_	
134-177	28139-28140	 	_	
134-178	28140-28143	7.9	_	
134-179	28144-28147	8.4	_	
134-180	28147-28148	 	_	
134-181	28148-28149	±	_	
134-182	28149-28150	 	_	
134-183	28150-28153	8.6	_	
134-184	28154-28157	6.0	_	
134-185	28157-28158	 	_	
134-186	28158-28159	±	_	
134-187	28159-28160	 	_	
134-188	28160-28163	7.6	_	
134-189	28164-28165	T	_	
134-190	28165-28166	 	_	
134-191	28166-28167	=	_	
134-192	28167-28168	 	_	
134-193	28168-28172	0.26	_	
134-194	28172-28173	;	_	
134-195	28174-28175	P	_	
134-196	28175-28176	 	_	
134-197	28176-28177	=	_	
134-198	28177-28178	 	_	
134-199	28178-28182	0.26	_	
134-200	28185-28186	 	_	
134-201	28186-28194	Cannabis	_	
134-202	28195-28196	0	_	
134-203	28196-28197	/	_	
134-204	28197-28198	1	_	
134-205	28198-28199	/	_	
134-206	28199-28200	2	_	
134-207	28200-28201	/	_	
134-208	28201-28202	3	_	
134-209	28202-28203	/	_	
134-210	28203-28204	4	_	
134-211	28205-28207	20	_	
134-212	28207-28208	/	_	
134-213	28208-28210	18	_	
134-214	28210-28211	/	_	
134-215	28211-28212	9	_	
134-216	28212-28213	/	_	
134-217	28213-28214	9	_	
134-218	28214-28215	/	_	
134-219	28215-28217	11	_	
134-220	28218-28219	8	_	
134-221	28219-28220	/	_	
134-222	28220-28221	6	_	
134-223	28221-28222	/	_	
134-224	28222-28223	3	_	
134-225	28223-28224	/	_	
134-226	28224-28225	0	_	
134-227	28225-28226	/	_	
134-228	28226-28227	3	_	
134-229	28228-28230	12	_	
134-230	28230-28231	/	_	
134-231	28231-28233	12	_	
134-232	28233-28234	/	_	
134-233	28234-28235	6	_	
134-234	28235-28236	/	_	
134-235	28236-28237	9	_	
134-236	28237-28238	/	_	
134-237	28238-28239	8	_	
134-238	28240-28241	P	_	
134-239	28241-28242	 	_	
134-240	28242-28243	>	_	
134-241	28243-28244	 	_	
134-242	28244-28248	0.99	_	
134-243	28251-28252	 	_	
134-244	28252-28259	Cocaine	_	
134-245	28260-28261	0	_	
134-246	28261-28262	/	_	
134-247	28262-28263	1	_	
134-248	28263-28264	/	_	
134-249	28264-28265	2	_	
134-250	28265-28266	/	_	
134-251	28266-28267	3	_	
134-252	28267-28268	/	_	
134-253	28268-28269	4	_	
134-254	28270-28272	43	_	
134-255	28272-28273	/	_	
134-256	28273-28275	14	_	
134-257	28275-28276	/	_	
134-258	28276-28277	4	_	
134-259	28277-28278	/	_	
134-260	28278-28279	4	_	
134-261	28279-28280	/	_	
134-262	28280-28281	2	_	
134-263	28282-28284	16	_	
134-264	28284-28285	/	_	
134-265	28285-28286	3	_	
134-266	28286-28287	/	_	
134-267	28287-28288	0	_	
134-268	28288-28289	/	_	
134-269	28289-28290	1	_	
134-270	28290-28291	/	_	
134-271	28291-28292	0	_	
134-272	28293-28295	27	_	
134-273	28295-28296	/	_	
134-274	28296-28298	11	_	
134-275	28298-28299	/	_	
134-276	28299-28300	4	_	
134-277	28300-28301	/	_	
134-278	28301-28302	3	_	
134-279	28302-28303	/	_	
134-280	28303-28304	2	_	
134-281	28305-28306	P	_	
134-282	28306-28307	 	_	
134-283	28307-28308	>	_	
134-284	28308-28309	 	_	
134-285	28309-28313	0.99	_	
134-286	28316-28317	 	_	
134-287	28317-28328	Amphetamine	_	
134-288	28329-28330	0	_	
134-289	28330-28331	/	_	
134-290	28331-28332	1	_	
134-291	28332-28333	/	_	
134-292	28333-28334	2	_	
134-293	28334-28335	/	_	
134-294	28335-28336	3	_	
134-295	28336-28337	/	_	
134-296	28337-28338	4	_	
134-297	28339-28341	52	_	
134-298	28341-28342	/	_	
134-299	28342-28344	11	_	
134-300	28344-28345	/	_	
134-301	28345-28346	1	_	
134-302	28346-28347	/	_	
134-303	28347-28348	3	_	
134-304	28348-28349	/	_	
134-305	28349-28350	0	_	
134-306	28351-28353	18	_	
134-307	28353-28354	/	_	
134-308	28354-28355	2	_	
134-309	28355-28356	/	_	
134-310	28356-28357	0	_	
134-311	28357-28358	/	_	
134-312	28358-28359	0	_	
134-313	28359-28360	/	_	
134-314	28360-28361	0	_	
134-315	28362-28364	34	_	
134-316	28364-28365	/	_	
134-317	28365-28366	9	_	
134-318	28366-28367	/	_	
134-319	28367-28368	1	_	
134-320	28368-28369	/	_	
134-321	28369-28370	3	_	
134-322	28370-28371	/	_	
134-323	28371-28372	0	_	
134-324	28373-28374	P	_	
134-325	28374-28375	 	_	
134-326	28375-28376	>	_	
134-327	28376-28377	 	_	
134-328	28377-28381	0.99	_	
134-329	28384-28385	 	_	
134-330	28385-28392	Ecstasy	_	
134-331	28393-28394	0	_	
134-332	28394-28395	/	_	
134-333	28395-28396	1	_	
134-334	28396-28397	/	_	
134-335	28397-28398	2	_	
134-336	28398-28399	/	_	
134-337	28399-28400	3	_	
134-338	28400-28401	/	_	
134-339	28401-28402	4	_	
134-340	28403-28405	39	_	
134-341	28405-28406	/	_	
134-342	28406-28408	18	_	
134-343	28408-28409	/	_	
134-344	28409-28410	6	_	
134-345	28410-28411	/	_	
134-346	28411-28412	4	_	
134-347	28412-28413	/	_	
134-348	28413-28414	0	_	
134-349	28415-28417	14	_	
134-350	28417-28418	/	_	
134-351	28418-28419	3	_	
134-352	28419-28420	/	_	
134-353	28420-28421	3	_	
134-354	28421-28422	/	_	
134-355	28422-28423	0	_	
134-356	28423-28424	/	_	
134-357	28424-28425	0	_	
134-358	28426-28428	25	_	
134-359	28428-28429	/	_	
134-360	28429-28431	15	_	
134-361	28431-28432	/	_	
134-362	28432-28433	3	_	
134-363	28433-28434	/	_	
134-364	28434-28435	4	_	
134-365	28435-28436	/	_	
134-366	28436-28437	0	_	
134-367	28438-28439	P	_	
134-368	28439-28440	 	_	
134-369	28440-28441	>	_	
134-370	28441-28442	 	_	
134-371	28442-28446	0.99	_	
134-372	28449-28450	 	_	
134-373	28450-28458	Ketamine	_	
134-374	28459-28460	0	_	
134-375	28460-28461	/	_	
134-376	28461-28462	1	_	
134-377	28462-28463	/	_	
134-378	28463-28464	2	_	
134-379	28464-28465	/	_	
134-380	28465-28466	3	_	
134-381	28466-28467	/	_	
134-382	28467-28468	4	_	
134-383	28469-28471	61	_	
134-384	28471-28472	/	_	
134-385	28472-28473	3	_	
134-386	28473-28474	/	_	
134-387	28474-28475	1	_	
134-388	28475-28476	/	_	
134-389	28476-28477	1	_	
134-390	28477-28478	/	_	
134-391	28478-28479	0	_	
134-392	28480-28482	18	_	
134-393	28482-28483	/	_	
134-394	28483-28484	1	_	
134-395	28484-28485	/	_	
134-396	28485-28486	0	_	
134-397	28486-28487	/	_	
134-398	28487-28488	0	_	
134-399	28488-28489	/	_	
134-400	28489-28490	0	_	
134-401	28491-28493	43	_	
134-402	28493-28494	/	_	
134-403	28494-28495	2	_	
134-404	28495-28496	/	_	
134-405	28496-28497	1	_	
134-406	28497-28498	/	_	
134-407	28498-28499	1	_	
134-408	28499-28500	/	_	
134-409	28500-28501	0	_	
134-410	28502-28503	P	_	
134-411	28503-28504	 	_	
134-412	28504-28505	>	_	
134-413	28505-28506	 	_	
134-414	28506-28510	0.99	_	
134-415	28513-28521	Symptoms	_	
134-416	28528-28529	 	_	
134-417	28529-28535	CAARMS	_	
134-418	28536-28541	total	_	
134-419	28543-28546	2.2	_	
134-420	28546-28547	 	_	
134-421	28547-28548	±	_	
134-422	28548-28549	 	_	
134-423	28549-28552	2.8	_	
134-424	28553-28557	41.3	_	
134-425	28557-28558	 	_	
134-426	28558-28559	±	_	
134-427	28559-28560	 	_	
134-428	28560-28564	18.1	_	
134-429	28565-28566	T	_	
134-430	28566-28567	 	_	
134-431	28567-28568	=	_	
134-432	28568-28569	 	_	
134-433	28569-28573	9.59	_	
134-434	28573-28574	;	_	
134-435	28575-28576	P	_	
134-436	28576-28577	 	_	
134-437	28577-28578	<	_	
134-438	28578-28579	 	_	
134-439	28579-28584	0.001	_	
134-440	28587-28588	 	_	
134-441	28588-28594	CAARMS	_	
134-442	28595-28603	positive	_	
134-443	28605-28608	0.3	_	
134-444	28608-28609	 	_	
134-445	28609-28610	±	_	
134-446	28610-28611	 	_	
134-447	28611-28614	0.6	_	
134-448	28615-28618	7.7	_	
134-449	28618-28619	 	_	
134-450	28619-28620	±	_	
134-451	28620-28621	 	_	
134-452	28621-28624	3.3	_	
134-453	28625-28626	T	_	
134-454	28626-28627	 	_	
134-455	28627-28628	=	_	
134-456	28628-28629	 	_	
134-457	28629-28633	10.0	_	
134-458	28633-28634	;	_	
134-459	28635-28636	P	_	
134-460	28636-28637	 	_	
134-461	28637-28638	<	_	
134-462	28638-28639	 	_	
134-463	28639-28644	0.001	_	
134-464	28647-28648	 	_	
134-465	28648-28653	PANSS	_	
134-466	28654-28662	positive	_	
134-467	28664-28667	7.0	_	
134-468	28667-28668	 	_	
134-469	28668-28669	±	_	
134-470	28669-28670	 	_	
134-471	28670-28673	0.0	_	
134-472	28674-28678	12.9	_	
134-473	28678-28679	 	_	
134-474	28679-28680	±	_	
134-475	28680-28681	 	_	
134-476	28681-28684	4.3	_	
134-477	28685-28686	T	_	
134-478	28686-28687	 	_	
134-479	28687-28688	=	_	
134-480	28688-28689	 	_	
134-481	28689-28693	6.10	_	
134-482	28693-28694	;	_	
134-483	28695-28696	P	_	
134-484	28696-28697	 	_	
134-485	28697-28698	<	_	
134-486	28698-28699	 	_	
134-487	28699-28704	0.001	_	
134-488	28707-28708	 	_	
134-489	28708-28713	PANSS	_	
134-490	28714-28722	negative	_	
134-491	28724-28727	7.0	_	
134-492	28727-28728	 	_	
134-493	28728-28729	±	_	
134-494	28729-28730	 	_	
134-495	28730-28733	0.0	_	
134-496	28734-28738	11.5	_	
134-497	28738-28739	 	_	
134-498	28739-28740	±	_	
134-499	28740-28741	 	_	
134-500	28741-28744	5.2	_	
134-501	28745-28746	T	_	
134-502	28746-28747	 	_	
134-503	28747-28748	=	_	
134-504	28748-28749	 	_	
134-505	28749-28753	3.90	_	
134-506	28753-28754	;	_	
134-507	28755-28756	P	_	
134-508	28756-28757	 	_	
134-509	28757-28758	<	_	
134-510	28758-28759	 	_	
134-511	28759-28764	0.001	_	
134-512	28767-28768	 	_	
134-513	28768-28773	PANSS	_	
134-514	28774-28781	general	_	
134-515	28783-28787	16.3	_	
134-516	28787-28788	 	_	
134-517	28788-28789	±	_	
134-518	28789-28790	 	_	
134-519	28790-28793	0.6	_	
134-520	28794-28798	27.2	_	
134-521	28798-28799	 	_	
134-522	28799-28800	±	_	
134-523	28800-28801	 	_	
134-524	28801-28804	7.6	_	
134-525	28805-28806	T	_	
134-526	28806-28807	 	_	
134-527	28807-28808	=	_	
134-528	28808-28809	 	_	
134-529	28809-28813	6.44	_	
134-530	28813-28814	;	_	
134-531	28815-28816	P	_	
134-532	28816-28817	 	_	
134-533	28817-28818	<	_	
134-534	28818-28819	 	_	
134-535	28819-28824	0.001	_	
134-536	28827-28828	 	_	
134-537	28828-28833	PANSS	_	
134-538	28834-28839	total	_	
134-539	28841-28845	30.3	_	
134-540	28845-28846	 	_	
134-541	28846-28847	±	_	
134-542	28847-28848	 	_	
134-543	28848-28851	0.6	_	
134-544	28852-28856	51.7	_	
134-545	28856-28857	 	_	
134-546	28857-28858	±	_	
134-547	28858-28859	 	_	
134-548	28859-28863	14.3	_	
134-549	28864-28865	T	_	
134-550	28865-28866	 	_	
134-551	28866-28867	=	_	
134-552	28867-28868	 	_	
134-553	28868-28872	6.68	_	
134-554	28872-28873	;	_	
134-555	28874-28875	P	_	
134-556	28875-28876	 	_	
134-557	28876-28877	<	_	
134-558	28877-28878	 	_	
134-559	28878-28883	0.001	_	
134-560	28886-28887	 	_	
134-561	28887-28895	Hamilton	_	
134-562	28896-28903	anxiety	_	
134-563	28905-28908	0.8	_	
134-564	28908-28909	 	_	
134-565	28909-28910	±	_	
134-566	28910-28911	 	_	
134-567	28911-28914	1.2	_	
134-568	28915-28919	11.9	_	
134-569	28919-28920	 	_	
134-570	28920-28921	±	_	
134-571	28921-28922	 	_	
134-572	28922-28925	9.8	_	
134-573	28926-28927	T	_	
134-574	28927-28928	 	_	
134-575	28928-28929	=	_	
134-576	28929-28930	 	_	
134-577	28930-28934	5.03	_	
134-578	28934-28935	;	_	
134-579	28936-28937	P	_	
134-580	28937-28938	 	_	
134-581	28938-28939	<	_	
134-582	28939-28940	 	_	
134-583	28940-28945	0.001	_	
134-584	28948-28949	 	_	
134-585	28949-28957	Hamilton	_	
134-586	28958-28968	depression	_	
134-587	28970-28973	0.8	_	
134-588	28973-28974	 	_	
134-589	28974-28975	±	_	
134-590	28975-28976	 	_	
134-591	28976-28979	1.2	_	
134-592	28980-28984	11.6	_	
134-593	28984-28985	 	_	
134-594	28985-28986	±	_	
134-595	28986-28987	 	_	
134-596	28987-28990	8.4	_	
134-597	28991-28992	T	_	
134-598	28992-28993	 	_	
134-599	28993-28994	=	_	
134-600	28994-28995	 	_	
134-601	28995-28999	5.77	_	
134-602	28999-29000	;	_	
134-603	29001-29002	P	_	
134-604	29002-29003	 	_	
134-605	29003-29004	<	_	
134-606	29004-29005	 	_	
134-607	29005-29010	0.001	_	
134-608	29014-29020	CAARMS	_	
134-609	29020-29021	:	_	
134-610	29022-29035	Comprehensive	_	
134-611	29036-29046	Assessment	_	
134-612	29047-29050	for	_	
134-613	29051-29053	At	_	
134-614	29054-29058	Risk	_	
134-615	29059-29065	Mental	_	
134-616	29066-29072	States	_	
134-617	29072-29073	;	_	
134-618	29074-29079	PANSS	_	
134-619	29079-29080	:	_	
134-620	29081-29089	Positive	_	
134-621	29090-29093	And	_	
134-622	29094-29102	Negative	_	
134-623	29103-29111	Syndrome	_	
134-624	29112-29117	Scale	_	
134-625	29117-29118	.	_	

#Text=For cannabis, cocaine, amphetamine, ecstasy and ketamine use, categories of 0/1/2/3/4 indicate never used/very occasional or experimental use/occasional or monthly use/moderate or weekly use/severe or daily use respectively.
135-1	29119-29122	For	_	
135-2	29123-29131	cannabis	_	
135-3	29131-29132	,	_	
135-4	29133-29140	cocaine	_	
135-5	29140-29141	,	_	
135-6	29142-29153	amphetamine	_	
135-7	29153-29154	,	_	
135-8	29155-29162	ecstasy	_	
135-9	29163-29166	and	_	
135-10	29167-29175	ketamine	_	
135-11	29176-29179	use	_	
135-12	29179-29180	,	_	
135-13	29181-29191	categories	_	
135-14	29192-29194	of	_	
135-15	29195-29196	0	_	
135-16	29196-29197	/	_	
135-17	29197-29198	1	_	
135-18	29198-29199	/	_	
135-19	29199-29200	2	_	
135-20	29200-29201	/	_	
135-21	29201-29202	3	_	
135-22	29202-29203	/	_	
135-23	29203-29204	4	_	
135-24	29205-29213	indicate	_	
135-25	29214-29219	never	_	
135-26	29220-29224	used	_	
135-27	29224-29225	/	_	
135-28	29225-29229	very	_	
135-29	29230-29240	occasional	_	
135-30	29241-29243	or	_	
135-31	29244-29256	experimental	_	
135-32	29257-29260	use	_	
135-33	29260-29261	/	_	
135-34	29261-29271	occasional	_	
135-35	29272-29274	or	_	
135-36	29275-29282	monthly	_	
135-37	29283-29286	use	_	
135-38	29286-29287	/	_	
135-39	29287-29295	moderate	_	
135-40	29296-29298	or	_	
135-41	29299-29305	weekly	_	
135-42	29306-29309	use	_	
135-43	29309-29310	/	_	
135-44	29310-29316	severe	_	
135-45	29317-29319	or	_	
135-46	29320-29325	daily	_	
135-47	29326-29329	use	_	
135-48	29330-29342	respectively	_	
135-49	29342-29343	.	_	

#Text=Exposure to childhood adversity in the total sample, control and UHR groups.
136-1	29344-29352	Exposure	_	
136-2	29353-29355	to	_	
136-3	29356-29365	childhood	_	
136-4	29366-29375	adversity	_	
136-5	29376-29378	in	_	
136-6	29379-29382	the	_	
136-7	29383-29388	total	_	
136-8	29389-29395	sample	_	
136-9	29395-29396	,	_	
136-10	29397-29404	control	_	
136-11	29405-29408	and	_	
136-12	29409-29412	UHR	_	
136-13	29413-29419	groups	_	
136-14	29419-29420	.	_	

#Text=Table 2\t \t
#Text=\tTotal\tControl\tUHR\tP value\t \tParental loss or separation\t40/65 (62%)\t10/20 (50%)\t30/45 (67%)\t0.27\t \tSevere physical or sexual abuse\t26/65 (40%)\t4/20 (20%)\t22/45 (49%)\t0.03\t \tSevere antipathy or neglect\t21/59 (36%)\t7/20 (35%)\t14/39 (36%)\t> 0.99\t \tMore than two family arrangements\t15/59 (25%)\t3/20 (15%)\t12/39 (31%)\t0.22\t \t
#Text=Data are presented as the number and percentage of participants reporting exposure/group total.
137-1	29421-29426	Table	_	
137-2	29427-29428	2	_	
137-3	29433-29438	Total	_	
137-4	29439-29446	Control	_	
137-5	29447-29450	UHR	_	
137-6	29451-29452	P	_	
137-7	29453-29458	value	_	
137-8	29461-29469	Parental	_	
137-9	29470-29474	loss	_	
137-10	29475-29477	or	_	
137-11	29478-29488	separation	_	
137-12	29489-29491	40	_	
137-13	29491-29492	/	_	
137-14	29492-29494	65	_	
137-15	29495-29496	(	_	
137-16	29496-29499	62%	_	
137-17	29499-29500	)	_	
137-18	29501-29503	10	_	
137-19	29503-29504	/	_	
137-20	29504-29506	20	_	
137-21	29507-29508	(	_	
137-22	29508-29511	50%	_	
137-23	29511-29512	)	_	
137-24	29513-29515	30	_	
137-25	29515-29516	/	_	
137-26	29516-29518	45	_	
137-27	29519-29520	(	_	
137-28	29520-29523	67%	_	
137-29	29523-29524	)	_	
137-30	29525-29529	0.27	_	
137-31	29532-29538	Severe	_	
137-32	29539-29547	physical	_	
137-33	29548-29550	or	_	
137-34	29551-29557	sexual	_	
137-35	29558-29563	abuse	_	
137-36	29564-29566	26	_	
137-37	29566-29567	/	_	
137-38	29567-29569	65	_	
137-39	29570-29571	(	_	
137-40	29571-29574	40%	_	
137-41	29574-29575	)	_	
137-42	29576-29577	4	_	
137-43	29577-29578	/	_	
137-44	29578-29580	20	_	
137-45	29581-29582	(	_	
137-46	29582-29585	20%	_	
137-47	29585-29586	)	_	
137-48	29587-29589	22	_	
137-49	29589-29590	/	_	
137-50	29590-29592	45	_	
137-51	29593-29594	(	_	
137-52	29594-29597	49%	_	
137-53	29597-29598	)	_	
137-54	29599-29603	0.03	_	
137-55	29606-29612	Severe	_	
137-56	29613-29622	antipathy	_	
137-57	29623-29625	or	_	
137-58	29626-29633	neglect	_	
137-59	29634-29636	21	_	
137-60	29636-29637	/	_	
137-61	29637-29639	59	_	
137-62	29640-29641	(	_	
137-63	29641-29644	36%	_	
137-64	29644-29645	)	_	
137-65	29646-29647	7	_	
137-66	29647-29648	/	_	
137-67	29648-29650	20	_	
137-68	29651-29652	(	_	
137-69	29652-29655	35%	_	
137-70	29655-29656	)	_	
137-71	29657-29659	14	_	
137-72	29659-29660	/	_	
137-73	29660-29662	39	_	
137-74	29663-29664	(	_	
137-75	29664-29667	36%	_	
137-76	29667-29668	)	_	
137-77	29669-29670	>	_	
137-78	29670-29671	 	_	
137-79	29671-29675	0.99	_	
137-80	29678-29682	More	_	
137-81	29683-29687	than	_	
137-82	29688-29691	two	_	
137-83	29692-29698	family	_	
137-84	29699-29711	arrangements	_	
137-85	29712-29714	15	_	
137-86	29714-29715	/	_	
137-87	29715-29717	59	_	
137-88	29718-29719	(	_	
137-89	29719-29722	25%	_	
137-90	29722-29723	)	_	
137-91	29724-29725	3	_	
137-92	29725-29726	/	_	
137-93	29726-29728	20	_	
137-94	29729-29730	(	_	
137-95	29730-29733	15%	_	
137-96	29733-29734	)	_	
137-97	29735-29737	12	_	
137-98	29737-29738	/	_	
137-99	29738-29740	39	_	
137-100	29741-29742	(	_	
137-101	29742-29745	31%	_	
137-102	29745-29746	)	_	
137-103	29747-29751	0.22	_	
137-104	29755-29759	Data	_	
137-105	29760-29763	are	_	
137-106	29764-29773	presented	_	
137-107	29774-29776	as	_	
137-108	29777-29780	the	_	
137-109	29781-29787	number	_	
137-110	29788-29791	and	_	
137-111	29792-29802	percentage	_	
137-112	29803-29805	of	_	
137-113	29806-29818	participants	_	
137-114	29819-29828	reporting	_	
137-115	29829-29837	exposure	_	
137-116	29837-29838	/	_	
137-117	29838-29843	group	_	
137-118	29844-29849	total	_	
137-119	29849-29850	.	_	

#Text=Associative Striatal Dopamine Function and Childhood Adversity.
138-1	29851-29862	Associative	_	
138-2	29863-29871	Striatal	_	
138-3	29872-29880	Dopamine	_	
138-4	29881-29889	Function	_	
138-5	29890-29893	and	_	
138-6	29894-29903	Childhood	_	
138-7	29904-29913	Adversity	_	
138-8	29913-29914	.	_	

#Text=Table 3\t \t
#Text=\tNo exposure\tExposure\tStatistic, effect size\t \tParental loss or separation\t0.11 ± 0.71\t− 0.02 ± 1.14\tT63 = 0.53; P = 0.60; d = 0.14\t \tSevere physical or sexual abuse\t− 0.25 ± 1.00\t0.44 ± 0.84\tT63 = 2.92; P = 0.005; d = 0.75\t \tSevere antipathy or neglect\t0.09 ± 0.94\t− 0.09 ± 1.03\tT57 = 0.68; P = 0.50; d = 0.18\t \tMore than two family arrangements\t− 0.17 ± 0.94\t0.59 ± 0.83\tT57 = 2.80; P = 0.007; d = 0.86\t \t
#Text=Dopamine function is expressed as the mean ± standard deviation z-scores for 18F-DOPA kicer values, representing presynaptic dopamine synthesis capacity.
139-1	29915-29920	Table	_	
139-2	29921-29922	3	_	
139-3	29927-29929	No	_	
139-4	29930-29938	exposure	_	
139-5	29939-29947	Exposure	_	
139-6	29948-29957	Statistic	_	
139-7	29957-29958	,	_	
139-8	29959-29965	effect	_	
139-9	29966-29970	size	_	
139-10	29973-29981	Parental	_	
139-11	29982-29986	loss	_	
139-12	29987-29989	or	_	
139-13	29990-30000	separation	_	
139-14	30001-30005	0.11	_	
139-15	30005-30006	 	_	
139-16	30006-30007	±	_	
139-17	30007-30008	 	_	
139-18	30008-30012	0.71	_	
139-19	30013-30014	−	_	
139-20	30014-30015	 	_	
139-21	30015-30019	0.02	_	
139-22	30019-30020	 	_	
139-23	30020-30021	±	_	
139-24	30021-30022	 	_	
139-25	30022-30026	1.14	_	
139-26	30027-30030	T63	_	
139-27	30030-30031	 	_	
139-28	30031-30032	=	_	
139-29	30032-30033	 	_	
139-30	30033-30037	0.53	_	
139-31	30037-30038	;	_	
139-32	30039-30040	P	_	
139-33	30040-30041	 	_	
139-34	30041-30042	=	_	
139-35	30042-30043	 	_	
139-36	30043-30047	0.60	_	
139-37	30047-30048	;	_	
139-38	30049-30050	d	_	
139-39	30050-30051	 	_	
139-40	30051-30052	=	_	
139-41	30052-30053	 	_	
139-42	30053-30057	0.14	_	
139-43	30060-30066	Severe	_	
139-44	30067-30075	physical	_	
139-45	30076-30078	or	_	
139-46	30079-30085	sexual	_	
139-47	30086-30091	abuse	_	
139-48	30092-30093	−	_	
139-49	30093-30094	 	_	
139-50	30094-30098	0.25	_	
139-51	30098-30099	 	_	
139-52	30099-30100	±	_	
139-53	30100-30101	 	_	
139-54	30101-30105	1.00	_	
139-55	30106-30110	0.44	_	
139-56	30110-30111	 	_	
139-57	30111-30112	±	_	
139-58	30112-30113	 	_	
139-59	30113-30117	0.84	_	
139-60	30118-30121	T63	_	
139-61	30121-30122	 	_	
139-62	30122-30123	=	_	
139-63	30123-30124	 	_	
139-64	30124-30128	2.92	_	
139-65	30128-30129	;	_	
139-66	30130-30131	P	_	
139-67	30131-30132	 	_	
139-68	30132-30133	=	_	
139-69	30133-30134	 	_	
139-70	30134-30139	0.005	_	
139-71	30139-30140	;	_	
139-72	30141-30142	d	_	
139-73	30142-30143	 	_	
139-74	30143-30144	=	_	
139-75	30144-30145	 	_	
139-76	30145-30149	0.75	_	
139-77	30152-30158	Severe	_	
139-78	30159-30168	antipathy	_	
139-79	30169-30171	or	_	
139-80	30172-30179	neglect	_	
139-81	30180-30184	0.09	_	
139-82	30184-30185	 	_	
139-83	30185-30186	±	_	
139-84	30186-30187	 	_	
139-85	30187-30191	0.94	_	
139-86	30192-30193	−	_	
139-87	30193-30194	 	_	
139-88	30194-30198	0.09	_	
139-89	30198-30199	 	_	
139-90	30199-30200	±	_	
139-91	30200-30201	 	_	
139-92	30201-30205	1.03	_	
139-93	30206-30209	T57	_	
139-94	30209-30210	 	_	
139-95	30210-30211	=	_	
139-96	30211-30212	 	_	
139-97	30212-30216	0.68	_	
139-98	30216-30217	;	_	
139-99	30218-30219	P	_	
139-100	30219-30220	 	_	
139-101	30220-30221	=	_	
139-102	30221-30222	 	_	
139-103	30222-30226	0.50	_	
139-104	30226-30227	;	_	
139-105	30228-30229	d	_	
139-106	30229-30230	 	_	
139-107	30230-30231	=	_	
139-108	30231-30232	 	_	
139-109	30232-30236	0.18	_	
139-110	30239-30243	More	_	
139-111	30244-30248	than	_	
139-112	30249-30252	two	_	
139-113	30253-30259	family	_	
139-114	30260-30272	arrangements	_	
139-115	30273-30274	−	_	
139-116	30274-30275	 	_	
139-117	30275-30279	0.17	_	
139-118	30279-30280	 	_	
139-119	30280-30281	±	_	
139-120	30281-30282	 	_	
139-121	30282-30286	0.94	_	
139-122	30287-30291	0.59	_	
139-123	30291-30292	 	_	
139-124	30292-30293	±	_	
139-125	30293-30294	 	_	
139-126	30294-30298	0.83	_	
139-127	30299-30302	T57	_	
139-128	30302-30303	 	_	
139-129	30303-30304	=	_	
139-130	30304-30305	 	_	
139-131	30305-30309	2.80	_	
139-132	30309-30310	;	_	
139-133	30311-30312	P	_	
139-134	30312-30313	 	_	
139-135	30313-30314	=	_	
139-136	30314-30315	 	_	
139-137	30315-30320	0.007	_	
139-138	30320-30321	;	_	
139-139	30322-30323	d	_	
139-140	30323-30324	 	_	
139-141	30324-30325	=	_	
139-142	30325-30326	 	_	
139-143	30326-30330	0.86	_	
139-144	30334-30342	Dopamine	_	
139-145	30343-30351	function	_	
139-146	30352-30354	is	_	
139-147	30355-30364	expressed	_	
139-148	30365-30367	as	_	
139-149	30368-30371	the	_	
139-150	30372-30376	mean	_	
139-151	30376-30377	 	_	
139-152	30377-30378	±	_	
139-153	30378-30379	 	_	
139-154	30379-30387	standard	_	
139-155	30388-30397	deviation	_	
139-156	30398-30406	z-scores	_	
139-157	30407-30410	for	_	
139-158	30411-30419	18F-DOPA	_	
139-159	30420-30425	kicer	_	
139-160	30426-30432	values	_	
139-161	30432-30433	,	_	
139-162	30434-30446	representing	_	
139-163	30447-30458	presynaptic	_	
139-164	30459-30467	dopamine	_	
139-165	30468-30477	synthesis	_	
139-166	30478-30486	capacity	_	
139-167	30486-30487	.	_	

#Text=Statistics in bold type indicate significant results (P < 0.05).
140-1	30488-30498	Statistics	_	
140-2	30499-30501	in	_	
140-3	30502-30506	bold	_	
140-4	30507-30511	type	_	
140-5	30512-30520	indicate	_	
140-6	30521-30532	significant	_	
140-7	30533-30540	results	_	
140-8	30541-30542	(	_	
140-9	30542-30543	P	_	
140-10	30543-30544	 	_	
140-11	30544-30545	<	_	
140-12	30545-30546	 	_	
140-13	30546-30550	0.05	_	
140-14	30550-30551	)	_	
140-15	30551-30552	.	_	

#Text=Striatal dopamine function in the control and UHR groups.
141-1	30553-30561	Striatal	_	
141-2	30562-30570	dopamine	_	
141-3	30571-30579	function	_	
141-4	30580-30582	in	_	
141-5	30583-30586	the	_	
141-6	30587-30594	control	_	
141-7	30595-30598	and	_	
141-8	30599-30602	UHR	_	
141-9	30603-30609	groups	_	
141-10	30609-30610	.	_	

#Text=Table 4\t \t
#Text=\tControl (n = 20)\tUHR (n = 47)\tStatistic\t \tWhole striatum\t0.30 ± 1.01\t0.54 ± 1.08\tT = 0.88; P = 0.38\t \tAssociative striatum\t− 0.20 ± 0.92\t0.09 ± 1.02\tT = 1.08; P = 0.28\t \tSensorimotor striatum\t0.80 ± 1.24\t1.10 ± 1.49\tT = 0.78; P = 0.44\t \tLimbic striatum\t0.43 ± 1.99\t0.55 ± 1.23\tT = 0.31; P = 0.76\t \t
#Text=Dopamine function is expressed as the mean ± standard deviation z-scores for 18F-DOPA kicer values, representing presynaptic dopamine synthesis capacity.
142-1	30611-30616	Table	_	
142-2	30617-30618	4	_	
142-3	30623-30630	Control	_	
142-4	30631-30632	(	_	
142-5	30632-30633	n	_	
142-6	30633-30634	 	_	
142-7	30634-30635	=	_	
142-8	30635-30636	 	_	
142-9	30636-30638	20	_	
142-10	30638-30639	)	_	
142-11	30640-30643	UHR	_	
142-12	30644-30645	(	_	
142-13	30645-30646	n	_	
142-14	30646-30647	 	_	
142-15	30647-30648	=	_	
142-16	30648-30649	 	_	
142-17	30649-30651	47	_	
142-18	30651-30652	)	_	
142-19	30653-30662	Statistic	_	
142-20	30665-30670	Whole	_	
142-21	30671-30679	striatum	_	
142-22	30680-30684	0.30	_	
142-23	30684-30685	 	_	
142-24	30685-30686	±	_	
142-25	30686-30687	 	_	
142-26	30687-30691	1.01	_	
142-27	30692-30696	0.54	_	
142-28	30696-30697	 	_	
142-29	30697-30698	±	_	
142-30	30698-30699	 	_	
142-31	30699-30703	1.08	_	
142-32	30704-30705	T	_	
142-33	30705-30706	 	_	
142-34	30706-30707	=	_	
142-35	30707-30708	 	_	
142-36	30708-30712	0.88	_	
142-37	30712-30713	;	_	
142-38	30714-30715	P	_	
142-39	30715-30716	 	_	
142-40	30716-30717	=	_	
142-41	30717-30718	 	_	
142-42	30718-30722	0.38	_	
142-43	30725-30736	Associative	_	
142-44	30737-30745	striatum	_	
142-45	30746-30747	−	_	
142-46	30747-30748	 	_	
142-47	30748-30752	0.20	_	
142-48	30752-30753	 	_	
142-49	30753-30754	±	_	
142-50	30754-30755	 	_	
142-51	30755-30759	0.92	_	
142-52	30760-30764	0.09	_	
142-53	30764-30765	 	_	
142-54	30765-30766	±	_	
142-55	30766-30767	 	_	
142-56	30767-30771	1.02	_	
142-57	30772-30773	T	_	
142-58	30773-30774	 	_	
142-59	30774-30775	=	_	
142-60	30775-30776	 	_	
142-61	30776-30780	1.08	_	
142-62	30780-30781	;	_	
142-63	30782-30783	P	_	
142-64	30783-30784	 	_	
142-65	30784-30785	=	_	
142-66	30785-30786	 	_	
142-67	30786-30790	0.28	_	
142-68	30793-30805	Sensorimotor	_	
142-69	30806-30814	striatum	_	
142-70	30815-30819	0.80	_	
142-71	30819-30820	 	_	
142-72	30820-30821	±	_	
142-73	30821-30822	 	_	
142-74	30822-30826	1.24	_	
142-75	30827-30831	1.10	_	
142-76	30831-30832	 	_	
142-77	30832-30833	±	_	
142-78	30833-30834	 	_	
142-79	30834-30838	1.49	_	
142-80	30839-30840	T	_	
142-81	30840-30841	 	_	
142-82	30841-30842	=	_	
142-83	30842-30843	 	_	
142-84	30843-30847	0.78	_	
142-85	30847-30848	;	_	
142-86	30849-30850	P	_	
142-87	30850-30851	 	_	
142-88	30851-30852	=	_	
142-89	30852-30853	 	_	
142-90	30853-30857	0.44	_	
142-91	30860-30866	Limbic	_	
142-92	30867-30875	striatum	_	
142-93	30876-30880	0.43	_	
142-94	30880-30881	 	_	
142-95	30881-30882	±	_	
142-96	30882-30883	 	_	
142-97	30883-30887	1.99	_	
142-98	30888-30892	0.55	_	
142-99	30892-30893	 	_	
142-100	30893-30894	±	_	
142-101	30894-30895	 	_	
142-102	30895-30899	1.23	_	
142-103	30900-30901	T	_	
142-104	30901-30902	 	_	
142-105	30902-30903	=	_	
142-106	30903-30904	 	_	
142-107	30904-30908	0.31	_	
142-108	30908-30909	;	_	
142-109	30910-30911	P	_	
142-110	30911-30912	 	_	
142-111	30912-30913	=	_	
142-112	30913-30914	 	_	
142-113	30914-30918	0.76	_	
142-114	30922-30930	Dopamine	_	
142-115	30931-30939	function	_	
142-116	30940-30942	is	_	
142-117	30943-30952	expressed	_	
142-118	30953-30955	as	_	
142-119	30956-30959	the	_	
142-120	30960-30964	mean	_	
142-121	30964-30965	 	_	
142-122	30965-30966	±	_	
142-123	30966-30967	 	_	
142-124	30967-30975	standard	_	
142-125	30976-30985	deviation	_	
142-126	30986-30994	z-scores	_	
142-127	30995-30998	for	_	
142-128	30999-31007	18F-DOPA	_	
142-129	31008-31013	kicer	_	
142-130	31014-31020	values	_	
142-131	31020-31021	,	_	
142-132	31022-31034	representing	_	
142-133	31035-31046	presynaptic	_	
142-134	31047-31055	dopamine	_	
142-135	31056-31065	synthesis	_	
142-136	31066-31074	capacity	_	
142-137	31074-31075	.	_	
